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General introduction and aims of the thesis
Published in revised form in:







The diagnosis of chronic kidney disease (CKD) is based on two criteria: the 
presence of impaired kidney function, expressed as glomerular filtration rate 
less than 60 ml/min/1.73m2, and signs of kidney damage, usually expressed 
as urinary albumin excretion more than 30 mg/day. In the last decade many 
studies have assessed to what extent CKD predicts outcomes, not only in 
terms of all-cause and cardiovascular mortality but also in terms of renal 
prognosis, that is, incident end-stage renal disease (ESRD) and/or 
progression of CKD.In this chapter it will be discussed, first, what the 
available evidence is that albuminuria is a predictor of both cardiovascular 
and renal prognosis independent of the level of estimated
glomerular filtration rate (eGFR). Second, it will  be described why 
albuminuria predicts these outcomes independently of eGFR. Third, it will 
evaluated whether risk prediction can be further improved by measuring 
manifestations of renal damage other than albuminuria and eGFR. 
Therefore, the question whether albuminuria is all  you need to predict 
outcomes in CKD or that specific  tubular damage markers can further 
improve our predictive capacity for outcomes in CKD will  be addressed. 
Lastly, a brief introduction to the various chapters of this thesis will be given. 
Albuminuria and glomerular filtration rate to predict cardiovascular 
outcome 
Although it has been appreciated for many years that patients with end-
stage renal disease (CKD stage 5) have a worse cardiovascular survival 
than age and sex-matched healthy controls, it was established only relatively 
recently that patients with mildly impaired kidney function (eGFR <60 ml/min/
1.73m2, CKD stage 3-4)) already have a worse cardiovascular prognosis. 1-7 
The association of albuminuria with cardiovascular outcomes has also been 
described in other studies. Although it has long been known that elevated 
albuminuria predicts worse cardiovascular survival in individuals with 
diabetes8, in the last decade similar associations have been observed in 
individuals with hypertension9, the elderly10, and in the general  population.11 
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In a recent meta-analysis the ‘dose dependency’ of this association was 
shown: microalbuminuria was associated with a 47% increased risk for 
cardiovascular events and macroalbuminuria with a 117% increased risk.12 
Elevated albuminuria and impaired eGFR frequently coincide. It is, therefore, 
important to study the interrelationship between albuminuria and impaired 
eGFR for predicting poor cardiovascular survival. This was done in a recent 
meta-analysis by the CKD Prognosis Consortium, in which it was shown that 
albuminuria and eGFR independently of each other – and independently of 
traditional cardiovascular risk factors – are associated with all-cause and 
cardiovascular mortality.13 
Albuminuria and glomerular filtration rate to predict renal outcome
Most of the data on the predictive value of albuminuria and GFR for kidney 
outcomes have been obtained from studies that included patients with 
known kidney disease in an advanced stage and/or macroalbuminuria.14-16 
Only recently, data on kidney outcomes in cohorts based on the general 
population have become available.17-20 In these studies the authors 
evaluated the need to start renal replacement therapy. The data show that 
the incidence of starting renal replacement therapy is increased not only for 
lower baseline eGFR, but also for higher baseline albuminuria. An increased 
risk for renal replacement therapy was manifest already in the 
microalbuminuria range.17-20  
Although all studies agreed upon the fact that low eGFR is associated with 
an increased risk for incident CKD, only few evaluated whether the same is 
true for albuminuria.18;20;21 These latter studies showed, similar to studies 
with ESRD as outcome, that albuminuria (and dipstick proteinuria) predict 
progressive CKD as well  as acute kidney injury independent of the level of 
eGFR. 
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Why do albuminuria and glomerular filtration rate predict renal and 
vascular outcomes independently of each other?
As it has become clear that eGFR and albuminuria, independently of each 
other and of traditional cardiovascular risk factors, predict both 
cardiovascular mortality and kidney outcomes, the question arises of why 
these two kidney-derived parameters add to each other’s predictive 
performance. Of course, impaired renal clearance and leakage of albumin 
through the glomerular filter are separate phenomena. It may well  be that the 
former contributes in a different way to vascular and renal  prognosis than the 
latter. Leakage of albumin from the circulation into urine is still frequently 
considered merely a glomerular representation of the presence and severity 
of systemic endothelial dysfunction.22;23 Once albumin is filtered by the 
glomerulus the majority is reabsorbed from the ultrafiltrate by proximal 
tubular epithelial cells.24 Although eGFR reflects glomerular function, 
albuminuria may well be more a reflection of tubular than of glomerular 
function. As tubulointerstitial  damage on histological examination is better 
associated with kidney function than glomerular damage in various kidney 
diseases, for example in diabetic nephropathy25, the association of 
albuminuria with tubular dysfunction may explain why albuminuria offers 
additive precision to predict renal prognosis. Given these considerations, 
why then does albuminuria add to GFR to predict cardiovascular prognosis? 
As the loss of albumin in urine is unlikely to be causally related to a worse 
cardiovascular outcome, it seems likely that albuminuria reflects another 
underlying phenomenon resulting in vascular events. The STENO 
hypothesis states that albuminuria is a reflection of endothelial  damage.23 As 
such it relates to a generalized endothelial abnormality and is not restricted 
to endothelial  damage in the kidney alone. It has been argued that 
albuminuria (especially in the microalbuminuria range) is just a marker of 
damage related to generalized atherosclerosis that also affects the kidneys.
26 This is in line with the tubular hypoxia hypothesis27, that generalized 
atherosclerosis may impair blood flow in peritubular capillaries more than it 
impairs overall renal blood flow. Such an impaired flow in the peritubular 
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capillaries may result in tubulointerstitial damage and interstitial fibrosis 
causing impaired oxygen diffusion and supply to tubular cells, resulting in 
impaired tubular albumin reabsorption. This may explain why albuminuria is 
closely related to both renal and vascular prognosis.
Can risk prediction by albuminuria and glomerular filtration rate be 
further improved?
In the PREVEND study the value of albuminuria and eGFR in addition to 
other cardiovascular risk factors to predict renal outcome has been 
investigated. The best predictive model  included not only age, systolic  blood 
pressure, C-reactive protein and known hypertension, but also eGFR and 
albuminuria,28 indicating an important independent predictive role for these 
renal parameters that is stronger than many other more conventional 
predictors of renal outcome. Another question to answer is whether other 
parameters, beyond the classical cardiovascular risk factors on the one hand 
and eGFR and albuminuria on the other, could further improve the predictive 
vale of renal risk scores. Previously, it has been shown in individuals with 
primary renal diseases that high-molecular-weight proteins29 and in 
particular urinary IgG excretion30 predict renal prognosis better than overall 
proteinuria. This may be true for individuals with overt proteinuria, in which 
the majority of the protein (>70%) is albumin and only a small  fraction is 
composed of high-molecular-weight proteins. In individuals with lower 
amounts of total  urinary protein, however, that is in individuals who excrete 
less than 500mg of proteins per day, a relatively small fraction of the protein 
(e.g. less than 50%) consists of albumin and the remainder consists of lower 
molecular weight proteins that are handled by the tubules. Whether the 
measurement of the urinary excretion of these tubular proteins may add to 
the predictive capacity of albumin for kidney outcomes is currently being 
investigated. For example, it has recently been shown that albuminuria and 
nonalbumin urinary protein excretion predict graft loss after renal 
transplantation in an additive manner.31
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Can specific tubular markers add to the predictive value of 
albuminuria?
In recent years, specific  damage markers of the proximal  and distal  tubule 
have been discovered. They have been extensively investigated in the field 
of acute kidney injury, and more recent, also in chronic kidney disease. In 
this thesis, several markers of the glomerulus, proximal tubule, distal tubule 
and general inflammation were measured, both in urine as in plasma. 
Urinary markers of renal injury are elevated during glomerular and 
tubulointerstitial injury and provide a non-invasive tool  to monitor renal 
damage. 
In this thesis IgG and IgG-4 were measured as glomerular markers. Urinary 
loss of the positively charged IgG (150 kDa) is associated with loss of size 
selectivity of the glomerular basement membrane, whereas urinary loss of 
the negatively IgG-4 is considered to reflect loss of charge selectivity.32 
Urinary IgG predicts the onset of end-stage-renal-disease in CKD patients 
even better than albuminuria. The fractional excretion of IgG is superior to 
proteinuria in predicting progression of CKD. 
The tubular injury markers investigated here reflect injury in different renal 
compartments and are mediated by different processes. KIM-1, NAG, 
Cystatine C and ß-2-microglobuline were measured as markers for proximal 
tubular damage. KIM-1 is selectively expressed by injured proximal tubular 
cells.33 KIM-1 expression is related to tubulointerstitial damage and 
correlates with the severity of kidney function impairment.34 Urinary excretion 
of KIM-1 predicts the onset of end stage renal disease.35
NAG (135 kDa) is a lysosymal enzyme that is predominantly produced in the 
proximal  tubule, and released into urine upon cellular damage. Elevated 
urinary NAG is elevated in hypertensive subjects, predicts the subsequent 
occurrence of albuminuria in diabetic patients, and was found to predict CKD 
progression better than proteinuria in non-diabetic CKD. 
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Cystatin C is an endogenous cysteine proteinase inhibitor, produced by most 
nucleated cells at a relatively constant rate and released into the plasma. In 
normal renal function, tubular reabsorption and catabolism of cystatin C is 
almost complete and cystatin C is thus only detectable in very small 
quantities in the urine.36 Little is yet known about the predictive value of 
urinary cystatin C in chronic  kidney disease, but in diabetes it is cross-
sectionally associated with eGFR and albuminuria.37
β-2-microglobulin (12 kDa) is a component of MHC class 1 molecules, which 
are present on all nucleated cells. β-2-microglobulin is freely filtered through 
the glomerulus and subsequently reabsorbed by proximal tubular cells. 
Urinary β-2-microglobulin is a marker of proximal tubular reabsorption 
incapacity and predicts the rate of CKD progression.38-40 
H-FABP was measured as marker of distal tubular damage. H-FABP 
(15kDa) is an intracellular carrier protein that is present in cytoplasm of distal 
tubular cells. Urinary H-FABP results from release by structurally damaged 
tubular cells.41;42 Elevated urinary H-FABP predicts prognosis in CKD.43 
NGAL and MCP-1 were measured as markers of general  inflammation. 
NGAL (25 kDa) is expressed by neutrophils and other epithelial cells. It was 
found to reflect damage to glomeruli, and proximal and distal tubules.44-46 
Elevated urinary NGAL predicts CKD progression.47 
MCP-1 (13-30 kDa) is expressed by inflammatory cells such as monocytes, 
and also by resident renal  cells, i.e. mesangial, endothelial, and tubular 
epithelial cells.48 Renal cells produce MCP-1 in response to a variety of pro-
inflammatory stimuli.49 Elevated urinary MCP-1 predicts the rate of renal 
function loss in CKD.50 
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Consequences?
Despite all  the evidence that albuminuria is an important and independent 
predictor of cardiovascular and renal outcomes in a diversity of populations, 
including the general population, the question whether albuminuria is all  you 
need to predict outcomes in CKD, should be answered with a ‘no’. To reliably 
predict outcomes one should, of course, also have information on other 
parameters, including eGFR, blood pressure, diabetes status and underlying 
renal disease. The fact that albuminuria predicts cardiovascular and kidney 
outcomes independent of baseline eGFR implies that measurement of 
albuminuria should at least be part of screening programs for CKD. It is 
argued that measurement of albuminuria could be used as a first step in 
screening programs to identify high-risk CKD individuals instead of 
measurement of eGFR. It may well be that albuminuria adds to the predictive 
value of eGFR because albuminuria is not only related to glomerular 
damage, but also relates to tubular damage. As such it would be interesting 
to study whether (other) tubular markers will  further improve the ability of 
albuminuria and eGFR to predict outcomes in CKD.
Aims of the thesis
The general  aim of this thesis was to explore whether measuring the 
aforementioned renal damage markers may have value in addition to 
measuring the at present clinically used damage marker, albuminuria. 
Several  purposes of use can be thought of. For instance, these markers 
could be of help in identifying patients with early tubulo-interstitial damage. 
Second, these markers could be useful in predicting renal prognosis. Third, 
they could potentially be used as markers to monitor the effect of medication.
Outline of the thesis
In chapter 2 damage markers of glomerular and tubular function were 
measured in a cohort of patients with diabetes mellitus. First, it was 
investigated how these damage markers correlate to renal damage, 
assessed as eGFR and albuminuria. A significant correlation between 
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damage marker and eGFR and albuminuria indicates that a marker is 
promising to study progression of renal disease. Second, it was investigated 
whether these damage markers are already elevated before albuminuria 
starts to rise. This would suggest that these markers are very early and 
sensitive markers of renal damage. Finally, we looked whether the damage 
markers under investigation are independently of albuminuria associated 
with GFR, since this might indicate whether these markers will add to the 
predictive capacity of albuminuria. 
Importantly, all damage markers were measured in fresh urine samples. In 
epidemiological  research, however, most studies use samples that have 
been stored frozen during prolonged periods of time. Previously it has been 
shown that frozen storage during 1 year is associated with a decrease in 
urinary albumin concentration, with a wide variation between urine samples 
in the amount to which albumin decreases.51;52  These storage effects are of 
importance, as is has been shown that the value of urinary albumin excretion 
to predict mortality is considerably better when assessed in fresh urine 
samples in comparison to when assessed in the same samples after 
prolonged frozen storage.53  Therefore in chapter 3 it is investigated whether 
alkalinisation of urine samples before freezing preserves albumin 
concentration. We stored unadjusted and alkalized urine samples of patients 
with diabetes mellitus for 1 year at -20º C and at -80º C. After 1 year of 
frozen storage we measured albumin concentration again.
Since we planned to further investigate whether specific tubular damage 
markers add to the predictive capacity of albuminuria, it was examined 
whether these markers can reliably be measured from urine samples that 
have been frozen stored for prolonged periods of time.  Therefore we 
investigated in chapter 4 the effect of frozen storage on urinary renal 
damage markers. First we measured urinary damage markers fresh, after 1 
week, after 6 months and after 1 year of frozen storage to see whether a 
potential  decline will stabilize. Second, it was similarly as in chapter 3 
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investigated whether the effect of 1 year frozen storage at -80º C and -20º C 
can be influenced by different storage protocols. 
As discussed in chapter 2 it may be that urinary damage markers predict 
renal outcome in addition to albuminuria. Therefore it is investigated in 
chapter 5 whether specific  damage markers predict renal outcome defined 
as progression of renal function loss or need for renal replacement therapy 
in a cohort of 606 renal transplant recipients. In this cohort with a median 
follow-up of almost 5 years we compared different urinary damage markers 
to proteinuria and albuminuria, the two as yet in clinical  practice most used 
markers for risk prediction. It was examined whether these markers add to 
the predictive capacity of proteinuria or albuminuria in predicting graft failure 
and renal function loss. 
Progression of CKD can be assessed as a decrease in GFR (as investigated 
in chapter 5) or as an increase in albuminuria. The latter is a relevant 
outcome since it has been shown that a rise in albuminuria is associated 
with a worse cardiovascular54 and renal prognosis.55 In chapter 6 therefore 
the value of these markers to predict outcome defined as progression of 
albuminuria during follow-up is investigated in the PREVEND cohort. This 
cohort of 8592 participants is selected from the general population. They are 
followed over time during serial screenings, with an average follow-up of 9.3 
years. 
Besides predicting outcome, tubular damage markers may also be of help to 
monitor the effect of treatment on short term basis. That is why in chapter 7 
the effect of various antiproteinuric regimens (i.c. dietary sodium restriction 
and addition of an angiotensin II receptor blocker (ARB)) on renal damage 
markers is investigated in 52 non-diabetic patients with chronic kidney 
disease. We investigated whether these antiproteinuric interventions are also 
followed by decrease in renal damage markers. Furthermore we looked 
whether intensified reduction of proteinuria to levels below 0.3 gram/day by 
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combinations of ACE inhibition, ARB and dietary sodium restriction, is 
accompanied by normalisation of tubular damage markers in these patients.
Chapter 8 summarizes all studies performed, integrates them into current 
literature and tries to answer the question whether assessment of urinary 
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We investigated in a cross-sectional study the levels of serum and urinary 
damage markers in patients with diabetes (n=94) and non-diabetic controls 
(n=45) to study the association of glomerular (IgG), proximal tubular (KIM-1, 
NAG, NGAL, cystatin C) and distal  tubular damage (H-FABP) markers with 
kidney disease severity as assessed by albuminuria and eGFR. 
Damage markers were measured in triplicate in fresh morning urine samples 
and in plasma. 
Of the diabetes patients, 41 were normo-, 41 micro- and 12 macro-
albuminuric. Urinary NAG (9 fold), NGAL (1.5 fold) and H-FABP (3.5 fold) 
were significantly elevated in normoalbuminuric diabetic  patients compared 
to non-diabetic controls. Urinary concentrations of all markers increased per 
albuminuria stratum, except KIM-1. All urinary damage markers except KIM1 
were significantly associated with albuminuria, independent of age, sex and 
plasma concentrations of the corresponding biomarker (Std βs between 0.35 
and 0.87; all p<0.001). All  urinary damage markers except KIM-1 were 
significantly associated with eGFR in univariate models (Std βs between 
-0.38 and -0.21; all  p<0.04). After adjustment for age, sex, plasma 
concentration of the corresponding damage marker and albuminuria, only 
the association of H-FABP with eGFR remained significant (Std β -0.26, 
p=0.037).
Glomerular and tubular markers are associated with albuminuria, 
independently of eGFR, suggesting that albuminuria reflects both glomerular 
and tubulo-interstitial damage. Only urinary H-FABP is associated with eGFR 
independently of albuminuria and therefore may be a promising urinary 
damage marker to assess diabetic kidney disease.
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Introduction
Diabetic nephropathy occurs in 20-40% of patients with diabetes mellitus 
and is the leading cause of chronic  kidney disease and end-stage renal 
disease in the United States and many other western countries.1;2 The onset 
of elevated levels of urinary albumin excretion is an early sign of diabetic 
nephropathy. Various studies have shown that in subjects with diabetes 
micro-albuminuria predicts the occurrence of macro-albuminuria and renal 
function decline.3 As a result, high albuminuria has become an established 
renal risk marker in these patients.4 
Classically, albuminuria is regarded as the consequence of diabetes-induced 
glomerular damage. More recently, it is increasingly appreciated that the 
renal tubulo-interstitium plays a role in the pathogenesis of diabetic 
nephropathy, with prolonged exposure to a variety of metabolic  and 
hemodynamic injuring factors associated with sustained diabetic disease as 
contributing factors.5;6 Furthermore, persistent albuminuria secondary to 
glomerular lesions, may be directly harmful to renal  tubular cells, leading to 
tubular inflammation and tubulo-interstitial fibrosis.7;8 
Several  tubular damage markers have recently been discovered. Increased 
levels of these markers are supposed to indicate proximal  tubular damage in 
the case of KIM-1, NGAL, NAG, cystatin C, and distal tubular damage in the 
case of H-FABP. These tubular damage markers have been extensively 
investigated in the field of predicting the occurrence of acute kidney injury 
after various nephrotoxic  insults, such as ischemia during cardiac  surgery, 
sepsis and administration of contrast medium.9-11 Little research has yet 
been done in patients with chronic  kidney disease. In this study we 
investigated the serum and urinary levels of the aforementioned damage 
markers in patients with diabetes and non-diabetic  controls in order to 
investigate the relation of these markers to the severity of kidney disease as 
assessed by albuminuria and eGFR. As a secondary aim we investigated 
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Patients with type 1 and 2 diabetes visiting a diabetes specialty clinic  were 
recruited. Inclusion was between April  2009 and September 2009. They 
were stratified by the amount of albuminuria, based on a first morning urine 
void. We included 94 diabetic  patients, of whom 41 had normo-albuminuria, 
41 had micro-albuminuria and 12 had macro-albuminuria. To ensure that 
macro-albuminuria was the consequence of diabetic  nephropathy, patients 
with macro-albuminuria were required to have diabetic retinopathy. Patients 
with cancer, infections or inflammatory conditions, renal  disease other than 
diabetic nephropathy, use of nephrotoxic drugs, renal  transplantation or 
pregnancy were excluded. Patients younger than 18 years of age were also 
excluded. As control group we included 45 non-diabetic subjects without 
chronic kidney disease (1:2 versus diabetic  patients). Subjects were 
excluded from the control group if they had a fasting glucose > 7.0 mmol/L, 
used glucose lowering medication, had an eGFR<60 ml/min/1.73m2 or an 
ACR>30 mg/g. The study protocol was approved by the local Ethics 
Committee. 
Measurements
We instructed patients to collect their first morning urine void on the day of 
their clinic  visit. Blood pressure was assessed with a single measurement. 
Urinary albumin concentration was determined by nephelometry (BNII; Dade 
Behring Diagnostics, Marburg, Germany). Serum and urine creatinine were 
measured with an enzymatic creatinine assay (Roche, Mannheim, 
Germany). Glucose, HbA1c and cholesterol levels were measured with 
standard laboratory testing. 
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Definitions
We defined history of cardiovascular disease as having had myocardial 
infarction, stroke or surgery or endovascular treatment for coronary carotid 
or peripheral (legs, abdominal, aorta) artery disease. Hypertension was 
defined as systolic  blood pressure >140 mmHg, a diastolic blood pressure > 
90 mmHg or use of blood-pressure-lowering medication. Normo-albuminuria 
was defined as urinary albumin to creatinine ratio (ACR) <3 mg/mmol, 
microalbuminuria as ACR 3-30 mg/mmol and macro-albuminuria as ACR 
>30 mg/mmol.12 Serum creatinine values were used to calculate an 
estimated glomerular filtration rate (eGFR), using the abbreviated MDRD 
formula. 
Damage markers
We measured immunoglobulin G (IgG) as glomerular damage marker. As 
markers of proximal  tubular damage we measured Kidney Injury Molecule 1 
(KIM-1), neutrophil gelatinase-associated-lipocalin (NGAL), N-acetyl-beta-D-
glucosaminidase (NAG) and Cystatin C. As a marker of distal tubular 
damage Heart Fatty Acid Binding Protein (H-FABP) was measured. Urinary 
concentrations of KIM-1, NGAL, H-FABP and IgG were measured by ELISA. 
For KIM-1 and NGAL, antibodies were obtained from R&D systems, 
Minneapolis, USA. H-FABP and IgG antibodies were obtained from Hytest, 
Finland. We measured urinary concentration of NAG using a modified 
enzyme assay according to Lockwood and corrected for nonspecific 
conversion (HaemoScan, Groningen, the Netherlands). Cystatin C was 
measured by nephelometry (reagents obtained from Siemens, Marburg, 
Germany). We measured all samples in triplicate in fresh samples of both 
urine and plasma. Urinary damage marker concentrations are expressed per 
mmol creatinine. 
Statistical analyses
Analyses were performed with SPSS version 16.0 (SPSS Inc., Chicago, IL). 
Characteristics were calculated per albuminuria stratum. Parametric 
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variables were expressed as mean ± standard deviation (SD), whereas non-
parametric variables were given as median (interquartile range). We tested 
pvalue for trend over albuminuria strata in diabetic patients using ANOVA for 
normal distributed variables. For non-normal  distributed variables we used a 
Kruskall-Wallis test. Logarithmic  transformation of damage marker excretion 
was applied. To investigate the association between the individual damage 
marker and eGFR or albuminuria we performed a linear regression analysis 
by using eGFR or albuminuria as independent variable and the various 
damage markers as dependent variable. Various models were gradually built 
to adjust for possible confounding. First, we investigated the crude 
association between damage marker and eGFR or albuminuria. Second, we 
performed multivariate analysis, adjusting for age and sex. Third, we tested 
whether plasma levels of the corresponding damage marker influenced the 
association between damage marker and eGFR or albuminuria. Lastly, to 
investigate whether knowledge on urinary damage marker concentration 
may be of value to assess severity of diabetic  kidney disease in addition to 
knowledge on albuminuria status, we performed multivariable regression 
analysis with eGFR as dependent variable and damage markers as 
independent variables, adjusting for albuminuria. We added the use of 
diuretics, use of ACEi/ARB and type of diabetes mellitus to the final 
multivariable models (model 3 for albuminuria and model 4 for eGFR) as 
sensitivity analysis. If any of these covariates showed a significant 
association with either albuminuria or eGFR, we tested for interaction by 
entering the urinary biomarker, the investigated characteristic, and their 
product term in the multivariable regression model. For all analyses, a two-
sided p < 0.05 was considered to indicate statistical significance. 
Results
A total  of 94 patients with DM and 45 controls participated in this study. 
Characteristics of patients and controls are given in table 1. Patients in the 
micro- and macro-albuminuric groups were more often male and smoking, 
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more often had a history of cardiovascular disease, used more 
antihypertensive medications and had a lower eGFR when compared to 
normo-albuminuric diabetic subjects.
Table 1 Characteristics of non-diabetic control subjects (n=45) and diabetic patients (n=94) 
according to albuminuria stratum
Subjects with DM
Non-diabetic Normo Micro Macro p-value in DM
N 45 41 41 12
Age (y) 53 (13) 59 (13) 64 (12)*** 63 (13)* 0.12
Male gender (%) 56% 73% 66% 83% 0.48
Duration DM (y) - 24 (11) 20 (9) 27 (8) 0.064
Type diabetes
(% type 2) - 49% 78% 83% 0.007
History CVD (%) 0% 22% 45% 64% 0.018
Smoking (%) 22% 10% 32% 33% 0.035
BMI (kg/m2) 27 (6) 30 (5)* 32 (6)** 32 (5)* 0.28
SBP (mm Hg) 132 (16) 139 (15)* 141 (17)** 152 (14)*** 0.052
DBP (mm Hg) 74 (9) 78 (10) 77 (77) 77 (13) 0.90
Antihypertensive 
medication (%) 18% 72%*** 95%*** 100%*** 0.006
- ACEi/ARB (%) 4% 65%*** 80%*** 83%*** 0.24
- Diuretics 11% 32%*** 63%*** 75%*** 0.015
Hypertension (%) 36% 85%*** 97%*** 100%*** 0.071
HbA1c (%) 5.4 (0.3) 7.7 (1.0)*** 7.6 (1.3)*** 7.8 (0.7)*** 0.87
eGFR MDRD (ml/min/
1.73 m2) 86 (14) 85 (21) 72 (22)** 55 (24)** <0.001







Parametric variables are expressed as mean ± standard deviation (SD) and non-parametric 
variables are given as median (interquartile range). *p<0.05, **p<0.01 and ***p<0.001 versus 
non-diabetic controls, calculated using independent sample t-test for normal distributed 
variables and Mann-Whitney U test for non-normal distributed variables. Abbreviations are: 
ACEi/ARB, ACE inhibitors or angiotensin receptor blockers; DM, diabetes mellitus; SBP, systolic 
blood pressure; DBP, diastolic blood pressure; BMI, body mass index; CVD, cardiovascular 
disease; ACEi/ARB, use of Angiotensin Converting Enzyme Inhibitors; ARB, Angiotensin 
Receptor Blockers; eGFR, estimated Glomerular Filtration Rate; ACR, Albumin Creatinine Ratio.
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Damage marker concentrations
Damage marker concentrations in non-diabetic controls and in diabetic 
patients are shown in table 2 and figure 1. Urinary damage marker 
concentrations of NAG, NGAL and H-FABP were higher in normo-
albuminuric patients with diabetes than in controls and increased with 
increasing categories of albuminuria in patients with diabetes. In contrast, 
cystatin C was lower in normo-albuminuric diabetic  patients than in non-
diabetic controls, but again increased with increasing categories of 
albuminuria in patients with diabetes. KIM-1 was higher in normo-
albuminuric patients with diabetes than in controls, but was not different 
between the categories of albuminuria in patients with diabetes (Figure 1 
and table 2). Differences between categories of albuminuria were most 
pronounced for the glomerular marker IgG (>30 fold increase from normo-
albuminuria to macro-albuminuria) and the distal tubular marker H-FABP 
(>21 fold). Differences were less pronounced for the proximal  tubular 
markers (from no increase to 8.5 fold for NGAL). Plasma concentrations of 
the various markers are given in supplemental table 1.
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Table 2 Damage marker concentrations in nondiabetic control subjects and in diabetic patients 
according to albuminuria stratum
Subjects with DM










































































Data are expressed per mmol urinary creatinine concentration and given as medians (25th-75th 
percentile) *p<0.05, **p<0.01 and ***p<0.001 versus non-diabetic controls, calculated using 
Mann-Whitney U test.
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Figure 1 Biomarker concentrations in nondiabetic controls subjects and in diabetic patients, 
according to albuminuria stratum (normoalbuminuria, microalbuminuria and macroalbuminuria). 
Box plots show medians (25th-75th percentile). Significance was tested using the Mann-Whitney 
U test.
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Associations of damage markers with albuminuria in diabetic patients
Associations between the various urinary damage markers and albuminuria 
were analyzed in all diabetic patients. All  damage markers were found to be 
significantly associated with albuminuria in crude models, except for KIM-1 
(table 3, model  1). Also, the results did not materially change when adjusted 
for age and sex (model  2), and additionally for the plasma concentration of 
the corresponding damage marker (model 3) and for eGFR (model 4). All 
investigated damage markers except KIM-1 remained associated with 
albuminuria. When information on use of diuretics, use of ACE-inhibitors/
ARB’s or type of diabetes was added to the multivariable regression 
analyses, only the type of diabetes was a significant covariate for the 
association between urinary KIM-1, NAG, NGAL, cystatin C and H-FABP 
with albuminuria. Sex was a significant covariate in only the association 
between NGAL and albuminuria. We subsequently tested for interaction 
between these covariates and these damage markers in their association 
with albuminuria. Of all tested interactions terms only the one between sex 
and NGAL reached statistical significance. 
Associations of damage markers with eGFR in diabetic patients
Table 3 also shows the associations between the various urinary damage 
markers and eGFR. Again, all  damage markers, except KIM-1, were 
significantly associated with eGFR in crude models (model 1). However, 
when adjusted for age and sex, only albumin, the glomerular marker IgG, the 
proximal  tubular markers NGAL and cystatin C and the distal  tubular marker 
H-FABP remained significantly associated with eGFR (model  2). When 
additionally adjusted for plasma concentration of the corresponding damage 
marker, IgG, albumin, NGAL and H-FABP remained significant, whereas 
cystatin C lost significance. The association between the distal tubular 
marker H-FABP and eGFR was the only one that remained significant, after 
further adjustment for albuminuria (std β -0.26, p-value=0.037). When 
information on sex, use of diuretics, use of ACE-inhibitors/ARBs or type of 
diabetes was added to the multivariable regression analyses, only sex was a 
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significant covariate for the association between urinary cystatin C with 
eGFR, but no significant interaction was found between sex and urinary 
cystatin C.
Table 3 Multivariable regression analysis of various damage markers vs albuminuria or eGFR
Damage markers vs. albuminuria
IgG KIM-1 NGAL Cys C NAG H-FABP
Model Std. β p Std. β p Std. β p Std. β p Std. β p Std. β p
1 0.78 <0.001 0.15 0.195 0.34 0.001 0.49 <0.001 0.37 <0.001 0.48 <0.001
2 0.80 <0.001 0.13 0.252 0.42 <0.001 0.51 <0.001 0.37 <0.001 0.49 <0.001
3 0.87 <0.001 0.12 0.311 0.45 <0.001 0.35 0.001 0.60 <0.001 0.50 <0.001
Damage markers vs. eGFR
Alb IgG KIM-1 NGAL Cys C NAG H-FABP
Model Std. β p Std. β p Std. β p Std. β p Std. β p Std. β p Std. β p
1 -0.37 <0.001 -0.35 0.034 -0.13 0.24 -0.38 <0.001 -0.26 0.012 -0.32 0.002 -0.34 0.001
2 -0.32 <0.001 -0.34 0.026 0.03 0.74 -0.29 0.004 -0.28 0.002 -0.19 0.053 -0.35 <0.001
3 -0.32 0.001 -0.39 0.018 -0.08 0.42 -0.26 0.014 -0.08 0.21 -0.23 0.074 -0.36 0.001
4 - - 0.03 0.91 0.11 0.27 -0.11 0.311 0.07 0.30 0.02 0.91 -0.26 0.037
Bold print shows associations between damage markers and albuminuria or eGFR that reach 
statistical significance. Model : crude; model 2: adjustment for age and sex; model 3: adjustment for 
age, sex, and plasma concentration of the corresponding damage marker; model 4: adjustment for 
age, sex, plasma concentration of the corresponding damage marker and albuminuria.
Discussion
In the present study, we measured markers of glomerular, proximal tubular 
and distal  tubular damage to study the relationship between these damage 
markers with the severity of diabetic kidney disease as assessed by 
albuminuria and estimated glomerular filtration rate. We found that urinary 
concentrations of glomerular, proximal tubular and distal  tubular damage 
markers were higher when patients had more albuminuria. Interestingly, 
even in normo-albuminuric  diabetic patients some of these markers were 
already elevated compared to non-diabetic  subjects. In regression analyses, 
all  damage markers that were significantly associated with albuminuria were 
also significantly associated with eGFR, except cystatin C and NAG. H-
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FABP was the only damage marker significantly associated with eGFR after 
adjustment for albuminuria. 
In the diabetic patients, the urinary concentration of the investigated 
glomerular damage marker IgG increased over the three albuminuria groups 
and is strongly associated with albuminuria. In healthy subjects, only trace 
amounts of these large molecular weight proteins are leaked by the 
glomerulus. These data suggest therefore that in albuminuric  diabetic 
patients the amount of albuminuria reflects glomerular damage at least to a 
certain extent. Similar observations have been described before.13;14
In general, all investigated tubular markers except KIM-1 increased in higher 
albuminuria strata. Only a limited number of studies have to date 
investigated the association of tubular markers with the severity of chronic 
kidney disease in diabetic nephropathy. Our results with respect to the 
proximal  tubular markers are similar to these studies insofar that they also 
showed that the urinary level of tubular damage markers parallels the degree 
of urinary albumin excretion.15-18 It can be argued that this may be due to the 
tubulotoxic  effect of albumin and other proteins that are leaked into the 
tubular lumen7. However, such tubulotoxic  effects cannot fully explain our 
findings, since some of the markers under investigation were already 
increased in the normo-albuminuric  diabetic patients compared to non-
diabetic  controls, whereas albuminuria (and eGFR) in these normo-
albuminuric diabetic  patients was comparable to non-diabetic  controls. A 
limited number of other studies have previously described elevated levels of 
tubular markers in normo-albuminuric diabetic subjects when compared to 
healthy controls17-19. Urinary excretion of NGAL and lysosomal enzymes as 
NAG and cathepsin have for instance been found to be increased. These 
data suggest a role of the tubulo-interstitium in the pathogenesis and 
progression of renal  damage in patients with diabetes mellitus. This 
assumption is strengthened by two other observations in our study. First, we 
found that some of these markers were associated with diabetes related 
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factors in normo-albuminuric diabetic subjects, such as BMI, duration of 
diabetes and metabolic regulation. Second, to our knowledge we are the first 
to show that a marker of distal tubular damage, H-FABP, is also associated 
with albuminuria, despite the fact that the distal  tubule is assumed less 
sensitive to toxic effects of urinary proteins.
Data in literature also support that in diabetic  kidney disease the severity of 
chronic kidney disease depends not only on the severity of glomerular 
lesions, but also on tubulo-interstitial  damage. A histological study showed 
that proximal tubular basement membrane width is already thickened 
compared to healthy controls in normo-albuminuric diabetic  patients.20 
Another study in micro-albuminuric diabetic  patients with similar GFR 
showed that only 29% had typical histological  glomerular features of diabetic 
nephropathy, whereas 42% had severe tubulo-interstitial  lesions 
disproportional to the mild glomerular involvement.21 
All  markers that were associated with albuminuria were also correlated with 
eGFR in crude models. However, the association of eGFR with urinary NAG 
concentration lost significance after adjustment for age and sex, and the 
association with urinary cystatin C lost significance after additional 
adjustment for its plasma concentration. In healthy subjects cystatin C is a 
marker for eGFR, with impaired GFR being associated with higher levels of 
cystatin C. Our data imply that the urinary concentration of cystatin C is 
largely determined by the amount that is filtrated through the glomerulus in 
subjects with diabetic nephropathy. 
As secondary aim in our study, we investigated which damage markers are 
associated with eGFR independent of albuminuria. Albuminuria is widely 
acknowledged to be associated with eGFR in subjects with diabetic 
nephropathy.3;22 We found that the associations of all markers under 
investigation with eGFR lost statistical significance when adjusted for 
albuminuria, except for HFABP. In addition, we found that urinary H-FABP 
concentration was already significantly elevated in normo-albuminuric 
patients with diabetes mellitus compared to non-diabetic control  patients 
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whom had a similar eGFR. These data suggest that urinary H-FABP 
concentration is a promising marker to predict clinical  outcome of diabetic 
nephropathy in addition to albuminuria. 
We acknowledge that the present study has limitations. First, the present 
study is a single-centre study and the association of the measured damage 
markers with albuminuria and eGFR needs to be confirmed. Second, this 
study has a cross-sectional  design. Whether or not the damage markers as 
assessed in our study predict progression of diabetic nephropathy has to be 
investigated in longterm, prospective, observational studies. Lastly, a larger 
number of patients would have allowed us to perform analyses in specific 
subgroups. However, the results of our multivariable regression analyses in 
which interactions were tested showed that there were almost no significant 
interactions between these covariates and the various urinary damage 
markers in their association with albuminuria or eGFR. This suggests that 
the associations between these damage markers and albuminuria or eGFR 
are not different in men versus women, in subjects using or not using 
diuretics, in subjects using or not using ACEi/ARBs, nor in type 1 versus type 
2 diabetes mellitus. Strengths of this study are that we measured a wide 
range of kidney damage markers, representing different parts of the 
nephron, ranging from glomerulus, proximal to distal  tubule. Furthermore, we 
measured all our markers in fresh urine samples to assure optimal sample 
quality. It has previously been shown for several markers that frozen storage 
and freeze-thaw cycles lead to a systematic  decrease and increase in 
variability,9;23;24 which may negatively influence association studies such as 
the present one. Finally, most authors investigating urinary excretion of renal 
damage markers did not measure plasma concentrations.9;25 We also 
measured the corresponding plasma concentration of all urinary markers to 
rule out that a high plasma concentration instead of renal  damage causes a 
high urinary concentration. This appeared to be the case for cystatin C.
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In conclusion, urinary concentrations of most investigated damage markers 
are elevated in patients with diabetes mellitus when compared to non-
diabetic controls. These damage markers are associated with the severity of 
diabetic nephropathy as assessed by albuminuria and eGFR. Interestingly, 
some of these markers are already elevated in normo-albuminuric  diabetic 
patients with normal eGFR. This renders these proteins as potential 
sensitive markers of early diabetic kidney damage. Only the distal tubular 
marker H-FABP was found to be associated with eGFR independent of 
albuminuria, suggesting that especially measuring urinary H-FABP 
concentration may be useful  to assess severity of diabetic kidney damage in 
addition to measuring albuminuria. 
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Supplemental table











- IgG (mg/ml) 6.3 (4.4-40.7) 21.8 (5.2-39.9) 7.0 (2.2-32.2) 0.80
Proximal tubular
- KIM-1 (ng/ml)) 0.05 (0.0-0.32) 0.16 (0.07-0.30) 0.19 (0.07-0.28) 0.88
- NAG (U/L) 31.8 (23.3-39.7) 32.6 (24.5-48.2) 23.2 (18.5-35.3) 0.19
- NGAL (ng/ml) 197 (117-323) 188 (131-288) 245 (193-430) 0.52
- CysC (mg/L) 0.79 (0.68-0.89) 1.00 (0.80-1.17) 1.30 (1.17-1.44) <0.001
Distal tubular
- H-FABP (ng/ml) 0.84 (0.36-2.63) 1.11 (0.00-2.53) 1.94 (0.47-17.08) 0.001
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In epidemiological studies in patients with diabetes, urine samples are often 
stored frozen prior to assessment of urinary albumin concentration (UAC). 
However, prolonged frozen storage may result in a falsely low urinary 
albumin concentration. In the current study, we investigated whether 
adjustment of urinary pH to alkaline values prior to frozen storage can 
prevent this problem. Urine samples were collected in 90 patients from our 
diabetes outpatient clinic and divided into two portions. One portion was first 
adjusted to pH > 8.0 with 0.1M sodiumhydroxide, the other was left 
unprocessed. Both portions were divided into aliquots. Urinary albumin 
concentration was assessed in fresh samples and after 7 days, 1, 6 and 12 
months of storage at -20 and -80 ºC. 
Until  1 month of storage there were no significant changes in urinary albumin 
concentration. After longer storage, urinary albumin concentration fell 
significantly in pH unadjusted samples stored at -20 ºC, with a -7.6% (27.8) 
and -13.6% (31.7) change after 6 and 12 months storage, respectively. No 
significant change in UAC occurred in pH adjusted samples stored at -20 ºC 
or when samples were stored at -80 ºC, both with and without pH 
adjustment. Variation in UAC assessed after 12 months of storage was 
larger for samples stored at -20 ºC without adjustment of pH than for the 
samples stored with pH adjustment or stored at -80 ºC.
Urine alkalinization to pH > 8.0 prevents the decline in UAC associated with 




In today’s practice of diabetes care, albuminuria has become an important 
marker for assessment of cardiovascular and renal  risk and, as such, is used 
as a predictor of events and an intermediate endpoint in epidemiological 
studies and intervention studies respectively.1-3 In epidemiological and 
intervention studies, urine samples are often stored frozen at -20º C for 
prolonged periods of time before assessment of urinary albumin 
concentration (UAC).4;5 The advantages are increased control on logistics 
and prevention of analytical day-to-day variation and drift. Although some 
studies found no effect of frozen storage on UAC6-8, others found 
erroneously low values, in particular if storage was for 6 months or longer.9-12 
Importantly, the decline in UAC during frozen storage has been reported to 
vary greatly between samples, making the decline for an individual sample 
very unpredictable.13;14 This variation in decline ultimately impairs the 
prognostic property of increased urinary albumin levels and results in loss of 
power for detection of effects on albuminuria as an intermediate endpoint in 
intervention studies.15 In a previous study, we found that urinary pH is a 
determinant of the decline in UAC during frozen storage at -20º C, with the 
largest declines at pH 5.0, whereas albumin in urine with pH 8.0 did not 
decline.16 In the current study, we investigated whether adjustment of urinary 
pH to > 8.0 prior to freezing prevents the decline in UAC during frozen 
storage at -20º C. Other aims were to investigate whether urinary 
alkalinization reduces the variation in decline in UAC and to make a 
comparison with storage at -80º C.
Patients and methods
Study population and urine samples
Urine samples were collected from patients with diabetes mellitus (both type 
1 and type 2), who visited the outpatient diabetes clinic  at the University 
Medical Center Groningen. During their visit to the outpatient department, 
participants were instructed to collect a spot midstream urine sample. 
Samples with a fresh urinary albumin concentration <5.0 mg/l were excluded 
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to ensure that a potential  decline in urinary albumin concentration could be 
detected, given the lower limit of detection of the assay of 2.4 mg/l. Urine 
samples were divided into two portions. One portion was adjusted to pH 
> 8.0 with 1 m sodium hydroxide; the other portion was left unprocessed. 
The amount of added sodium hydroxide was calculated by weighing the 
urine sample before and after addition of sodium hydroxide. This was carried 
out to correct UAC for the added volume. Both urine portions were 
subsequently divided into several aliquots. Urinary albumin was assessed in 
fresh, pH unadjusted and adjusted urine samples within 2 h after collection 
(reference value). Other portions of fresh urine were stored in polystyrene 
vials for assessment after storage at -20 and -80º C for 7 days, 1, 6 and 12 
months. In addition, the intra-assay coefficient of variation (CV) was 
calculated in fresh pH adjusted and unadjusted samples. To reassess the 
intra-assay CV after 12 months, three portions of both pH adjusted and pH 
unadjusted urine samples were stored at -20 and -80º C. Handling of fresh 
and frozen urine samples, including hand inversion and centrifuging before 
analysis by nephelometry, was performed as described previously.16
Laboratory methods Urinary albumin concentration was measured using a 
Behring BNTM II immunonephelometer (Dade Behring, Marburg, Germany). 
The variability encountered with calibration and reagent lots ranged between 
1.6–4.5 and 1.1–2.4%, respectively. The intra- and interassay CV were 2.1% 
and 4.5% respectively.17 The lower limit of detection was 2.4 mg/l. To assess 
the change in albumin : creatinine ratio over time, urinary creatinine 
concentrations were also measured. Urinary creatinine was determined by 
an enzymatic method (Modular Analytics SWA; Roche, Tokyo, Japan) with 
intra-assay and interassay CV evaluated in our laboratory of 1.9% and 2.1%, 
respectively. Urinary pH was determined by a combined pH electrode 
connected to a C833 multi-channel analyser (Consort, Turnhout, Belgium).
Statistical analyses
Data are presented as mean ± standard deviation, or mean (range) where 
appropriate. In case of skewed distribution, data are presented as median 
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(interquartile range). Differences among groups were assessed by anova 
and differences between groups by post-hoc  analysis according Tukey. 
Linear regression analysis was used to assess the association between 
baseline urinary pH and percentage change in urinary albumin concentration 
after 12 months’ frozen storage. The amount of variation in assessed UAC 
after frozen storage was calculated for each storage condition with the 
formula: P absolute (percentage change in UAC individual sample—mean 
change UAC) and tested for statistical significance by means of a paired 
Student’s t-test. Two sided P-values ≤ 0.05 were considered to indicate 
statistical significance.
Results
Ninety urine samples from patients with diabetes [age 50.4 ± 16.8 years, 
65.1% males, glycated haemoglobin (HbA1c) 8.3 ± 1.3%, systolic blood 
pressure 138 ± 17 mmHg] were collected between July and December 2006. 
Fresh unadjusted urinary pH was 5.9 (range 4.8–7.4). To alkalinize the urine 
samples, 0.02 ± 0.016 ml 1 m sodium hydroxide was added per ml urine, 
resulting in a urinary pH of 8.4 (range 8.0–9.7) after adjustment (P < 0.001 
vs. fresh). Before adjustment of pH, fresh UAC and urinary creatinine 
concentration were 15.5 mg/l (8.6–39.4) and 1.25 ± 0.7 g/l, respectively, 
compared with 15.6 mg/l (8.5–38.9) and 1.22 ± 0.7 g/l after adjustment (P = 
0.67 for difference in UAC and P = 0.10 for difference in urinary creatinine 
concentration). Percentage changes in UAC during frozen storage are 
shown in Fig. 1. Until 1 month of storage, no significant changes were 
observed compared with fresh samples (reference values). In samples that 
were stored at -20º C without adjustment of pH, UAC decreased significantly 
by 7.6 ± 27.8 and 13.6 ± 31.7% after 6 and 12 months of storage, 
respectively.
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!Figure 1 Percentage change in urinary albumin concentration (UAC) during the study in pH 
unadjusted and in adjusted samples stored at -20 and -80 ºC. Percentage change in UAC 
compared with fresh samples after 6 and 12 months’ frozen storage are shown.  
Baseline urinary pH significantly predicted change in UAC in these samples, 
both at 6 months (R2 = 0.10, P < 0.01) and 12 months (R2 = 0.18, P < 0.01) 
of storage. In samples in which pH was adjusted prior to storage at -20º C, 
decline in UAC was completely prevented, both at 6 and 12 months of 
storage (Fig. 1). The same was true for samples stored at -80º C, 
irrespective whether pH was adjusted or not. The percentage change in UAC 
assessed after 6 and 12 months’ frozen storage varied widely in samples 
stored at -20º C without prior pH adjustment (Fig. 2a; data for 12 months 
storage are shown). The variation in change in UAC after 6 and 12 months’ 
storage at -20º C was, to a large extent, prevented in urine samples in which 
the pH was adjusted. The Σ absolute (percentage change in UAC individual 
sample—mean change UAC) after 12 months of storage at -20º C in pH 
unadjusted and adjusted samples was 2315% and 715%, respectively 
(P < 0.001). Storage at -80º C also reduced the variation in change in UAC 
after 12 months, irrespective of whether pH was adjusted or not (both P < 
0.001 vs. storage at -20º  C).The intra-assay CV after 12 months of storage 
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at -20º C was slightly higher compared with fresh samples (4.2% vs. 2.1%, 
respectively; P < 0.01), whereas it remained unchanged in alkalinized 
samples stored at -20º C (2.9% vs. 2.7%, respectively; P = 0.61) or samples 
stored at -80º C (2.6% vs. 2.1%, P = 0.27).
Current diabetes and nephrology guidelines advocate measurement of the 
urinary albumin : creatinine ratio rather than UAC alone.1;18 To determine 
change in the albumin : creatinine ratio, we measured urinary creatinine 
concentrations. Change in urinary creatinine concentration after 12 months 
at the various storage conditions was -0.8 ± 10.9% at -20º C, 0.4 ± 4.5% at 
-20º C pH > 8.0, 1.2 ± 4.8% at -80º C and 2.6 ± 8.9% at -80º C pH> 8.0 
(P = NS vs. zero for all storage conditions). As urinary creatinine 
concentrations did not change significantly, the percentage change in the 
albumin : creatinine ratio after 12 months’ storage was comparable with the 
percentage change in UAC (Fig. 2b).
!
Figure 2 Percentage change in UAC and albumin:creatinine ratio after 12 months storage in pH 
unadjusted and adjusted samples stored at -20°C and -80°C.
51
Discussion
In the present study, we found that urine alkalinization to pH > 8.0 
completely prevents the decline in UAC otherwise observed during 
prolonged frozen storage of urine samples of patients with diabetes at -20º 
C. Importantly, after alkalinization, storage at -20º C was equivalent to 
storage at -80º C, both in terms of recovery of urinary albumin and variability 
between individual samples. Urine alkalinization is a relatively simple and 
cheap method to preserve urine for prolonged frozen storage. In this study, a 
mean of 0.02 ml 1 mNaOH, equivalent to three droplets 1 m NaOH, was 
added per ml of urine. From a practical point of view, we recommend the 
addition of three droplets 1 m NaOH per ml urine to alkalinize samples 
instead of precise titration to pH 8.0. Interestingly, the intra-assay CV for 
samples stored at -20º C was almost similar compared with fresh samples. 
These data thus imply that the decline in UAC is similar in each portion of 
the same urine sample and is not caused by random variability. Adequate 
mixing of samples after thawing allows storage of urine for up to 3 months at 
-20º C without large changes in UAC, whereas inadequate mixing results in 
significant declines.11 Some studies report a significant decline in UAC after 
storage durations of only up to 8 weeks.10;19;20 As it is not mentioned in these 
studies whether samples were mixed, the decline in UAC reported in these 
studies could be the consequence of inadequate mixing of samples prior to 
analysis. One of these studies reported no decline in UAC in pH adjusted 
samples, although no actual data on UAC before and after storage were 
provided.20 Furthermore, the limited sample size of that study (n = 33) and 
short duration of storage hampers interpretation and applicability for future 
studies, as samples in epidemiological  and intervention studies are usually 
meant to be stored for longer periods of time. The study also lacked a 
comparison with -80º C, thus leaving open the question whether storage at 
-80º C was superior to storage at -20º C with adjustment of pH. 
What could be the mechanism underlying prevention of decline in UAC 
during frozen storage by urine alkalinization? First, because the iso-electric 
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point of albumin is 4.7, relatively less aggregationmay occur at a higher pH. 
This probably results in less entrapment of albumin in the precipitate 
andmore efficient antibody binding, which is needed for determination by 
immunochemical methods. Second, urine alkalinization may prevent 
conformational changes of albumin resulting from frozen storage and as 
such improve antibody binding required for immunochemical  determination. 
Third, it is also possible that falsely low urinary albumin concentration values 
reflect contamination with bacterial  proteases.17 Bacterial proteases may 
hydrolyse urinary albumin. Alkalinization of urine before storage may reduce 
activity of bacterial proteases, leading to improved preservation for albumin 
assessment. Unfortunately, bacterial protease activity was not measured in 
our study and further studies are warranted to investigate this possibility. 
In conclusion, urinary alkalinization to pH > 8.0 is a simple technique to 
prevent a decline in UAC during frozen storage at -20º C and a suitable 
alternative for storage at -80º C, both in terms of recovery of urinary albumin 
and in variation between individual  samples. The latter is particularly 
important for maximization of power for detection of effects of treatment in 
intervention studies in which urinary albumin is used as an intermediate 
endpoint.
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Little is known about the effect of frozen storage on urinary concentrations of 
renal damage markers. We therefore investigated the effect of storage at -20 
and -80 °C on concentration and variability of these markers.
Urine samples of 95 patients with diabetes mellitus were collected, in which 
we measured IgG, IgG-4, KIM-1, NGAL, NAG, cystatin C and H-FABP. 
Damage marker concentrations were first measured in fresh samples. 
Subsequently urine samples were frozen at -80 ºC and remeasured after 1 
week, 6 months and 1 year. Furthermore, the effect of 1 year frozen storage 
at -20 0C and the effect of specific  storage protocols (adding protease 
inhibitors, and alkalizing before and after storage) were investigated.
Average marker concentrations showed a decrease after frozen storage at 
-80 ºC, with KIM-1, NAG and NGAL concentrations being significantly lower 
after 1 year. Also, an increase in variability was observed. Specific  storage 
protocols could not prevent this. Importantly, after frozen storage all marker 
concentrations remained significantly associated with the fresh baseline 
concentrations (all p<0.001). 
Renal damage markers should preferably be measured in fresh urine 
samples. If this is not possible, urine samples can be stored at -80º C or -20º 
C. Frozen storage is, however, associated with a reduction in average value 
and an increase in variability of most markers. Marker studies using frozen 
urine samples should therefore be interpreted with caution. 
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Introduction
Measurement of urinary concentrations of tubular damage markers has 
achieved growing attention to predict the outcome of acute kidney damage.1 
More recently the value of these markers to predict the course of chronic 
renal disease has also been investigated.2-4 Urine samples that are used for 
these studies are often stored frozen during prolonged periods of time prior 
to analysis.
Previously we have shown that frozen storage during 1 year is associated 
with a decrease in  urinary albumin concentration, with a wide variation 
between urine samples in the amount to which albumin decreases.5;6 
Furthermore we have shown that this effect is more outspoken after storage 
at -20 0C when compared to storage at -80 0C6,7, and that alkalinisation of 
urine samples before freezing at -20 ºC prevents to a certain extent the 
average decrease in albumin concentration and the increase in variability.7 
These storage effects are of importance, as we showed that the value of 
urinary albumin excretion to predict mortality is considerably better when 
assessed in fresh urine samples in comparison to when assessed in the 
same samples after prolonged frozen storage.8 As yet little is known about 
the effect of frozen storage on concentration and variability of other urinary 
renal damage markers.
With this study we aimed to investigate the effect of frozen storage at -20 
and -80 °C on concentration and variability of various urinary renal damage 
markers. For this study we investigated the glomerular markers IgG and 
IgG-4, the proximal tubular markers KIM-1, NAG, NGAL, cystatin C and the 
distal tubular marker H-FABP. Secondly we investigated whether specific 
storage protocols influence the concentration and variability in these markers 
after one year frozen storage. 
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Materials and Methods
Study population and samples
This study was performed in patients with diabetes mellitus (both Type 1 and 
Type 2), who consecutively visited a diabetes specialty clinic. Inclusion was 
between April  2009 and September 2009, and was stratified by the amount 
of albuminuria measured in a fresh first morning void urine sample by 
nephelometry (BNII; Dade Behring Diagnostics, Marburg, Germany). We 
aimed to include 100 diabetic  patients, of which 40 with normo-albuminuria 
(<3mg/mmol), 40 with micro-albuminuria (3-30mg/mmol) and 20 with macro-
albuminuria (> 30mg/mmol).4 This stratification was done in order to obtain a 
wide variation in urinary renal damage markers. Patients with cancer, 
infections or inflammatory conditions, renal disease other than diabetic 
nephropathy, use of nephrotoxic drugs, renal  transplantation or pregnancy 
were excluded, as were patients younger than 18 years of age. This study 
protocol was approved by the institutional Ethics Committee.
Study design and sample handling
Patients were invited to participate at regular clinic visits. After having 
obtained written informed consent patients were instructed to collect a first 
morning urine void at the day of visit to a research clinic, and to bring this 
sample to the clinic. During the visit demographic  and anthropometric  data 
were obtained. Urine samples were vortexed and subsequently centrifuged 
(14.000 rpm, 20.817 g). The supernatant was used for further studies. 
Concentrations of the various renal damage markers were measured the 
same day as the urine collection. Furthermore, urine samples were divided 
and stored in polystyrene vials for assessment after 1 year frozen storage at 
-20 ºC and -80 ºC. Samples that were stored at -80 ºC were also assessed 
after 1 week and 6 months of storage to investigate the time course of 
possible changes in urinary concentration and variability of the markers 
under study. In addition, the effect of three specific  storage protocols were 
investigated in samples stored during 1 year at -80º C: a. alkalinisation 
before frozen storage by adjusting urinary pH to > 8.0 with 1 M sodium 
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hydroxide (primary alkalinisation), b. alkalinisation after thawing, similarly by 
adjusting urinary pH to > 8.0 with 1 M sodium hydroxide (secondary 
alkalinisation), and c. adding a cocktail  of protease-inhibitors before frozen 
storage. Protease inhibitors that were added were leupeptin (1 µmol/l), NaN3 
(10 mmol/l) and phenylmethanesulfonyl fluoride PMSP (0.5mM).9 
Measurements of Damage Markers
Urinary renal damage markers were measured in fresh urine samples in 
triplicate to calculate the intra-assay coefficient of variation. Inter-assay 
coefficient of variation was determined by measuring the same sample three 
times using different assays. For quantification of  immunoglobuline G, 
immunoglobuline G type 4, kidney injury molecule 1 (KIM-1),  neutrophil 
gelatinase-associated lipocalin (NGAL), and heart-type fatty acid-binding 
protein (H-FABP) we used direct sandwich-enzyme-linked immunosorbent 
assays using monoclonal coating antibodies and labeled polyclonal 
detection antibodies on a Maxisorp plate (Nunc, Denmark) in which the 
concentration of the analyte was determined spectrophotometrically by 
conversion of o-phenylenediamine by Horse-Radish Peroxidase label. IgG, 
IgG-4 and H-FABP antibodies were obtained from Hytest (Turku, Finland) 
and KIM-1 and NGAL antibodies were obtained from R&D systems 
(Minneapolis, USA)). Urinary concentration of N-acetyl-β-D-glucosaminidase 
(NAG) was measured using a modified enzyme assay according to 
Lockwood and corrected for nonspecific  conversion (HaemoScan, 
Groningen, The Netherlands). Cystatin C was measured by nephelometry 
(reagents obtained from Siemens (Marburg, Germany). The intra- and 
interassay coefficients of variation were for IgG 13.3% and 25.1%, 
respectively, for IgG-4 14.0% and 15.8%, for KIM-1 7.4% and 14.5%, for 
NAG 3.1% and 13.7%, for cystatin C 2.7% and 8.4%, for NGAL 6.8% and 
19.6%, and for H-FABP 9.3% and 17.6%. Samples were diluted to obtain 
optimal concentration for measurement.
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Statistical analyses
Statistical  analyses were performed with SPSS version 18.0 (SPSS Inc., 
Chicago, IL). Parametric variables are expressed as mean ± standard 
deviation (SD), whereas non-parametric variables are given as median 
(interquartile range). P-values for differences between renal damage marker 
concentrations when measured in fresh samples compared to when 
measured in samples after frozen storage were assessed using the 
Wilcoxon Signed Rank test.  Intra-assay coefficients of variation are 
calculated as SD / mean of 3 measurements performed in one assay and 
are expressed as a percentage. Inter-assay coefficients of variation are 
calculated as SD / mean of 3 separate measurements of the same sample in 
3 different assays and similarly expressed as a percentage. Linear 
regression analysis was used to assess the correlation between 
concentrations of the various urinary renal damage markers when measured 
in fresh urine samples and when measured after different modalities of 
frozen storage. To fulfil  the requirements for linear regression analysis all 
urinary damage marker concentrations were 10log-normalized. Because the 
R2 value of the regression analysis is a measure of the strength of the linear 
associations rather than a measure of agreement, we also assessed 
agreement with the Bland Altman method.10 Bland Altman agreements are 
calculated by dividing the difference between concentration measured from 
fresh samples and the concentrations measured from frozen stored samples 
by the mean of the fresh concentrations and concentration measured from 
frozen samples. Smaller values indicate better agreement. For all analyses a 
two sided p < 0.05 was considered to indicate statistical significance. 
Results
In total 95 patients were included (67 males and 28 females). Their mean 
age was 61 ± 13 years, and mean systolic  and diastolic blood pressure were 
142 ±16 and 77±10 mmHg, respectively. Of these subjects 41 were normo-
albuminuric, 41 micro-albuminuric and 13 macro-albuminuric. 
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Table 1 Concentration of various renal damage markers 
Fresh -80 0C
1 week 6 months 1 year
IgG-total (µg/ml) 6.4 (2.1-28.9) 5.7 (1.9-10.7)* 5.2 (3.4-11.0) 5.0 (2.2-15.3)
IgG-4 (µg/ml) 1.2 (0.9-2.6) 0.8 (0.3-2.5) 0.6 (0.6-0.7)** 0.7 (0.3-2.9)
KIM-1 (ng/ml) 1.27 (0.67-2.17) 0.95 (0.42-1.46)** 1.01 (0.61-1.66) 0.67 (0.37-0.97)**
NAG (U/L) 8.5 (5.4-13.3) 7.8 (5.4-14.1) 2.0 (1.2-3.6)** 0.3 (0.2-0.3)**
Cystatin C (mg/L) 0.03 (0.01-0.05) 0.03 (0.02-0.05) 0.03 (0.01-0.05) 0.04 (0.02-0.06)**
NGAL (ng/ml) 34.2 (13.3-98.3) 32.4 (7.8-89.6) 18.3 (3.7-93.6) 18.3 (7.3-77.5)*
H-FABP (ng/ml) 1.56 (0.39-7.59) 1.50 (0.39-4.26)* 0.97 (0.39-4.64) 0.95 (0.39-4.05)
Data are shown as medians (interquartile range). p<0.05, ** p < 0.001 compared to fresh 
samples (Wilcoxon Signed Rank Test).
Change in renal damage markers after frozen storage
Table 1 shows the urinary concentrations of the various renal damage 
markers when measured in fresh urine samples and when measured at 
different time points after frozen storage at -80 0C. All markers, except 
cystatin C, showed a gradual decline in median concentration after frozen 
storage, although not all values reached statistical  significance. Most 
outspoken was the decline in urinary NAG concentration, which decreased 
28-fold after frozen storage during 1 year. 
Variability in renal damage markers after frozen storage 
Figure 1 shows for each renal damage marker the change (median and 
interquartile ranges) in concentration from values measured in fresh urine 
samples when a. using the same fresh urine sample and the same assay 
(representing intra-assay variation), b. using the same fresh urine sample 
but another assay (representing inter-assay variation), c. after 1 week, d. 
after 6 months and e. after 1 year of frozen storage at -80 0C. These figures 
show that in general the interquartile range after frozen storage is wider than 
when concentrations are measured in fresh urine samples, indicating that 
frozen storage induces an increase in variability for all measured markers. In 
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general, however, these interquartile ranges do not become wider after 
longer storage.  
Effect of various storage protocols
We tested whether different storage protocols could minimize the average 
decline in urinary renal damage markers observed after frozen storage 
during 1 year at -800C. Results are shown in table 2. In general, none of the 
investigated storage protocols could prevent this decline. 
Correlation to fresh samples
Table 3 shows the R square values of the correlations and Bland Altman 
agreements between urinary damage markers when assessed in fresh urine 
samples and when assessed after 1 year storage at -80 or -20 0C in the 
same samples using various storage protocols. This table shows that the 
concentrations of all  markers using all storage protocols are significantly 
correlated to the freshly measured concentrations and that agreement is not 
fundamentally improved by different storage protocols. In general the various 
storage protocols (primary alkalinisation, secondary alkalinisation and adding 
protease inhibitors) did not result in relevantly higher R square values or 
smaller Bland Altman agreements when compared to the situation when no 
specific storage protocol was followed. 
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Table 2 Concentration of various renal damage markers when measured in fresh urine samples 
(n=95) and in the same urine samples after 1 year frozen storage at -80 and -20 ºC using 
various storage protocols.
























































































































Data are shown as medians (interquartile range). * p<0.05, ** p<0.01 compared to fresh samples 
(Wilcoxon Signed Rank Test). # p<0.05, ## p<0.01 compared to -80 0C 1 year storage (Wilcoxon 
Signed Rank Test)
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Table 3 Relation between urinary damage markers when assessed in fresh urine samples and 
when assessed after 1 year storage at -80 or -20 0C using various storage protocols (same 
samples)












IgG-total NA 0.46** 0.34** 0.31** 0.40** 0.20** 0.27**
IgG-4 NA 0.16** 0.21* 0.16** 0.12* 0.38** 0.45**
KIM-1 NA 0.54** 0.66** 0.44** 0.50** 0.21** 0.27**
NAG NA 0.21** 0.16** 0.20** 0.15** 0.27** 0.19**
Cystatin C NA 0.84** 0.92** 0.95** 0.94** 0.81** 0.07*
NGAL NA 0.44** 0.48** 0.40** 0.44** 0.53** 0.57**
H-FABP NA 0.54** 0.33** 0.54** 0.39** 0.30** 0.35**













































































Upper panel shows R square values, and lower panel agreement according to Bland Altman, 
mean (SD).  Abbreviations: NA, not applicable. * p<0.05, ** p < 0.001, Wilcoxon Signed Rank 
Test.
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Figure 1 Absolute change in concentration of various urinary renal damage markers. INTRA 
means the difference between 2 samples measured in one run in the same assay, INTER 
means the difference between 2 samples measured using different assays, 1 wk, 6 mo and 1 yr 
mean the difference between concentrations assessed after frozen storage at -80º c in fresh 
samples and in samples stored during 1 week, 6 months and 1 year.
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Sensitivity analyses
When all aforementioned investigations were redone with markers 
subdivided according to being under or above the median value measured in 
fresh urine samples essentially similar results were obtained in the high 
versus low marker concentration groups.
Discussion
In the present study, we investigated the influence of frozen storage on the 
concentration and variability of various urinary renal damage markers. We 
found that all  markers, except cystatin C, show a decrease. Already after 1 
week of frozen storage at -80 ºC remeasurement resulted in lower 
concentrations. Furthermore, all markers show an increase in variability after 
remeasurement after frozen storage. None of the investigated storage 
protocols could prevent or reduce these effects. Importantly, however, after 
frozen storage all markers remained significantly associated with values 
obtained when measured in fresh urine samples. No fundamental 
differences were observed when these investigations were done in samples 
stored at -20 ºC when compared to storage at -80 ºC.
We previously showed that 8 months of storage at -20 ºC results in a 
decrease in urinary albumin concentration of approximately 30%5. Only a 
limited number of studies has investigated the effect on the renal  damage 
markers studied in the present protocol  when measured in urine samples 
after frozen storage in comparison to when measured in fresh urine samples. 
First, in line with our findings Grenier et al reported that urinary NGAL 
concentrations declined significantly after 6 months storage at -20º C.11 In 
contrast to our results, however, they found that NGAL concentrations did 
not decrease significantly when stored at -80°C. Second, Chaturvedi et al 
found no decline in KIM-1 concentration after 14 days of storage at -80º C as 
well as at -20º C12, whereas we did observe a decrease. This may be due to 
the short duration of storage in this study, since we found a significant 
decline in urinary KIM-1 concentration especially after prolonged storage. 
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Third, Herget-Rosenthal  et al found no decline in urinary cystatin C after 
frozen storage during 7 days,13 which is in agreement with our data. 
The results we observed were rather uniform, with two exceptions. Average 
urinary cystatin C concentration after frozen storage was nearly similar to the 
average concentration in fresh urine samples, even being slightly, but 
significantly higher, with a very accurate association between concentrations 
in fresh and frozen urine samples. On the other hand, average NAG 
concentrations declined strikingly in our study, both at -20º C as well as at 
-80º C. A reason for the decline in NAG concentration could be that we used 
an enzymatic assay that needs intact NAG to convert a substrate. However, 
no important differences have been described in NAG concentrations after 
frozen storage between measurement with an ELISA and an enzymatic 
assay.14 Another explanation could be that the enzymatic activity of NAG 
decreases during storage due to pH effects, since it has been described that 
NAG isoenzyme A, which constitutes 80-90% of total NAG activity, is 
deactivated after 8 hours at pH >7 up to 40% and at pH >8 up to 100%.14 
However, mean urinary pH in our samples was 5.8, and only 5 out of our 95 
samples had a pH > 7. Such a pH effect is therefore not a likely explanation 
for the degradation in NAG concentrations that we found. 
The studies that previously investigated the effect of frozen storage on 
urinary renal damage marker concentration did not systematically study 
possible increases in variability, although one showed graphically that NGAL 
concentration showed higher variability after frozen storage at 20º C.11 Our 
data indicate that all  investigated markers, except cystatin C, increase in 
variability already after 1 week of frozen storage compared to their intra- and 
inter-assay variability assessed in fresh samples. 
Why marker concentrations in general  decline and show increased variability 
after frozen storage is unknown. Theoretically it may be that the molecules 
are trapped in the precipitate because of an alteration in pH of the urine 
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samples during freezing and thawing15-17 or that bacterial contamination 
causing hydrolysis by bacterial proteases affects marker concentrations.18 
Furthermore, confirmational changes that occur during freezing or thawing 
may lead to loss of the antibody recognition site of the ELISA. To address 
the question why marker concentrations decline during frozen storage, we 
stored our urine samples under different conditions. Alkalizing urine samples 
or adding protease-inhibitors for instance, may be expected to prevent 
precipitate formation and hydrolysis due to bacterial proteases. Secondary 
alkalinisation might reverse a possible conformational change that could 
have occurred during freezing or thawing, or dissolve the investigated 
protein in case of entrapment in a precipitate. Since all these procedures did 
not prevent the decline in marker concentration during frozen storage, nor 
did they reduce variability to a substantial  amount, no conclusions can be 
drawn from our results on the cause of the reduction in urinary biomarker 
concentration.
Should our data be interpreted that urinary biomarkers can not be assessed 
from urine specimens after prolonged frozen storage? In our opinion this is 
not the case. Although after frozen storage these markers show on average 
a reduction and an increase in variability, our data also show that in general 
the situation after 1 year of storage is not fundamentally different when 
compared to situation after 1 month of storage. Moreover, measurement 
after 1 year yields significant correlations with values measured in fresh 
urine samples. We therefore conclude that urinary biomarkers should be 
measured preferably in fresh urine samples, but measurement in urine 
samples that have been stored at -80º C or -20º C is acceptable for most 
markers. However, our data indicate that results from studies that for 
instance measure biomarkers from frozen urine samples as potential 
predictors for clinical outcome should be interpreted with caution. Absence of 
predictive value could be due to the fact that the marker under investigation 
indeed has no predictive value, but could also be due to the fact that the 
decline or variability that is induced by frozen storage has obscured the 
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relation that in reality was present. Previously we have shown this principle 
for urinary albumin concentration.8 
We acknowledge that our study has limitations. First, all marker 
concentrations have been measured with 1 assay only. It can not be 
excluded that other assays with antibodies directed against other epitopes 
will  yield other results. However, since all markers that we investigated 
showed more or less the same pattern it is unlikely in our opinion that 
different conclusions will be reached using other assays. Second, damage 
markers were determined in urine samples of patients with CKD. Damage 
marker concentrations are thus relatively low when compared to the situation 
in urine samples of patients with acute kidney injury. Storage effects might 
be different in a higher concentration range. However, we found within the 
range of concentrations we measured no essentially different results 
between low and high concentrations. Third, in urine samples of patients 
with diabetes certain constituents might play a role in the decline of marker 
concentrations that are not present in urine samples of patients with other 
kidney diseases (or vice versa).
Strengths of this study are that we measured multiple markers in a large 
number of urine samples, investigating two storage temperatures and the 
time course of changes in marker concentration. Other studies investigating 
stability of tubular damage markers have measured maximally 1-3 
markers11;13;19, in a limited number of samples.19 Furthermore, we tried to 
identify possible mechanisms of loss of concentration by investigating 
whether specific  storage conditions result in more reliable results after frozen 
storage. 
In conclusion, based on our observations we recommend that urinary renal 
damage markers should preferably be measured in fresh urine samples. If 
this is not possible, they can be stored at -80º C or -20º C. Frozen storage is, 
however, associated with a reduction in average value and an increase in 
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variability of most markers. Studies using frozen urine samples should 
therefore be interpreted with caution.  
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Chapter 5
Albuminuria, proteinuria and novel urine biomarkers as 
predictors of long term allograft outcomes in kidney 
transplant recipients





Jaap J. Homan van der Heide
Harry van Goor




Proteinuria is an established marker of chronic renal  transplant dysfunction. 
Recently it has been suggested that albuminuria might be a more reliable 
marker for allograft injury. Albuminuria is often regarded as a marker of 
glomerular damage. However, since chronic  renal  allograft injury is thought 
to be predominantly an interstitial  process, albuminuria might in this case 
reflect tubular damage. We aimed to study the value of albuminuria, 
proteinuria and tubular damage markers (KIM-1, NAG, NGAL, H-FABP) 
predicting graft outcome in a cohort of renal transplant recipients. 
606 patients visiting our renal  transplant outpatient clinic between 2001 and 
2003 were included and were used in the analysis for death censored graft 
failure. Median follow-up was 4.7 (3.8-5.2) year. 577 patients had follow-up 
>1 year and were included the analysis for renal  function decline. Median 
follow-up was 3.2 (2.7-3.7)
We have measured urinary protein, albumin and specific  tubular damage 
markers in 24h-urine samples. Primary outcomes were occurrence of death 
censored graft failure and renal  function decline. 42 patients developed graft 
failure and mean change in renal function was -0.46 (3.7) ml/min per year. 
ROC-curve analysis revealed that albuminuria has the highest area under 
the curve (95%CI) in predicting death-censored graft failure (0.78, 
0.59-0.76), significantly higher than proteinuria (0.67, 0.59-0.76; p= 0.001), 
NGAL (0.63, 0.52-0.74; p=0.02) and H-FABP (0.62 0.53-0.73; p=0.005), but 
not different than the area under the curve of KIM-1 and NAG excretion. 
We conclude that measuring albuminuria to predict long-term renal outcome 
in renal transplant recipients may be superior to measuring total  proteinuria. 
Additional  assessment of the urinary excretion of tubular damage markers 
has limited value to predict outcome.
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Introduction
One year graft survival after kidney transplantation has greatly improved 
over the years. In contrast, long-term graft survival has changed only to a 
limited extent. Approximately half of all deceased renal allografts are still lost 
within 10 to 12 years after transplantation.1  One of the leading causes of 
late allograft loss is Chronic Transplant Dysfunction2 , which is characterised 
by decline in renal function with hypertension and proteinuria.3;4 This is 
accompanied by tubular histological changes as interstitial  fibrosis and 
tubular atrophy. 5;6
There is a need for markers that can predict the initiation and progression of 
chronic transplant dysfunction in an early phase. 7 This would enable 
intervention or change in therapy. In clinical  practice estimates of glomerular 
filtration rate and proteinuria are used for identification of transplant 
recipients at increased risk for late renal  allograft loss. 8-10 Proteinuria results 
from the urinary loss of various proteins, whereas albuminuria is less 
heterogenic. Interestingly, it has recently been suggested that albuminuria 
may be a more reliable marker of chronic renal allograft injury than 
proteinuria.11 Although albuminuria may be less heterogenic than proteinuria, 
it still  is the resultant of two counteracting processes, glomerular leakage 
and tubular reabsorption. Since chronic  transplant dysfunction is 
predominantly an interstitial process, it might be that in renal  transplant 
recipients specific  tubular damage markers, such as Kidney Injury Molecule 
1 (KIM-1) or Neutrophil  Gelatinase-Associated Lipocalin (NGAL), are better 
predictors for renal  function outcome than albuminuria. We investigated as 
proximal  tubular markers KIM-1, NAG (N-Acetyl-beta-D-Glucosaminidase) 
and NGAL because these markers have different mechanisms of release 
and represent a different kind of tubular damage, and because in recent 
years they are extensively being investigated. As distal tubular marker we 
investigated H-FABP (Heart Fatty Acid Binding Protein) since it is a sensitive 
and rapid new marker of distal tubular injury.12
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Given this background, we studied whether albuminuria is superior to 
proteinuria in predicting graft failure and change in renal function in renal 
transplant recipients.  Also, we aimed to investigate whether specific tubular 
damage markers predict change in renal function and graft failure, and 
whether these markers add to the predictive value of albuminuria.
Methods
Study design and patients
After a baseline visit all  participating subjects visited the out-patient clinic at 
least once a year.  Current medication was taken from the medical record. 
Details of this study, among others standard immunosuppressive treatment, 
have been described previously.13  Excluded from our study were recipients 
with missing samples at baseline (n=8). The Institutional Review Board 
approved the study protocol (METc 01/039) which was in adherence to the 
declaration of Helsinki. Funding sources had neither a role in the collection 
and analysis of data, nor in the submission and publication of the 
manuscript.
Definition of endpoints
The primary endpoints of this study were death censored graft failure and 
change in renal  function.  Death censored graft failure was defined as return 
to dialysis or retransplantation. Change in renal function was defined as 
eGFR at baseline subtracted by eGFR at the last follow-up visit, divided by 
time from baseline to follow up, and expressed in ml/min*1.73m2 per year. 
This is preferred to a slope since renal  function decline in CTD does usually 
not happen in a linear manner.14 Calculating a slope instead of a change in 
eGFR will therefore underestimate a patient’s true renal function decline.
For patients who died with a functioning graft (n=78) eGFR at follow-up was 
defined as renal function at the last visit to the out-patient clinic  prior to 
death, and for patients with graft failure (n = 42) eGFR at follow-up was 
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defined as the eGFR value at the last visit to the out-patient clinic before 
starting dialysis or retransplantation. There was no loss to follow-up. 
Measurements 
Serum creatinine levels were determined using the Jaffé method (MEGA AU 
510, Merck Diagnostica, http://www.merck.de/en/index.html). Urinary 
creatinine excretion was normalized to body weight by dividing the 24h 
urinary creatinine excretion by the patient’s weight in kilograms. GFR was 
estimated with the 4-variable MDRD formula: we have previously 
documented the validity of this formula to estimate GFR in our transplant 
population15 At baseline all participating subjects collected a 24 hr urine. 
After collection, these 24-hour urinary samples were centrifuged. A sample 
was used for routine measurements such as creatinine, and was 
immediately stored (-80°C) in plastic aliquots until measurement. No 
protease inhibitors were added. After thawing all  urine samples were 
vortexed and subsequently centrifuged (14.000 rpm). The supernatant was 
used for measurements. All urinary biomarkers were determined from these 
frozen samples in one run.
Total protein concentration was analysed using the pyrogallol  red-molybdate 
method (Merck Dianostica,MEGA, http://www.merck.de/en/index.html, intra-
assay CV 14%). Urinary albumin was measured by nephelometry (Dade 
Behring Nephelometer, intra-assay CV 2.7%, http://www.dadebehring.com/
edbna2/ebusiness/home.jsp). For biomarker quantification in urine we 
developed direct sandwich-enzyme-linked immunosorbent assays (ELISA’s) 
using monoclonal coating antibodies (MAb) and labeled polyclonal detection 
antibodies on a Maxisorp plate (Nunc, http://www.nuncbrand.com/en/
default.aspx) in which is the concentration of the analyte was determined 
spectrophotometrically by conversion of o-phenylenediamine by Horse-
Radish Peroxidase label. Samples were diluted before measurement (2 
times for KIM-1, 100 times for NGAL, 5 times for HFABP). KIM-1 and NGAL 
antibodies were obtained from R&D systems (http://www.rndsystems.com). 
79
H-FABP antibodies were obtained from Hytest http://www.hytest.fi). The 
intra-assay coefficients of variation were 7.4%, 6.8% and 9.3%, respectively. 
The lower limits of detection were 1.0 (ng/ml), 2.5 (ng/ml), and 3.0 
respectively. Urinary concentration of NAG was measured using a modified 
enzyme assay according to Lockwood and corrected for nonspecific 
conversion (HaemoScan, http://haemoscan.com, intra-assay CV 3.1%). The 
lower limit of detection was 2.7 (U/L). Urinary biomarker excretion is 
expressed per 24 hours. 
Statistical analysis
Analyses were performed with SPSS version 16.0 (SPSS Inc., Chicago, IL). 
Parametric variables are expressed as mean ± standard deviation (SD), 
whereas non-parametric variables are given as median (interquartile range). 
A two sided p < 0.05 was considered to indicate statistical significance. 
To investigate the predictive value of proteinuria, albuminuria and tubular 
damage markers at baseline for death censored graft failure, various 
analyses were performed. To visualise the associations between these 
urinary biomarkers and graft failure, we divided our cohort into quartiles of 
increasing urinary excretion of each biomarker. These quartiles were plotted 
against the incidence of graft failure (figure 1). Furthermore, ROC curves 
were drawn for each biomarker (figure 2). Calculation of the statistical 
significance between the various ROC curves was performed using Stata 
version 10.1 software (StataCorp, Texas, USA) using time independent C-
statistics.
Lastly, Cox regression analyses were performed to investigate whether 
these urinary biomarkers at baseline are independently associated with 
graft-failure during follow-up (table 3). First, these analyses were performed 
crude. Second, multivariate regression analyses were performed, adjusting 
for age, sex, and baseline eGFR. Third, we tested whether information on 
the urinary excretion of the various tubular damage markers adds to the 
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predictive value of albuminuria by implementing both albuminuria and the 
urinary excretion of the biomarker under investigation in the model. Hazard 
ratios (HR) are reported with 95% confidence interval. As secondary 
analyses we investigated the composite of graft failure and doubling of 
serum creatinine and the composite of doubling of serum creatinine, kidney 
failure and death. These outcomes being of clinical  interest and offering the 
advantage of enhancing power by including more end-points.
To investigate the predictive value of proteinuria, albuminuria and tubular 
damage markers at baseline for change in renal  function during follow-up, 
patients with a follow-up < 1 year were excluded from the analysis (n=29). 
We again divided our cohort into quartiles of increasing urinary excretion of 
each biomarker, and these quartiles were plotted against change in renal 
function during follow-up (figure 3).  Furthermore, linear regression analyses 
were performed (table 4) with baseline urinary biomarker excretion as 
independent and change in renal function as dependent variable. Second, 
this association was adjusted for gender, age, and baseline eGFR. Third, we 
tested whether tubular damage markers add to the predictive value of 
albuminuria by implementing both albuminuria and the urinary excretion of 
the biomarker in the model.
Biomarker excretion was log2-normalised to fulfil the requirements for linear 
regression analysis. These log transformed values have been standardized 
to enable comparison between markers. We tested for significant 
interactions between patient characteristics and baseline urinary biomarker 
excretion by entering the urinary biomarker, the investigated characteristic, 
and their product term in the same multivariate regression model.
Results
In this prospective longitudinal study, all renal  transplant recipients were 
eligible who visited our out-patient clinic  between August 2001 and July 2003 
and had a functioning graft for at least 1 year. Patients with known or 
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apparent systemic illnesses (e.g. malignancies or opportunistic  infections) 
were considered ineligible. A total of 606 out of 847 (72%) subjects signed 
written informed consent. 16 (Figure 1) Recipients participated at a median of 
5.9 (2.6-11.4) years post transplant in baseline measurements. Follow-up 
time for graft failure beyond baseline was 4.7 (3.8-5.2) years and for change 
in renal function 3.2 (2.7-3.7) years. The number of patients that developed 
graft failure was 42 and the mean change in renal  function was -0.46 (3.7) 
ml/min per year. Patient characteristics are presented in table 1 stratified for 
albuminuria. All  endpoints and their composites are shown in table 2. Urinary 
creatinine excretion normalized to body weight was 17.7 ± 4.6 mg/kg. 
Median proteinuria was 568 (340-872) mg/24h and albuminuria 40 (15-170) 
mg/24h. Median biomarker excretions are also presented in table 1 and their 
distribution is shown graphically in figure 2. Correlations between all markers 
are shown in supplementary table 1.
Figure 1 Flow diagram shows formation of the cohort
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Graft failure
Rates of graft failure during follow-up according to quartiles of 24hr urinary 
excretion of the various biomarkers under study are depicted in figure 3. 
This figure shows clear associations between 24hr excretions of total protein 
excretion, albumin, KIM-1 and NAG versus incidence of death censored graft 
failure, whereas the association between baseline excretion of H-FABP and 
NGAL versus incident graft failure is less clear.
ROC curves for urinary biomarker excretion predicting graft failure are 
shown in figure 4. The areas under the ROC curve (95%CI)  for urinary 
excretion of total  protein, albumin, KIM-1, NAG, H-FABP and NGAL were 
0.67 (0.59-0.76; p<0.001), 0.78 (0.70-0.87; p<0.001), 0.74 (0.66-0.82; 
p<0.001), 0.75 (0.67-0.83; p<0.001), 0.62 (0.53-0.72; p=0.009) and 0.63 
(0.53-0.74; p=0.007) resp. Albuminuria has the highest AUC in predicting 
graft failure. The AUC’s for the predictive value of urinary excretion of total 
protein, H-FABP and NGAL were significantly lower (p=0.001, p=0.005 and 
p=0.02, respectively) than for albuminuria. The AUC’s for the predictive value 
of KIM-1 and NAG did not differ significantly from albuminuria (p=0.19, 
p=0.19 resp.).
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Table 1 Patient characteristics in albuminuria strata 
Variable (<10 mg/24h) 10-30 mg/24h) (30-300 mg/24h) (>300 mg/24h)
N=96 N=159 N=237 N=106
Age (years) 53 (44-60) 53 (42-61) 53 (44-62) 50 (41-58)
Male gender (%) 45 49 57 62
Current smoking (%) 19 22 20 30
BMI (kg/m2) 26.1 (4.6) 26.3 (4.3) 26.0 (4.2) 25.8 (4.4)
MAP (mm Hg) 107 (13) 108 (13) 112 (12) 116 (13)
Plasma cholesterol
(mg/dL) 220 (197-236) 213 (189-236) 217 (189-240) 224 (193-251)
Time after transplantation 
(years) 5.1 (2.2-11.6) 4.7 (1.7-10.6) 6.0 (2.8-10.7) 9.1 (5.4-14.0)
Time on dialysis prior to 
transpantation (years) 2.6 (1.3-3.9) 2.2 (0.9-4.0) 2.3 (16-49) 1.9 (0.8-4.1)
Living donation (%) 13 17 14 11











eGFR  at baseline 
(MDRD) (ml/min* 1.73m2) 51 (13) 50 (14) 45 (14) 41 (15)
-   Proteinuria (mg/24h) 395 (259-621) 410 (288-659) 568 (370-789) 1100 (710-1512)
-   Albuminuria (mg/24h) 7 (5-8) 18 (13-24) 90 (47-144) 572 (409-1031)
Proximal tubular markers
-   KIM-1 (µg/24h) 0.6 (0.2-1.1) 0.7 (0.3-1.3) 1.6 (0.9-2.3) 2.4 (1.4-3.4)
-   NGAL (µg/24h) 281 (227-358) 320 (249-409) 339 (270-491) 353 (254-490)
-   NAG (U/24h) 4.8 (2.6-9.7) 7.8 (4.1-12.1) 9.6 (6.1-15.2) 13.0 (8.8-20.4)
Distal tubular marker
-   H-FABP (µg/24h) 3.1 (1.6-5.8) 4.1 (2.1-7.8) 5.2 (2.5-10.8) 10.7 (3.8-23.2)
Creatinine excretion
(g/24h) 1.33 (1.10-1.61) 1.32 (1.06-1.61) 1.31 (1.04-1.61) 1.36 (1.12-1.62)
N = 598. Parametric variables are expressed as mean ± SD, whereas non-parametric variables 
are given as median (25th-75th percentile).  Abbreviations are: BMI, body mass index; MAP, 
Mean Arterial Pressure; eGFR, estimated Glomerular Filtration Rate; KIM-1, Kidney Injury 
Molecule 1; NGAL, Neutrophil Gelatinase-Associated Lipocalin; NAG, N-acetyl-beta-D-
glucosaminidase; H-FABP, Heart Fatty Acid Binding Protein.
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Table 2  Endpoints specified in albuminuria strata
Variable (<10 mg/24h) 10-30 mg/24h) (30-300 mg/24h) (>300 mg/24h)
N=96 N=159 N=237 N=106
Graft failure (death censored) (n) 2 (2.1%) 3 (1.9%) 11 (4.6%) 26 (24.5%)
Doubling of serum creatinine (n) 2 (2.1%) 1 (0.6%) 7 (3.0%) 4 (5.7%)
Composite of graft failure + 
doubling of serum creatinine (n)
4 (4.2%) 4 (2.5%) 13 (5.5%) 26 (24.5%)
All cause mortality (n) 7 (7.3%) 22 (13.8%) 40 (16.9%) 22 (20.8%)
Composite graft failure + doubling 
serum creatinine + ACM (n)
10 (10.4%) 25 (15.7%) 52 (21.9%) 40 (37.7%)
Follow-up (years) 4.6 (1.0) 4.4 (1.3) 4.3 (1.3) 3.7 (1.8)
Change in eGFR (ml/min per year) -0.14 (2.71) 0.07 (4.23) -0.42 (3.8) -1.57 (2.89)
N=598. Various end points and the composites used in analyses are shown. Values shown as 
number, number (percentage), or mean ± standard deviation. Abbreviations: eGFR, estimated 
glomerular filtrations rate; ACM, all cause mortality. 
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The results of Cox regression analyses are given in table 3. These data 
show that univariate all urinary biomarkers predict graft failure (left columns). 
When adjusted for age, sex, and baseline eGFR NGAL and H-FABP loose 
statistical significance for predicting outcome, whereas KIM-1 and NAG 
pertain statistical significance (middle columns). When the various urinary 
biomarkers are forced into a model  that also contains albuminuria, 
albuminuria remains a significant predictor of outcome, whereas none of the 
urinary biomarkers reach statistical significance (right columns). Also when 
adjustments are made for a large number of possible confounders (model 4) 
the results do not change materially. As secondary analyses we investigated 
the composite of graft failure and doubling of serum creatinine and the 
composite of doubling of serum creatinine, kidney failure and death (table 3). 
These analyses rendered the same conclusion. Urinary total  protein, KIM-1 
and NAG excretion are all significant independent predictors of these 
composite endpoint in addition to albuminuria. As second sensitivity analysis 
we have also calculated the damage marker to creatinine ratio to correct for 
potential  urine collection errors. Analyses on graft failure provides similar 
results as 24-hour excretions (see supplementary table 2). Furthermore, 
when separate analyses are performed in normo-albuminuric  patients (<30 
mg/24h) or in patients with albuminuria <100 mg/24h, none of the 
investigated damage markers adds significantly to the predictive capacity of 
albuminuria (data not shown).
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Figure 2 Distribution of markers
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Table 4 Association between biomarkers at baseline and change in eGFR per year during 
follow-up


































































































Data are given as standardized β (95% CI) and p-values. Biomarker excretions are 2log 
transformed to fulfil requirements of linear regression analysis. Standardized β show increased 
risk on 1 ml/min/per year decrease in eGFR per two fold increase of biomarker excretion. Model 
1: Crude model; model 2: Adjustment for age, sex and eGFR; model 3: Model 2 + albuminuria; 
Model 4: Model 3 + time between renal Tx and baseline, donor age, living related or cadaveric 
Tx, BMI, MAP, smoking, total cholesterol, duration warm ischemia time, duration cold ischemia 
time, acute rejections, use of calcineurin inhibitors, diabetes mellitus and daily dose of 
prednisolon at baseline.
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Figure 3 Quartiles of increasing urinary excretion of various biomarkers at baseline versus 
incidence of graft failure per 1.000 years of follow-up.
Figure 4 Areas under the curve
Change in renal function
Changes in renal  function according to quartiles of 24hr urinary excretion of 
the various biomarkers under study are depicted in figure 5. This figure 
shows clear associations between 24hr excretions of albumin, KIM-1 and 
NAG versus change in renal function per year, whereas the association 
between baseline excretion of total protein H-FABP and NGAL versus 
change in renal function per year is less clear. 
The results of linear regression analyses are given in table 4. These data 
show that univariately all urinary biomarkers but total protein, NGAL and 
NAG predict change in renal function (left column). When adjusted for age, 
sex, and baseline eGFR, the markers total protein, NGAL and NAG remain 
statistical unsignificant for predicting outcome (middle columns). When the 
various urinary biomarkers are forced into a model that also contains 
albuminuria, these data show that in all cases albuminuria remains a 
significant predictor of outcome, whereas of the urinary biomarkers only H-
FABP remains a statistical  significant predictor.  To investigate the 
contribution of other known risk factors for graft failure to the predictive 
model we adjusted in a sensitivity analysis for a large number of potential 
confounders (model  4). This did not materially change the results. In all 
outcomes albuminuria remained significantly associated with change in renal 
function. As sensitivity analysis this analysis has also been repeated with 
damage marker to creatinine ratio’s. This provided similar results (see 
supplementary table 3). 
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Figure 5 Quartiles of increasing urinary excretion of various biomarkers at baseline versus 
mean change in eGFR per year during follow-up. Cut-off values of quartiles are for proteinuria 
<340.3 mg/24h, 340.3-568.0 mg/24h, 568.0-871.0 mg/24h and > 871.0 mg/24h; for albuminuria 
<14.5 mg/24h, 14.5-40.4 mg/24h, 40.4-169.7 mg/24h and >169.7 mg/24h; for KIM-1 <0.52 µg/
24h, 0.52-1.22 µg/24h, 1.22-2.13 µg/24h and >2.13 µg/24h; for NGAL <254 µg/24h, 254-321µg/
24h, 321-443 µg/24h and >443 µg/24h; for NAG <4.8 U/24h, 4.8-9.0 U/24h, 9.0-14.8 and >14.8 
U/24h; for H-FABP <2.3 µg/24h, 2.3-4.8 µg/24h, 4.8-12.0 µg/24h and >12.0 µg/24h.
Discussion
In this longitudinal prospective study, we found that albuminuria is a powerful 
independent risk marker for both graft failure and change in renal function 
during follow-up. Albuminuria outperforms proteinuria with respect to renal 
prognosis. Furthermore, two out of four investigated tubular damage markers 
(KIM-1 and NAG) predict graft failure and kidney function loss, however, not 
independent from albuminuria. 
With respect to our primary endpoint we found that all investigated tubular 
damage markers predict death censored graft failure when considered 
separately. These markers have predominantly been investigated for the 
prediction of acute kidney injury and acute rejection.17-19 Little is known 
about tubular biomarkers beyond the first year after transplantation. 
KIM-1 is a transmembrane immunoglobulin, which is undetectable in normal 
kidneys, but markedly upregulated in damaged tubular epithelial  cells after 
different types of renal injury20-22 Urinary KIM-1 levels correlate to intrarenal 
KIM-1 expression23, and elevated urinary KIM-1 decreases upon resolution 
of renal damage and renoprotective intervention24. Our data are in 
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agreement with an earlier study showing that the urinary excretion of KIM-1 
related to the extent of renal  damage in various renal diseases.25 In a cohort 
of 145 kidney transplant patients we previously reported that KIM-1 is a 
powerful  predictor of graft failure.26 In this larger cohort we corroborate that 
KIM-1 is a predictor of graft failure (HR 3.3; p<0.001), adding information 
that the predictive value of KIM-1 is not independent of albuminuria.
NAG is a lysosymal enzyme predominantly produced in proximal tubules. It 
has a high molecular weight of 130-140 kDa and therefore not subject to 
glomerular filtration. It is a sensitive marker of tubular impairment. Elevated 
urinary NAG is also associated with acute graft rejection and tubular 
necrosis in the early post-transplantation period,27 as well as with ischemic 
renal damage.28 As yet only 1 study investigated the predictive value of NAG 
for long term outcome in renal  transplant recipients. This study, in only 33 
patients, paradoxically found that a low urinary NAG concentration is 
associated with chronic rejection and ultimately graft loss.29 In contrast, in 
our much larger cohort we find that urinary NAG at baseline is significantly 
and positively associated with graft failure, also after correction for age, sex 
and eGFR at baseline. However, after adjustment for albuminuria NAG does 
not significantly predict graft failure anymore. 
H-FABP is an intracellular carrier protein and has a low molecular mass of 
15 kDa. It is present in the cytoplasm of human distal tubular cells. Little is 
known about urinary H-FABP in human renal  disease. It predicts prognosis 
in patients with idiopathic  membranous nephropathy.30 We found that urinary 
H-FABP predicts graft failure in the crude model, suggesting that distal tubuli 
are also affected in chronic allograft nephropathy. 
NGAL is a 25 kDa protein bound to gelatinase from neutrophils and normally 
expressed at very low levels in human tissues, including the kidney. 
Expression is augmented in injured epithelia. 31 NGAL has been investigated 
extensively in acute kidney disease and the acute phase after 
transplantation, and more recently in ischemic  renal  function impairment in 
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heart failure.32 Little is known about NGAL in the chronic  phase after kidney 
transplantation. One study in patients with a stable graft showed that 
subclinical tubulitis was associated with higher levels of NGAL. 
The finding that albuminuria outperforms proteinuria is in line with the study 
of Halimi11, that also showed that albuminuria is a good predictor of graft 
loss, even in non-proteinuric  patients. This cohort has differences compared 
to our study. Mean donor age is lower in our study (36.9 vs 48 years), partly 
because our percentage of deceased donors is lower (86 vs 99%), and our 
follow-up time for graft failure is longer (median follow-up 4.7 vs 3.33 years). 
Furthermore, we not only looked at albuminuria and proteinuria, but also at 
specific tubular damage markers. Thus, although the risk profile for graft 
failure might be lower in our cohort, we show that albuminuria predicts graft 
failure better than proteinuria. 
With respect to change in eGFR during follow-up, there are to our knowledge 
no other studies in kidney transplant recipients investigating the predictive 
value of albuminuria, proteinuria and tubular damage markers. Our data 
indicate that albuminuria predicts change in eGFR during follow-up better 
than proteinuria or tubular damage markers.  Furthermore, albuminuria 
predicts renal function decline independent of age, sex, eGFR at baseline, 
as do 2 out of 4 tubular damage markers; KIM-1 and H-FABP. In addition, we 
found that H-FABP is the only biomarker that predicts renal function decline 
independent of albuminuria. Whereas KIM-1 is a marker of damage of the 
proximal  tubule, H-FABP is a marker of distal  tubular damage. These 
findings thus suggest that not only the proximal tubule, but also the distal 
tubule is affected in chronic renal allograft injury. 
Why does albuminuria predict renal transplant outcome better than 
proteinuria? In our cohort almost all patients (97%) have proteinuria >0.1g/
24hour whereas only 57% of all patients have albuminuria >30 mg/24 hour. 
This is in line with a study that showed in renal  transplant recipients that low-
grade proteinuria (<1 g/d) consists mostly of non-albumin-proteins, whereas 
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massive proteinuria (>1 g/d) consists mostly of albumin.33 Total protein 
excretion in our patients will  consist of a large variety in proteins, with very 
different charge and size characteristics. The more uniform character of 
albuminuria could make albuminuria outperform proteinuria in predicting 
kidney outcome.
We found that all  tubular damage markers predict graft failure in crude 
models. However, when albuminuria is added, these markers do not have 
additive predictive value. The only exception is H-FABP, but this tubular 
damage marker had additive predictive value for only change in eGFR.. 
These data suggest that albuminuria in these patients reflects or inflicts 
tubular damage. Furthermore, this observation makes that the clinical use of 
these tubular biomarkers on top of albuminuria to predict renal outcome in 
stable renal transplant recipients is limited. 
We acknowledge that this study has limitations. First, it is a single-center 
study and the predictive capacity of the investigated biomarkers needs to be 
confirmed in multicenter studies. Second, the renal transplant recipients 
were included at different time points after transplantation. This could 
theoretically induce healthy survivor bias. It is therefore advisable to 
investigate the predictive capacity of the urinary biomarkers on renal 
outcome at a fixed time-point after transplantation. Patients were included at 
least one year after transplantation and 80% had proteinuria <1 gram/day. 
The validity of the results is therefore limited to such selected population. 
Furthermore, the investigated biomarkers should be analyzed in relation to 
the histological diagnosis. Strengths of this study are that, as far as we know, 
it is the first study to investigate the predictive value of these tubular damage 
markers on renal  transplant outcome in stable renal transplant recipients. 
We not only looked at graft failure but also at renal function decline, which 
may enable much earlier identification of patients at risk. Furthermore, we 
studied several  tubular damage markers representing different functional 
entities of the tubule. Lastly, this study has been performed in a relatively 
large number of subjects and has sufficient duration of follow up.
94
In conclusion, we show that albuminuria outperforms proteinuria in predicting 
graft failure and renal function decline. We also show that all investigated 
tubular damage markers predict graft failure in a crude model. However, 
when adjusted for age, sex and baseline eGFR only KIM-1 predicts both 
change in eGFR and graft failure during follow-up. When albuminuria is 
entered into the models no tubular damage marker has added value in 
predicting both renal  outcome measures. Therefore, we conclude that 
assessing tubular damage markers has limited clinical  value in renal 
transplant recipients. In contrast, albuminuria is a strong predictor of both 
eGFR loss and graft failure, independent of all four tubular damage markers 
and proteinuria. Therefore, this study indicates that albuminuria instead of 
proteinuria, may be superior for identification of subjects at risk for renal 
allograft failure who may benefit from intervention or change in therapy.  
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Supplementary tables
Supplementary table 1 Correlation between all 24 hour damage marker excretions.
Protein Albumin KIM-1 NGAL NAG H-FABP
Protein 0.46 * 0.35 * 0.33 * 0.34 * 0.24 *
Albumin 0.46 * 0.54 * 0.18 * 0.36 * 0.27 *
KIM-1 0.35 * 0.54 * 0.10 ** 0.39 * 0.26 *
NGAL 0.33 * 0.18 * 0.10 ** 0.24 * 0.18 *
NAG 0.34 * 0.36 * 0.39 * 0.24 * 0.27 *
H-FABP 0.24 * 0.27 * 0.26 * 0.18 * 0.27 *
Data are given as Spearmans Rho. * Correlation is significant at the 0.001 level (2-tailed). ** 
Correlation is significant at the 0.05 level (2-tailed).
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Sensitivity analysis by using biomarker/creatinine ratio instead of 24h biomarker excretion
Supplementary table 2 Association between biomarkers at baseline and death censored graft failure 
during follow-up










- Proteinuria 2.1 (1.5-2.9) <0.001 1.7 (1.3-2.4)   0.001 1.2 (0.8-1.8) 0.3 1.8 (1.2-2.8)   0.007
- Albuminuria 3.4 (2.4-4.9) <0.001 2.1 (1.5-3.0) <0.001 NA NA NA NA
Proximal 
tubular
- KIM-1 3.7 (20.-6.7) <0.001 2.2 (1.2-3.8)   0.007 1.2 (0.6-2.3) 0.6 20. (1.3-3.0)   0.002
- NAG 4.2 (2.6-6.9) <0.001 2.0 (1.2-3.3)   0.006 1.6 (0.9-2.7) 0.09 1.9 (1.3-2.8) <0.001
- NGAL 1.7 (1.3-2.2) <0.001 1.4 (1.0-1.8)   0.03 1.2 (0.9-1.6) 0.2 2.0 (1.4-2.9) <0.001
Distal tubular 







- Proteinuria 1.3 (0.8-2.0) 0.3 1.8 (1.1-3.0)   0.02
- Albuminuria NA NA 2.1 (1.4-3.2) <0.001
Proximal 
tubular
- KIM-1 1.1 (0.6-2.2) 0.7 2.0 (1.2-3.3)   0.007
- NAG 1.6 (0.9-2.8) 0.09 2.0 (1.4-2.9)   0.001
- NGAL 1.3 (1.0-1.7) 2.0 (1.4-3.0) <0.001
Distal tubular 
- H-FABP 1.1 (0.7-1.5) 0.8 2.1 (1.4-3.2)   0.001
Data are given as Hazard Rates (95% Confidence Interval) and p-values. Biomarker excretions 
are 2log transformed, resulting in expression of Hazard Ratios indicating a risk for death 
censored graft failure per two fold increase of the biomarker excretion under investigation. 2log 
biomarker excretions have been converted to a Z-scale, enabling Hazard Rates to be compared 
with another. Model 1: Crude model ; model 2: Adjustment for age, sex and eGFR; model 3: 
Model 2 + albuminuria; model 4: Model 3 + time between renal Tx and baseline, donor age, 
living related or cadaveric Tx, BMI, MAP, smoking, total cholesterol, duration warm ischemia 
time, duration cold ischemia time, acute rejections, use of calcineurin inhibitors, diabetes 
mellitus and daily dose of prednisolon at baseline.
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Sensitivity analysis by using biomarker/creatinine ratio instead of 24h biomarker 
excretion. 
Supplementary table 3 Association between biomarkers at baseline and change in eGFR per 
year during follow-up






































































































Data are given as standardized β and p-values. Biomarker excretions are 2log transformed to 
fulfil requirements of linear regression analysis. Standardized β show increased risk on 1 ml/
min/per year decrease in eGFR per two fold increase of biomarker excretion. Model 1: Crude 
model; model 2: Adjustment for age, sex and eGFR; model 3: Model 2 + albuminuria; model 4: 
Model 3 + time between renal Tx and baseline, donor age, living related or cadaveric Tx, BMI, 
MAP, smoking, total cholesterol, duration warm ischemia time, duration cold ischemia time, 





Glomerular and tubular damage markers in subjects with 











Albuminuria is associated with risk for renal and cardiovascular disease. It is 
difficult to predict which subjects will progress in albuminuria. We 
investigated whether assessment of urinary markers representing damage to 
different parts of the nephron help to identify subjects that will  progress in 
albuminuria.
Subjects were selected from a prospective community-based cohort study 
with serial follow-up (PREVEND, n=8592) and defined as progressor if they 
were in the 20% with most rapid annual increase in albuminuria and reached 
albuminuria 150 mg/d during follow-up. Subjects with known renal disease 
were excluded. Each progressors was matched to 2 control  subjects, based 
on age, sex and baseline albuminuria. IgG and IgG-4 were measured as 
glomerular markers, KIM-1, NAG, β-2-microglobulin, cystatin C as proximal 
tubular damage markers, H-FABP as marker of distal tubular damage and 
NGAL and MCP-1 as inflammatory markers.
After a median follow-up of 9.3 yrs, 183 subjects met criteria for progressive 
albuminuria. Baseline clinical  characteristics were comparable between 
progressors and controls. However, both urinary and fractional excretion of 
IgG were significantly higher in progressors (p<0.001), whereas urinary and 
fractional excretion of all proximal  tubular markers except cystatin C were 
lower (all p<0.01).
These data suggest that albuminuria associated with glomerular damage is 
more likely to progress, whereas albuminuria associated with tubulo-
interstitial damage is more likely to remain stable.
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Introduction
Albuminuria predicts cardiovascular events and renal  function decline in 
patients with diabetes mellitus1 and hypertension2, in elderly subjects3 and 
even in the general  population4-7. A spontaneous increase in albuminuria is 
even more strongly associated with accelerated renal function decline and 
mortality in patients with diabetes.8 This has also been demonstrated for 
cardiovascular events in the general population.9 
Albuminuria is the result of two counteracting processes; glomerular leakage 
and tubular reabsorption. It has been argued that albuminuria (especially in 
the micro-albuminuric range) is a marker of glomerular damage related to 
generalized atherosclerosis10. However, higher levels of albuminuria may 
also be explained by another process. According to the tubular hypoxia 
hypothesis11 generalized atherosclerosis decreases blood flow in peritubular 
capillaries. This results in impaired oxygen diffusion and oxygen supply to 
tubular cells, leading to tubulo-interstitial damage and interstitial fibrosis. In 
turn, these processes lead to impaired tubular albumin reabsorption. 
Recently, it has become possible to measure in urine samples markers that 
represent damage to different parts of the nephron.12 These damage 
markers have initially drawn much attention as possible early predictors of 
acute kidney injury, but lately also as predictors for progressive CKD.13-16 In 
these studies progressive CKD was defined as loss of GFR. As yet, no study 
has investigated whether progressive albuminuria is accompanied by a 
higher excretion of glomerular or tubular damage markers. 
We therefore measured the excretion of various of these markers in urine 
samples of subjects from the general population that had progressive 
albuminuria and of matched control subjects. As glomerular damage markers 
we measured IgG and IgG-4; as proximal tubular damage markers KIM-1, 
NAG, β-2-microglobulin, cystatin C; as distal tubular damage marker H-




This study is performed as a nested case-control  study using information 
and samples obtained from subjects participating in the Prevention of Renal 
and Vascular End Stage Disease (PREVEND) study. The PREVEND study is 
a prospective cohort study, that investigates the association of albuminuria 
with renal  and cardiovascular disease progression. Details of this study have 
been published elsewhere.17 The PREVEND study was approved by the 
medical ethics committee of our institution and conducted in accordance with 
the guidelines of the Declaration of Helsinki. All  participants gave written 
informed consent.
Measurements and definitions
At the baseline and follow-up screening rounds, all participants completed a 
questionnaire on demographics, disease history, smoking habits and use of 
medication. For each screening round, participants visited an outpatient unit. 
During this visit, height, weight and blood pressure was measured (Dinamap 
XL Model 9300; Johnson-Johnson Medical, Tampa, FL), and a fasting blood 
sample was drawn. Hypertension was defined according the JNC-7 criteria 
as use of antihypertensive drugs, a systolic  blood pressure >140 mmHg, or a 
diastolic  blood pressure >90 mmHg. Diabetes Mellitus was defined 
according the ADA criteria as use of glucose lowering drugs, a fasting 
glucose >7 mmol/L or a non-fast ing glucose >11.1 mmol/L. 
Hypercholesterolemie was defined as total  cholesterol  >= 6.0 mmol/L. 
Concentrations of cholesterol, glucose, and creatinine were measured using 
standard methods.  Furthermore, plasma samples used for biomarker 
measurements were stored at -80 ºC. GFR was estimated (eGFR) with the 
modified Modification of Diet in Renal  Disease (MDRD) formula, taking into 
account gender, age, race, and serum creatinine concentration. At each 
screening round two 24-h urine samples were collected. Urine samples for 
biomarker measurements were stored at -20 C. Urinary albumin 
concentration was determined in fresh urine samples by nephelometry with a 
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threshold of 2.3 mg/L and intra- and interassay coefficients of variation (CV) 
of 2.2 and 2.6%, respectively (BNII; Dade Behring Diagnostic, Marburg, 
Germany). Urinary albumin excretion (UAE) is given as the mean of the two 
24-h UAEs.
Definition of cases and controls
For the present analyses subjects were excluded when the were known with 
renal  disease according to their questionnaire or in case baseline 
albuminuria exceeded 300 mg/24h (n=381), leaving 8,211 subjects. Change 
in albuminuria during follow-up was assessed as last available albuminuria 
value during follow-up minus baseline albuminuria, divided by follow-up time 
in years. Subjects were defined as having progressive albuminuria (cases) 
when they belonged to the 20% of subjects with the most rapid progression 
in albuminuria, and that had an albuminuria in excess of 150 mg/24h during 
follow-up. These subjects were 1:2 randomly matched to controls, with 
matching criteria being sex, age and baseline albuminuria. 
Measurements of Damage Markers
After thawing urine and plasma samples were vortexed and subsequently 
centrifuged (14.000 rpm). The supernatant was used for measurements. All 
urinary as well as all plasma biomarkers were determined in one run. As 
markers of glomerular damage we measured urinary Immunoglobulin G 
(IgG) and Immunoglobulin G4 (IgG-4)18,19 The tubular injury markers 
investigated here reflect injury to different segments of the nephron and are 
mediated by different processes. Kidney-Injury-Molecule 1 (KIM-1), N-acetyl-
β-D-glucosaminidase (NAG), Cystatine C and ß-2-microglobuline (β2MG) 
were measured as markers for proximal tubular damage.20-22  As marker of 
distal tubular damage we measured heart-type fatty acid-binding protein (H-
FABP),23;24 whereas neutrophil  gelatinase-associated lipocalin (NGAL) and 
monocyte chemoattractant protein-1 (MCP-1) were measured as markers of 
inflammation.25;26
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For quantification of IgG and IgG-4, NGAL, β2MG, MCP-1, and H-FABP we 
used direct sandwich-enzyme-linked immunosorbent assays using 
monoclonal coating antibodies and labelled polyclonal detection antibodies 
on a Maxisorp plate (Nunc, Denmark) in which is the concentration of the 
analyte was determined spectrophotometrically by conversion of o-
phenylenediamine by Horse-Radish Peroxidase label. H-FABP antibodies 
were obtained from Hytest (Turku, Finland), whereas KIM-1, β-2-
microglobulin, MCP-1 and NGAL antibodies were obtained from R&D 
systems (Minneapolis, USA). The intra-assay coefficients of variation of 
these ELISA’s were 9.3%, 7.4%, 9.7%,15.7 and 6.8% respectively. Cystatin 
C was measured by nephelometry (reagents obtained from Siemens, 
Marburg, Germany, intra-assay CV 2.7%). Urinary concentration of NAG was 
measured using a modified enzyme assay according to Lockwood and 
corrected for nonspecific  conversion (HaemoScan, Groningen, The 
Netherlands, intra-assay CV 3.1%). All samples were measured in duplicate 
in both urine and plasma. Fractional excretions were calculated as: FE 
damage marker = ([marker]u x [creat]p) / ([marker]p x [crea]u )) x 100%, 
where abbreviations are : FE, fractional excretion; crea, creatinine; u, 
urinary; p, plasma.
Statistical analyses
Analyses were performed with SPSS version 18.0 (SPSS Inc., Chicago, IL). 
Parametric variables are expressed as mean ± standard deviation (SD), 
whereas non-parametric  variables are given as median (25th and 75th 
percentile). P-values for differences in damage markers between 
progressors and controls were tested using a Mann-Whitney test. 
Correlations and corresponding p-values are expressed as Spearmans 
correlation coefficients (rho). Glomerular charge selectivity was calculated by 
dividing the fractional  excretion of the positively charged total IgG by the 
fractional excretion of the negatively charged IgG-4. For all  analyses a two 
sided p< 0.05 was considered to indicate statistical significance.
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Results
The selection of subjects with progression in albuminuria (“progressors”) 
from the general  PREVEND cohort is shown in figure 1. From a total  of 
8,394 subjects at baseline, 183 met our criteria for defining progression in 
albuminuria. Of note, for each subject the last available information during 
follow-up was used to define progressive albuminuria. For 111 subjects 
information was available of 4 screening rounds, for 44 subjects information 
was available of 3 screening rounds, and for 28 subjects information was 
available of only 2 screening rounds. These subjects were 1:2 matched on 
age, sex and baseline albuminuria to subjects not selected as progressor. 
Characteristics at baseline and their last follow-up visit are shown in table 1 
for progressors and controls. Progressors were in general male (77%), 59 
years old (11) and had a median urinary albumin excretion of 58 mg/24h 
(33-106). Clinical characteristics between progressors and matched controls 
were in general similar, although progressors used more antihypertensive 
drugs (41% vs 27%), but had a lower diastolic  blood pressure (79 vs 81 
mmHg) and a slightly higher BMI (28 vs 27 kg/m2). Baseline eGFR and 
mean follow-up time were comparable between progressors and controls (75 
vs 76 ml/min, and 9.4 vs 9.3 years, respectively). During follow-up 
progressors had an increase in albuminuria from 58 to 254 mg/24h 
(p<0.001), whereas albuminuria decreased slightly in controls (from 52 to 39 
mg/24h, p<0.001).
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Table 1 Characteristics at baseline and last follow-up visit of subjects with progressive 
albuminuria (“progressors”) and their controls (matched for age, sex and baseline albuminuria) 





visit p-value  
Age (yr) 50 (13) 59 (11) 67 (11) 59 (11) 67 (11) 0.88
Male (%) 50 77 77 77 77 0.97
Follow-up (years) - - 9.4 (0.8) - 9.3 (0.8) -
Smoking (%) 38 40 23 36 18 0.39
Baseline history CVD (%) 5 14 - 11 - 0.24
BMI (kg/m2) 26.1 (4.2) 28.3 (4.1) 28.7 (4.8) 27.5 (4.1) 27.6 (4.8) 0.03
SBP (mmHg) 129 (20) 141 (21) 146 (23) 145 (23) 138 (20) 0.076
DBP (mmHg) 74 (10) 79 (9) 79 (10) 81 (10.6) 77 (9) 0.024
Blood pressure lowering 
drugs (%) 15 41 60 27 58 0.001
ACEi/ARB (%) 5.5 14 - 36 - 0.36
Hypertension (%) 33 66 78 65 69 0.78
Cholesterol (mmol/L) 5.6 (1.1) 5.8 (1.2) 4.9 (1.2) 5.9 (1.1) 4.9 (1.1) 0.068
Lipid lowering drugs (%) 6 14 38 11 35 0.42












Glucose lowering drugs (%) 2 4 18 5 17 0.74
Diabetes Mellitus 3 12 21 11 18 0.90












P-values are shown for difference in baseline values between progressors and controls. Mean (SD) or 
median (25th -75th percentile). P-values are calculated using Mann Whitney U test. Abbreviations are: 
CVD, cardiovascular disease; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; ACEi, Angiotensin Converting Enzyme inhibitor; ARB, Angiotensin II Receptor 
Blockers; eGFR, estimated Glomerular Filtration Rate; UAE, urinary albumin excretion.
Figure 1 Selection of subjects with progressive albuminuria (n=183) from the PREVEND cohort. 
Urinary excretion of renal damage markers
Table 2 Baseline urinary excretions of renal damage markers at baseline 
Progressors Controls p-value
- Albumin (mg/24h) 58 (33-106) 52 (31-88) 0.24
Glomerular
- IgG (µg/24g) 1285 (926-2181) 1118 (696-2039)   0.009
- IgG-4 (µg/24g) 158 (0-239) 174 (0-290) 0.14
Proximal tubular
- KIM-1 (µg/24h) 3.9 (1.9-7.0) 7.4 (3.2-15.0) <0.001
- CysC (µg/24h) 0.011 (0.005-0.030) 0.015 (0.005-0.041) 0.24
- β-2-microglobulin (µg/24h) 103 (39-395) 169 (58-641)   0.004
- NAG (U/24h) 0.011 (0.000-0.255) 0.694 (0.000-1.863) <0.001
Inflammatory
- NGAL (µg/24h) 5.5 (2.7-9.6) 6.7 (3.9-11.4)   0.011
- MCP-1 (ng/24h) 467 (261-825) 741 (522-911) <0.001
Distal tubular
- H-FABP (µg/24h) 3.4 (0.8-7.2) 2.0 (5.9-7.3)   0.083
Medians (25-75 pct). P-values are calculated using Mann-Whitney test
Table 2 shows the urinary excretion of markers representing damage to 
different segments of the nephron. As listed, the glomerular marker total  IgG 
was significantly higher in progressors, whereas negatively charged IgG-4 
was similar in both groups. All  proximal tubular markers, except cystatin C, 
and the general  inflammation markers NGAL and MCP-1 were significantly 
lower in progressors compared to controls. In contrast, the distal tubular 
marker H-FABP tended to be higher in the progressors. 
Fractional excretions of renal damage markers
To exclude that differences in plasma concentrations of the damage markers 
may have caused the differences in urinary excretion between progressors 
and controls, we also measured also plasma concentrations of these 
damage markers and calculated their fractional  excretions. As listed in table 
3, these findings corroborate the results observed with respect to urinary 
excretion: the fractional  excretion of the glomerular marker IgG was 
significantly higher in progressors, whereas the fractional excretions of all 
proximal  tubular markers, except cystatin C, and of general inflammation 
markers were significantly lower in progressors. The fractional excretion of 
the distal  tubular marker H-FABP, however, was significantly higher in 
progressors. The index of the fractional excretions18;19 of total IgG and IgG-4 
was 0.28 (0.11-0.73) for progressors and 0.10 (0.03-0.28) for controls 
(p<0.001).
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- IgG (%) 8.0*10-5 (5.0 -15*10-5) 5*10-5 (2-16*10-5) <0.001
- IgG-4 (%) 1.1*10-4 (0-4.0*10-4) 1.0*10-4 (0-4.2*10-4) 0.59
Proximal tubular
- KIM-1 (%) 13.9 (0.9-1713) 1095 (5.2-4368) <0.001
- CysC (%) 0.01 (0-0.02) 0.01 (0-0.02) 0.58
- β-2-microglobulin (%) 0.04 (0.01-0.20) 0.07 (0.02-0.36) 0.03
- NAG (%) 1.2 *10-3 (0-3.1*10-2) 55*10-3 (0-0.16) <0.001
Inflammatory
- NGAL (%) 0.04 (0.02-0.07) 0.05 (0.03-0.10)   0.002
- MCP-1 (%) 7.00 (3.58-11.25) 17.46 (11.05-28.54) <0.001
Distal tubular
- H-FABP (%) 1.31 (0.23-6.71) 0.69 (0.09-3.86) 0.03
Medians (25-75 pct). P-values are calculated using Mann Whitney U test. 
Correlations between markers
Table 4 shows correlations between all markers under investigation. Data 
are given separately for progressors and controls. As listed, almost all 
markers were significantly correlated to albuminuria and to each other. 
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Correlations are shown as Spearmans rho and corresponding p-value in subjects with 




Several  sensitivity analyses were performed. Theoretically participants 
defined as progressor or controls could have been misclassified because of 
urine collection errors at baseline. For instance, when progressors missed a 
portion of their 24hr urine collection, their baseline albuminuria will be falsely 
low. When their urine collection at the next visit is correct, they may be 
misclassified as progressor in albuminuria. Concomitantly these subjects will 
also have low values for renal damage markers at baseline, since these are 
measured in the same 24hr urine samples, which may lead to bias. 
However, 24hr urinary volume and creatinine excretion did not differ between 
progressors and controls at baseline (1644 vs 1573 ml/24h, p=0.10) and 
(13.2 vs 13.5 mmol/24h, p=0.29). Furthermore, when all  damage marker 
concentrations were expressed per mmol urinary creatinine this yielded 
similar results as when 24-hour excretions were studied (data not shown). 
Furthermore, we investigated whether a difference in prescription rate of 
albuminuria lowering drugs during follow-up in controls versus progressors 
may have influenced our results. When all subjects were excluded that 
started with blood pressure lowering drugs (including ACEi and ARB’s) and 
glucose lowering drugs, 103 progressors and 195 controls remain. Using 
these strict criteria essentially similar results were obtained. 
Discussion
In the present study, we investigated the 24hr urinary excretion of markers 
representing damage to different parts of the nephron in subjects that 
progress in albuminuria and in matched controls. We found that in subjects 
that progress in albuminuria the urinary excretion of the glomerular marker 
IgG and the distal  tubular damage marker H-FABP were higher when 
compared to controls. In contrast, the urinary excretion of most proximal 
tubular damage markers and general inflammation markers were lower in 
progressors. Analysis of fractional excretion data yielded similar results, 
suggesting that differences in plasma concentrations did not influence our 
results. 
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How do these data compare to current literature? Recently, a number of 
studies have been published investigating whether urinary excretion of these 
damage markers is associated with progression of chronic kidney disease. 
For instance, the glomerular damage marker IgG was found to predict the 
onset of end-stage-renal-disease in CKD patients.27 Several  markers of 
damage to the proximal tubule have been reported to predict renal function 
decline in patients with CKD14,15,28 and renal transplant recipients.29 Similar 
findings have been obtained for the urinary excretion of the distal  tubular 
marker H-FABP30 and the inflammation markers NGAL and MCP-1.16;31 It is 
important to note that in all these studies progression of CKD was expressed 
as decrease in GFR. However, definition and staging of CKD is not only 
dependent on level of GFR, but also on level of albuminuria.32 Therefore 
progression of CKD can also be expressed as a change in albuminuria. Of 
note, an increase in albuminuria generally is an early sign of CKD 
progression, whereas a fall  in GFR mostly refers to a later phase of CKD 
progression. Higher levels of albuminuria are associated with an increased 
risk for all-cause and cardiovascular mortality and with an increased risk for 
several kidney related outcomes.33-35 Furthermore, an increase in 
albuminuria was especially associated with increased mortality and renal 
function decline.8 Little is known how glomerular and tubular damage 
markers relate to progression in albuminuria. Kern at el  reported that in 
patients with diabetes mellitus urinary NAG predicted the occurrence of 
albuminuria.36 We are to our knowledge the first to investigate in subjects 
selected form a population based cohort how a panel of markers 
representing damage to different parts of the nephron relate to progression 
of albuminuria. 
A priori  we hypothesised that all damage markers would be higher, or at 
least equal, in subjects that progress in albuminuria when compared to 
subjects with stable albuminuria. We expected to find that markers related to 
a specific  part of the nephron would be especially increased and helpful  to 
identify subjects that will  show progressive albuminuria. We indeed found 
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that in these subjects at baseline the urinary excretion of markers indicating 
damage to the glomerulus (IgG) was significantly higher. This suggests that 
especially damage to the glomerulus is associated with progression in 
albuminuria. Furthermore, since in our study progressors had higher urinary 
excretion and fractional excretion of IgG, but not of the neutrally charged 
IgG-4, this suggests that loss of glomerular size selectivity is associated with 
progressive albuminuria, rather than loss of charge selectivity. This is 
corroborated by a higher total IgG / IgG-4 index in progressors compared to 
controls. 
To our surprise we found that markers representing damage to the proximal 
tubule and markers representing inflammation were significantly lower in the 
subjects with progressive albuminuria than in controls. In retrospect we think 
that this may be explained by the fact that by design controls were matched 
to progressors on baseline albuminuria. We choose for this design because 
a priori it seemed most suited to answer the question whether it is possible 
to make a distinction between subjects with a given level  of albuminuria that 
will  progress or remain stable. As explained in the introduction section 
albuminuria is the result of two counteracting processes, glomerular filtration 
and tubular reabsorption. When controls have similar albuminuria when 
compared to progressor, but less glomerular loss of albuminuria, they should 
qualitate qua have less tubular reabsorption of albumin. This may explain 
why we found proximal tubular damage markers to be higher in controls than 
in cases. This finding, however, does not deny that subjects with progressive 
albuminuria have also damage to their proximal tubules. At baseline cases 
as well as controls had more albuminuria than the overall population of our 
cohort study. We and others have found that albuminuria is positively 
associated with the urinary excretion of markers indicating damage tot the 
proximal  tubule.37;38 This is corroborated in the present study, since we found 
such an association in cases as well  as controls (Table 4A and 4B, 
respectively).        
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Our study has limitations that need to be mentioned. First, albuminuria is 
known to show short-term fluctuations that are not due to real progression. 
For that reason, however, we choose strict criteria to define progression. 
Consequently, the subjects that met our definition of progressive albuminuria 
showed an increase in albuminuria from 58 mg/24h at baseline to 254 mg/
24h at the last follow-up visit. Such a rise in albuminuria is unlikely to be the 
result of random fluctuation, but suggests true progression in albuminuria. 
Second, all  markers were measured in urine samples that have been stored 
at -20º C. It has been suggested that prolonged frozen storage influences 
urinary biomarker concentration.39 However, we recently investigated 
whether these markers can be measured from frozen samples with sufficient 
reliability. We found for all damage markers that were used in the present 
study that concentrations measured in urine samples after storage at -20º C 
yielded significant associations with the concentrations of these markers 
when measured in fresh urine samples (data submitted). Furthermore, a 
possible storage effect would affect samples from progressors and controls 
to the same extent, since they have been stored under exactly the same 
conditions. Storage effects are therefore unlikely to account for the 
differences between progressors and controls that we found. 
This study also has several strengths. First, we used 24hr urine collections, 
which is the gold standard for assessing albumin and damage marker 
excretions. Other studies use spot urines, which induces more variation.40 
Second, in contrast to most studies investigating the value of these markers 
in CKD, we measured not only one, but a panel of markers, reflecting 
damage to different parts of the nephron. Third, our nested case-control 
study design, selecting subjects with a clinical relevant increase in 
albuminuria from a large cohort of 8592 persons with serial  follow-up with 
respect to albuminuria during more than 9 years, renders a relatively large 
number of cases resulting in sufficient power to draw conclusions. Fourth, 
we investigated not only urinary excretion of these damage markers, but we 
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also corrected for their plasma concentrations by calculating fractional 
excretions. Importantly, this analysis yielded similar results. 
What may be the implications of this study? Our data suggest that subjects 
with albuminuria that is associated with glomerular damage are more likely 
to develop progressive albuminuria than subjects with albuminuria that is 
associated with proximal tubular damage. However, we found considerable 
overlap in damage marker excretions between progressors and controls. It 
will  therefore difficult to predict which subject will progress in albuminuria 
using just one marker. Measuring a panel of markers might be more 
effective. Determining which marker, or combination of markers, is best 
suited for this goal necessitates complex analyses investigating among 
others sensitivity, specificity, predictive value and incremental value of these 
marker combination beyond traditional risk factors. Such analyses are 
beyond the scope of the present study, which was designed primarily to have 
a hypothesis generating pathophysiological character. In that respect it is of 
interest that we showed that measuring the urinary excretions of these 
markers provided nearly the same results as measuring their fractional 
excretions. This renders measuring solely urinary excretions of these 
markers a reliably method to investigate renal damage. 
In conclusion, subjects with albuminuria associated with glomerular damage 
are more likely to develop progressive albuminuria than subjects with 
albuminuria that is more associated with proximal tubular damage. 
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Abstract
Amelioration of proteinuria-driven tubulo-interstitial  injury by renin-
angiotensin-aldosterone system (RAAS) blockade and sodium reduction 
induces renoprotection, and can be monitored by tubular injury markers. We 
tested whether intensive proteinuria reduction -that is below 0.3 g/day- by 
sodium restriction and dual RAAS blockade, further decreases a broad panel 
of tubular markers. Here fore we tested in a cross-over randomized 
controlled trial 52 non-diabetic renal patients with proteinuria (1.9 [0.9-3.4] g/
day) and mildly impaired renal function (69 [50-110] mL/min), and 52 healthy 
subjects.
Patients were treated with combinations of ACE inhibition (lisinopril  40 mg/d), 
placebo, angiotensin receptor blockade (valsartan 320 mg/d), regular sodium 
diet (189±8 mmol Na+/d), and low sodium diet (106±7 mmol Na+/d, p<0.001): 
during four randomly-ordered six-week study periods: 1. Lisinopril+placebo
+regular sodium diet (baseline), 2. Lisinopril+valsartan+regular sodium diet, 
3. Lisinopril+placebo+low sodium diet, 4. Lisinopril+valsartan+low sodium 
diet. We measured 24-hour urinary excretion of markers of proximal (NAG, 
KIM-1, β2MG) and distal  (H-FABP) tubular injury and inflammation (MCP-1, 
NGAL).
All  tubular injury markers were elevated in the renal patients at baseline. 
NAG, β2MG, KIM-1 and H-FABP correlated positively with proteinuria, and 
were reduced along with further proteinuria reduction by combinations of 
lisinopril, valsartan and low sodium diet. The lowest levels of NAG, β2MG, 
and H-FAPB were achieved when proteinuria fell below 0.3 g/day. In 
contrast, MCP-1 and NGAL did not correlate with proteinuria, and were not 
reduced during proteinuria reduction.
In conclusion, markers of proximal and distal tubular injury and inflammation 
are elevated in proteinuric  renal  patients on ACE inhibition, consistent with 
ongoing renal  injury. Intensified treatment with dietary sodium restriction and 
dual  RAAS blockade reduces tubular injury markers in proportion to 
proteinuria, without improvement of tubular inflammation markers.
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Introduction
Reduction of proteinuria and hypertension are the main treatment targets for 
renoprotection1;2. This can be achieved by blockade of the renin-angiotensin-
aldosterone system (RAAS) with angiotensin converting enzyme inhibition 
(ACEi) or angiotensin receptor blockade (ARB) and sodium depletion with 
dietary sodium restriction or diuretics3-6. One of the mechanisms allegedly 
contributing to the renoprotective effect of proteinuria reduction is 
amelioration of proteinuria-driven tubulo-interstitial  injury7. Tubulo-interstitial 
injury is a main determinant of renal  outcome but cannot be assessed 
directly on a routine basis, as this requires renal biopsy8;9. Urinary tubular 
injury markers might provide a useful non-invasive alternative, as these 
markers correlate with tubulo-interstitial injury and predict renal outcome10;11. 
It has recently been reported that reduction of proteinuria by combinations of 
ARB, dietary sodium restriction, and diuretics, is associated with reduction of 
the tubular injury markers N-Acetyl-β-glucosaminidase (NAG) and Kidney 
Injury Molecule 1 (KIM-1) in renal patients12. Interestingly, the lowest levels 
of NAG and KIM-1 were achieved when proteinuria fell below the current 
treatment target of <1.0 g/day, although even in this condition NAG en KIM-1 
remained substantially elevated compared to healthy subjects.13 This may 
reflect ongoing renal  damage and is in line with the hypothesis that further 
reduction of proteinuria, i.e. to below 0.3 g/day, may augment 
renoprotection6. In the current study, we investigated therefore whether 
intensified proteinuria reduction to levels below 0.3 g/day by combinations of 
ACEi, ARB, and dietary sodium restriction, results in further reduction of a 
broad panel of urinary markers reflecting diverse aspects of tubular injury, in 
patients with chronic kidney disease (CKD).
Methods
Patients
This is a post-hoc  analysis of a randomized double-blind placebo-controlled 
cross-over multicenter trial. The protocol was described in detail 
elsewhere14. In short, we studied 52 patients with non-diabetic nephropathy. 
Inclusion criteria were blood pressure ≥ 125/75 mmHg in combination with 
residual  proteinuria ≥ 1.0 g/d during ACEi on maximal  dose (lisinopril 40 mg/
d), creatinine clearance ≥ 30 mL/min, and age ≥18 years. Exclusion criteria 
were systolic  blood pressure ≥ 180 mmHg, diastolic blood pressure ≥ 110 
mmHg, diabetes mellitus, renovascular hypertension, instable renal disease 
as indicated by a decrease in creatinine clearance ≥ 6 mL/min in the 
previous year, a cardiovascular event in the previous six months, 
immunosuppressive treatment, regular use (>1 day/week) of non-steroidal 
anti-inflammatory drugs, pregnancy or breast feeding.
Protocol 
During a run-in period of at least six weeks, patients received ACEi at 
maximal dose (lisinopril  40 mg/day) and stopped other RAAS blockers. 
Additional  antihypertensives were allowed and kept stable during the study. 
No dietary intervention took place during the run-in period. After the run-in 
period patients were treated with combinations of lisinopril 40 mg/d, placebo 
(PLA), ARB at maximal  dose (valsartan 320 mg/d), regular sodium diet (RS; 
target  200 mmol  Na+/day), and low sodium diet (LS; target intake 50 mmol 
Na+/day), during four randomly-ordered six-week study periods: 1. ACEi
+PLA+RS, 2. ACEi+ARB+RS, 3. ACEi+PLA+LS, 4. ACEi+ARB+LS. (Figure 
1) The drug interventions were double blind, whereas the dietary 
interventions were open label. 
 Figure 1 Study design. During a run-in period of ≥6-weeks, ACEi on maximal dose (lisinopril 40 
mg/d) was instituted and other RAAS blockers were stopped. Subsequently, patients were 
treated during four 6-week periods with ACEi on maximal dose (lisinopril 40 mg/d) plus placebo, 
and ACEi plus ARB on maximal dose (lisinopril 40 mg/d plus valsartan 320 mg/d), combined 
with consecutively a regular sodium diet and a low sodium diet, in random order. 
Healthy controls
Fifty-two race, age and gender matched healthy subjects that had no renal 
disease (eGFR >60ml/min and albuminuria <30 mg/24h) or diabetes served 
as controls. These subjects followed a regular sodium diet.
Measurements and calculations
At the end of each 6-week treatment period, patients collected 24 hour urine 
samples, and blood pressure was measured and blood was sampled after 
an overnight fast. Proteinuria was measured in 24 hour urine samples with a 
turbidimetric assay using benzethonium chloride (Modular, Roche 
Diagnostics, Mannheim, Germany). Blood pressure was measured for 15 
minutes at one minute intervals with an automatic device (Dinamap, G E 
Medical Systems, Milwaukee, WI, USA) in the supine position and we used 
the mean of the last three readings. Blood electrolytes, proteins, and urinary 
electrolytes were determined by using an automated multianalyser (Modular, 
Roche Diagnostics, Mannheim, Germany). We assessed dietary sodium 
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intake from urinary sodium excretion. Creatinine clearance was calculated 
from creatinine concentrations in plasma and in 24 hour urine samples.
Damage markers
NAG (N-Acetyl-β-glucosaminidase; 135 kDa) is a lysosymal  enzyme that is 
predominantly produced in the proximal tubule, and released into urine upon 
cellular damage. Elevated urinary NAG predicts the subsequent occurrence 
of albuminuria in diabetic patients16, and was found to predict CKD 
progression better than proteinuria in non-diabetic  CKD17. KIM-1 (kidney 
injury molecule-1; 104 kDa) is a transmembrane glycoprotein that is 
abundantly expressed on proximal tubular cells and shed into urine, during 
acute or chronic  renal  injury.18-20 No other organs express KIM-1 to a degree 
that would influence renal excretion of KIM-1.21 Urinary KIM-1 predicts long-
term renal  outcome in acute renal  injury and renal transplant recipients.22-24 
So far, long-term data on the prognostic significance of urinary KIM-1 in CKD 
are lacking. ß2MG (β2-microglobulin; 12 kDa) is a component of MHC class 
1 molecules, which are present on all nucleated cells. ß2MG is freely filtered 
through the glomerulus and subsequently reabsorbed by proximal  tubular 
cells. Urinary ß2MG is a marker of proximal tubular reabsorption incapacity 
and predicts the rate of CKD progression.25-27 H-FABP (heart-type fatty acid-
binding protein; 15kDa) is an intracellular carrier protein present in cytoplasm 
of distal tubular cells.28;29 Urinary H-FABP results from release by structurally 
damaged tubular cells. Elevated urinary H-FABP predicts prognosis in 
CKD.30 NGAL (neutrophil  gelatinase-associated lipocalin; 25 kDa) is 
expressed by neutrophils and other epithelial  cells. NGAL was found to 
reflect damage to glomeruli, and proximal and distal tubules.31-33 Elevated 
urinary NGAL predicts CKD progression.34 MCP-1 (monocyte 
chemoattractant protein-1; 13-30 kDa) is expressed by inflammatory cells 
such as monocytes, and also by resident renal  cells, i.e. mesangial, 
endothelial, and tubular epithelial  cells.35 Renal cells produce MCP-1 in 
response to a variety of pro-inflammatory stimuli.36 Elevated urinary MCP-1 
predicts the rate of renal function loss in CKD.37;38
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We stored (-80˚C) aliquots from 24 hour urine until  biomarker analysis. All 
urine samples were vortexed and centrifuged (14.000 rpm) after thawing. 
The supernatant was used for measurements. Samples were diluted to 
obtain the optimal concentration for measurement. All  tubular markers were 
determined in one run. We measured urinary albumin levels by 
nephelometry (Dade Behring Nephelometer, intra-assay CV 2.7%). For 
quantification of neutrophil gelatinase-associated lipocalin (NGAL), β2-
microglobulin (β2MG), monocyte chemoattractant protein-1 (MCP-1), and 
heart-type fatty acid-binding protein (H-FABP) we used direct sandwich-
enzyme-linked immunosorbent assays using monoclonal  coating antibodies 
and labeled polyclonal  detection antibodies on a Maxisorp plate (Nunc, 
Denmark) in which is the concentration of the analyte was determined 
spectrophotometrically by conversion of o-phenylenediamine by Horse-
Radish Peroxidase label. H-FABP, NGAL, β2MG, and MCP-1 antibodies 
were obtained from Hytest (Turku, Finland, intra-assay CV 9.3%) and R&D 
systems (Minneapolis, USA, intra-assay CV 6.8 %, 9.7 and 15.7 &, 
respectively). We measured KIM-1 using microbead based ELISA 
(microsphere-based Luminex xMAP technology (Luminex, Austin, TX), with 
polyclonal antibodies raised against the human KIM-1 ectodomain as 
described previously.15 The intra-assay variability was less than 15%. 
Urinary concentration of N-acetyl-β-D-glucosaminidase (NAG) were 
measured using a modified enzyme assay according to Lockwood and 
corrected for nonspecific  conversion (HaemoScan, Groningen, The 
Netherlands, intra-assay CV 3.1%). 
Statistical analysis
Data are given as mean with standard error (SE) when normally distributed 
or otherwise as median with interquartile range (IQR). We used paired t 
tests, Wilcoxon signed rank tests, and Pearson’s χ2 tests (which account for 
the same patients providing data for both treatments) to determine effects of 
treatment. To determine differences between patients and healthy subjects 
independent t tests or Mann-Whitney U tests were used. Multivariate models 
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were used to investigate which factors predict change in tubular injury 
marker excretion. To this purpose, we calculated the change in tubular injury 
marker excretion from baseline (ACEi+RS) for each treatment period and 
used this as a dependant variable in the model. Change in proteinuria, 
change in blood pressure, salt intake and addition of ARB were added as 
covariates in the model. Alpha was set at P<0.05. For all analyses SPSS 
16.0 for Windows (SPSS Inc., Chicago, Illinois, USA) was used.
Results
Participants characteristics
CKD patients and healthy controls were matched for age (51 (2) vs. 53 (2) 
years, p=0.49), gender (83% vs. 73% male, p=0.24) and race (all 
Caucasian). During ACEi combined with regular sodium diet (ACEi+RS), 
which was taken as the reference baseline period, CKD patients had overt 
proteinuria (1.9 (0.9-3.4) g/d), high-normal blood pressure (SBP 134 (3) 
mmHg, DBP 80 (2) mmHg), and mildly impaired renal function (creatinine 
clearance 69 (50-110) mL/min). As expected, healthy controls had no 
relevant albuminuria (8 (6-13) mg/24h, p<0.001), normal renal  function 
(creatinine clearance 130 (6) mL/min, p<0.001), a lower blood pressure 
(SBP 122 (2) mmHg, p=0.002; DBP 74 (1) mmHg, p=0.008) compared to 
CKD patients. Dietary sodium intake, as reflected by urinary sodium 
excretion, was comparable in CKD patients during ACEi+RS and in controls 
(189 (8) vs. 198 (12) mmol Na+/d, p=0.51). Other patient characteristics are 
shown in Table 1. 
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Table 1 Patients characteristics
Number of patients 52
Renal diagnosis
- IgA nephropathy n (%) 15 (29)
- FSGS n (%) 16 (31)
- Membranous NP n (%) 7 (13)
- Hypertensive NP n (%) 6 (12)
- Other / inconclusive n (%) 8 (15)
Use of non-study medication
- Betablocker n (%) 12 (23)
- Calcium channel blocker n (%) 10 (19)
- Alpha blocker n (%) 6 (12)
- Thiazide diuretic n (%) 8 (15)
- Loop diuretic n (%) 5 (10)
- Lipid lowering agent n (%) 30 (58)
Renal diagnoses and non-study medication as used at the end of the run-in period. Non-study 
medication was kept stable during the study. Abbreviations: NP, nephropathy; FSGS, focal 
segmental glomerulosclerosis.
Clinical parameters during the four treatment regimens
In CKD patients, urinary creatinine excretion was comparable during all 
treatment periods, indicating accurate 24-hour urine collection (Table 2). 
Dietary sodium intake, as reflected by urinary sodium excretion, was 
considerably and consistently lower during the LS periods compared with the 
RS, thus reflecting dietary compliance.  Addition of ARB to ACEi resulted in a 
modest decrease in proteinuria, but LS reduced proteinuria more effectively, 
and the lowest proteinuria was achieved by combined ARB and LS added to 
ACEi. ARB did not decrease systolic blood pressure, whereas addition of LS 
significantly reduced systolic  blood pressure, with no further effect of 
combined ARB and LS. Likewise, ARB had no effect on creatinine clearance, 
whereas creatinine clearance was decreased by LS, and was further 
reduced by combined ARB and LS. 
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Table 2 Clinical parameters during the study periods
Regular sodium diet Low sodium diet
ACEi ACEi+ARB ACEi ACEi+ARB
General parameters
- Systolic blood pressure 
(mmHg)
134 (3) 131 (3) 123 (3) * † 121 (3) * †
- Diastolic blood pressure 
(mmHg)
80 (2) 77 (2) 73 (2) * 71 (2) * † 
- proteinuria (g/day) 1.9 (0.9-3.4) 1.6 (0.6-3.4) * 0.9 (0.5-1.7) * † 0.7 (0.4-1.4) * † ‡
- Albuminuria (mg/day) 1635 (759-3159) 1188 (500-2718) * 717 (325-1204) * † 522 (215-1259)*† ‡
- Creatinine clearance 
(mL/min)
69 (50-110) 72 (54-105) 67 (43-93) * † 59 (42-81) * † ‡
- Urinary creatinine 
excretion (mmol/day)
13.8 (0.6) 14.0 (0.5) 13.5 (0.6) 13.4 (0.6)
Sodium status
Urinary sodium excretion 
(mmol/day)
189 (8) 180 (9) 106 (7) * † 105 (8) * †
Body weight (kg) 89 (3) 89 (2) 87 (2) * † 87 (2) * †
Edema n (%) 35 (8) 38 (8) 15 (6) † 8 (4) * †
Plasma sodium (mmol/L) 140.7 (0.4) 140.8 (0.4) 139.5 (0.4) * † 139.1 (0.4) * †
Plasma albumin (g/L) 38 (1) 39 (1) 40 (1) * † 40 (1) * †
Plasma total protein (g/L) 68 (1) 69 (1) 71 (1) * 72 (1) * †
Abbreviations: ACEi, ACEi inhibition; ARB, angiotensin receptor blockade; *p<0.05 vs. ACEi on regular 
sodium diet, †p<0.05 vs. ACEi-ARB on regular sodium diet, ‡p<0.05 vs. ACEi on low sodium diet.  
Tubular injury markers during the four treatment regimens
During ACEi+RS urinary levels of NAG, KIM-1, β2MG, H-FABP, NGAL and 
MCP-1 were all  elevated in CKD patients compared to healthy controls 
(Table 3). The levels of NAG (rho=0.66, p<0.001), KIM-1 (rho= 0.46, 
p=0.001), β2MG (rho=0.42, p=0.003) and H-FABP (rho=0.58, p<0.001) 
positively correlated with proteinuria during ACEi+RS. In contrast, the levels 
of NGAL (rho=-0.12, p=0.40) and MCP-1 (rho=0.18, p=0.22) did not 
correlate significantly with proteinuria during ACEi+RS.
NAG was not significantly altered by the addition of ARB, but was lowered by 
the addition of LS or ARB+LS to ACEi (Table 3). Likewise, KIM-1 was 
reduced by addition of LS or ARB+LS, but not significantly altered by the 
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addition of ARB. β2MG was reduced by addition of ARB, LS, or ARB+LS, to 
ACEi. H-FABP was reduced by the addition of ARB and further reduced by 
the addition of LS, with the lowest levels of H-FABP during the addition of 
ARB+LS to ACEi. NGAL was reduced by the addition of LS, but was not 
significantly altered by the addition of ARB or ARB+LS to ACEi. MCP-1 was 
not altered by any of the regimens.
Table 3 Urinary injury markers during 4 different treatment regimens
Healthy subjects CKD patients
Regular sodium diet Low sodium diet
ACEi ACEi ACEi+ARB














(µg/24h) 108 (65-166) 148 (78-2444)
# 140 (62-712)* 136 (51-362) * 106 (57-760) *
H-FABP
(µg/24h) 4 (1-6) 29 (17-94)
# 31 (12-65)# * 18 (9-41)# *† 13 (8-39)# *† ‡
NGAL
(µg/24h) 3 (2-3) 42 (3-65)




(470-1276) # 717 (468-1069)
# 810 (407-1200)# 763 (421-1448)#
Abbreviations: ACEi, ACEi inhibition; ARB, angiotensin receptor blockade; RS, regular sodium 
diet, LS, low sodium diet. #p<0.05 vs. healthy subjects, *p<0.05 vs. CKD on ACEi+RS, †p<0.05 
vs. CKD on ACEi+ARB+RS, ‡p<0.05 vs. CKD on ACEi+LS.
Tubular injury markers according to achieved proteinuria
The number of patients that reached the proteinuria target of <0.3 g/day was 
largest (n=12) during combined treatment with ACEi+ARB+LS (Table 2). 
Individual data for this treatment period, with respect to the levels of the 
different tubular markers are given in figure 2 by a break-up by achieved 
proteinuria. For the proximal tubular injury markers NAG and β2MG and the 
distal tubular injury marker H-FABP, the levels were progressively lower in 
the patients that achieved proteinuria < 1 and < 0.3 g/day respectively. In 
contrast, the proximal tubular marker KIM-1 showed no differences for the 
different proteinuria categories, and the tubular inflammation markers NGAL 
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and MCP-1 were not lower in patients with a lower achieved proteinuria. 
Similar trends as during e.g. ACEi+ARB+LS were found during the other 
treatment regimens (data not shown). Underlying renal  diagnoses were not 
essentially different between the patients groups that achieved proteinuria 
<0.3 (g/d) and >0.3(g/d). We further studied the subgroup of patients that 
reached proteinuria < 0.3 g/day during ACEi+ARB+LS, and found no 
differences in patient characteristics between patients in whom tubular 
inflammatory markers rose versus patients in whom tubular inflammatory 
markers decreased during ACEi+ARB+LS. 
Predictors of change in tubular markers
In a multivariate analysis we investigated whether the change in urinary 
tubular marker excretion is associated with the change in proteinuria, blood 
pressure, salt intake or addition of ARB. We found that for all  markers the 
change in tubular marker was positively correlated with the change in 
proteinuria, whereas for change in blood pressure the same was only true for 
NAG and MCP-1 excretion. In this model the treatment regimen per se (ARB 
or salt restricted diet) was no significant predictor of urinary marker 
excretion.
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Figure 2 Individual values for urinary markers subdivided according to achieved proteinuria 
during combined treatment with ACE inhibition plus angiotensin receptor blockade plus low 
sodium diet. *p<0.05 vs. proteinuria >1.0 g/day, †p<0.05 vs. proteinuria between 0.3-1.0 g/day. 
The areas between dotted lines represent the interquartile range in healthy subjects. 
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Discussion 
We found that urinary markers of proximal  tubular injury (NAG, KIM-1, 
β2MG), tubular inflammation (MCP-1, NGAL), and remarkably also distal 
tubular injury (H-FABP), are elevated in non-diabetic  proteinuric  CKD 
patients despite treatment with ACEi on maximally recommended dose. At 
baseline, the proximal  and distal  tubular injury markers (NAG, KIM-1, β2MG, 
H-FABP) correlated with residual  proteinuria, and were reduced along with 
reduction of proteinuria, irrespective the mode of treatment. The lowest 
levels of proximal and distal tubular injury markers were achieved when 
proteinuria fell  below 0.3 g/day. In contrast, the tubular inflammation markers 
(MCP-1, NGAL) did not correlate with proteinuria, and remained roughly 
unaltered despite reduction of proteinuria.
Urinary markers of tubular injury provide a potential  non-invasive tool to 
monitor renal damage10;11. We studied a broad panel of  tubular  markers, 
that reflect different aspects of renal injury in different renal compartments, 
and that are mediated by different processes. NAG, KIM-1 and ß2MG were 
measured as markers for proximal  tubular damage, H-FABP was measured 
as a marker for distal tubular damage, and NGAL and MCP-1 were 
measured as inflammation markers.
All  measured tubular markers were elevated in proteinuric CKD patients 
during monotherapy ACEi compared to healthy controls, suggesting ongoing 
proximal  and distal  tubular injury and tubular inflammation. Indeed, despite 
the proven benefits of monotherapy RAAS blockade, the residual  renal  risk 
remains high in CKD patients4;39. The elevated tubular markers in our CKD 
patients probably reflect this ongoing renal  injury. At baseline, the proximal 
and distal tubular injury markers correlated with proteinuria, and were 
moreover reduced in proportion to the reduction of proteinuria irrespective 
the mode of intervention, suggesting a beneficial  effect of intervention on 
tubular damage. Previous studies also found a tight relationship between 
proteinuria and proximal tubular injury markers12;17;30;37;40;41, and a reduction 
of these markers by antiproteinuric therapy12;17;42. Our data are the first to 
demonstrate a similar association for H-FABP and proteinuria, including an 
effect of antiproteinuric therapy. This is remarkable, as the distal  tubule is 
classically assumed to be less sensitive to the toxic  effects of urinary 
proteins. In line with our current findings, recent other data challenge this 
latter assumption30;41.
In contrast, the tubular inflammation markers (MCP-1, NGAL) remained 
roughly unaltered despite reduction of proteinuria irrespective of the mode of 
intervention. This was unexpected, as reduction of proteinuria is assumed to 
protect the tubulointerstitium by amelioration of the proinflammatory effects 
of leaked proteins43-45. Whereas the latter assumption is supported by our 
findings on NAG, KIM-1, ß2MG and H-FABP, their reductions dissociate from 
the lack of effect on tubular inflammation makers. It cannot be excluded that 
in our study the interventions were not rigorous enough, or that six weeks of 
treatment was too short for an anti-inflammatory effect to become apparent. 
Alternatively, tubular inflammation as reflected by MCP-1 and NGAL may not 
have been exclusively proteinuria-driven, which would be in line with the 
absence of a correlation between MCP-1, NGAL and proteinuria in these 
patients. Possibly, anti-inflammatory  effects of a reduction in proteinuria per 
se may have been offset by reactive increases in renin or aldosterone, which 
can exert proinflammatory effects.45;51;52 Others also reported absence of a 
correlation between MCP-1 and proteinuria in renal patients without (high-
grade) inflammatory nephropathy treated with RAAS blockade.46;47 However, 
a correlation between (a change in) MCP-1 and proteinuria was present in 
patients with inflammatory nephropathy and in renal patients that were 
treated with immunosuppressive therapy, antibiotics, or oral antidiabetics.
48-50 Hence, the presence of a relationship between (change in) MCP-1 and 
proteinuria may be dependent on renal diagnosis and the mode of treatment. 
Of note, we found no clear association between the various histological 
diagnoses and the level of tubular or inflammatory markers in our study.
The levels of proximal and distal tubular injury markers were lowest in 
patients in whom proteinuria levels fell  below 0.3 g/day. This is in line with 
previous, principally observational, data suggesting that proteinuria below 
0.3 g/day is associated with a better renal outcome.53;6 These data can be 
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considered to support the notion that the current treatment target for 
proteinuria to below 1.0 g/day is too liberal and that titration of treatment to 
obtain proteinuria to levels below 0.3 g/day may be needed for optimal 
renoprotection53;6. However, such a conclusion should be taken with caution. 
First, the discrepancies between the level of inflammatory markers and 
residual  proteinuria indicate that ongoing tubular damage is a complex 
process. Second, it is also not known whether specific titration of residual 
proteinuria to below 0.3 g/day will improve urinary tubular marker profile and 
outcome, or whether the better reduction of tubular injury markers in subjects 
in whom proteinuria fell below 0.3 g/day simply reflects a more benign 
phenotype. It remains to be proven by prospective intervention studies 
whether our short-term findings translate into long-term renal  outcome, in 
other words, whether patients with treatment titration to proteinuria below 0.3 
g/day and low levels of tubular injury markers have slower -or even absent- 
progression to end stage renal disease.
The strengths of this study are that we measured not a single tubular injury 
marker, but a broad panel that reflect diverse aspects of tubular injury and 
are mediated by different processes. We studied not only the cross-sectional 
association between tubular injury markers and proteinuria, but also the 
effect of interventions. Furthermore all samples were measured in one run, 
thus avoiding interassay variation. The major limitations of this study are, 
first, that it is a post-hoc analysis, and second, that it provides short term 
data only. The impact of our data for long-term outcome will require separate 
study. 
In conclusion, urinary markers of proximal and distal tubular injury, and 
tubular inflammation are elevated in non-diabetic proteinuric CKD patients 
with persistent proteinuria despite maximal ACEi, probably reflecting ongoing 
renal injury. Proximal and distal tubular injury markers are reduced along 
with intensified reduction of proteinuria by combinations of ACEi, ARB and 
low sodium diet. Lowest values were obtained during the combination of 
ACEi, ARB and sodium restriction, pleading for prescription of such a 
regimen to achieve optimal  long-term renoprotection. However, markers of 
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tubular inflammation remained largely unaffected and, if anything, increased 
in patients with the lowest proteinuria values. Long-term prospective 
intervention studies should investigate therefore whether titration of 
treatment to achieve proteinuria levels below 0.3 g/day will  further improve 
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Chronic kidney disease is recognized as a major global  public health 
problem.1;2 The disease affects 10–16% of the adult population in Asia, 
Australia, Europe, and the USA.3-6 and increases the risk of all-cause 
mortality, cardiovascular disease, and progression to kidney failure, even 
after accounting for traditional  risk factors such as hypertension and diabetes 
mellitus.1;7 Chronic kidney disease is defined as persistent kidney damage, 
usually marked by albuminuria and reduced glomerular filtration rate (GFR). 
Recently, a meta-analysis of 21 studies has been published investigating the 
combined predictive value of both albuminuria and eGFR on cardiovascular 
and all-cause mortality in the general population.8 It was shown that 
albuminuria and eGFR are independently of each other associated with 
cardiovascular and all-cause mortality. On a smaller scale it has also been 
shown that low eGFR and higher albuminuria predict renal  function decline 
in chronic kidney disease9-11, in high risk population (defined by presence of 
diabetes, hypertension or a cardiovascular disease history), as well  as in the 
general population.12-14 This can be important since albuminuria is also a 
predictor of outcome when eGFR is still  normal. Detection of CKD in an early 
stage offers possibilities to start early treatment and thereby to delay or 
prevent complications of CKD.15
The question arises why albuminuria adds to GFR to predict renal 
prognosis? Albuminuria is the end result of glomerular filtration and tubular 
reabsorption of albumin.16;17 Increased urinary albumin excretion can 
therefore be the result of damaged glomeruli or tubulointerstitial damage. 
GFR and albuminuria independently of each other predict outcomes. Since 
GFR represents glomerular function, this suggests that albuminuria is the 
result of tubular reuptake dysfunction. Therefore it might be that specific 
markers of tubular damage outperform albuminuria or add to the predictive 
capacity of albuminuria to predict renal prognosis. In acute kidney disease it 
has been demonstrated that specific  urinary markers of tubular damage or 
inflammation can predict the onset of kidney failure even before an increase 
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in serum creatinine is observed.18;19 Until recently, little research has been 
done regarding the value of these markers in chronic  kidney disease and in 
the general population. How can these markers be of aid? Several  purposes 
for use can be thought of. First, these markers could be of help in identifying 
patients with early tubulo-interstitial damage. Second, these markers could 
be useful in predicting renal prognosis. Third, they could potentially be used 
as markers to monitor the effect of medication. 
As also stated in the introduction of this thesis, we have measured markers 
of the glomerulus, proximal tubule, distal tubule and general inflammation, 
both in urine as in plasma. Urinary markers of renal injury are elevated 
during glomerular and tubulointerstitial injury and provide a non-invasive tool 
to monitor renal damage. In the studies described in this thesis we measured 
IgG and IgG-4 as glomerular markers. Urinary loss of the positively charged 
IgG (150 kDa) is associated with loss of size selectivity of the glomerular 
basement membrane, whereas urinary loss of the negatively IgG-4 is 
considered to reflect loss of charge selectivity.20
The tubular injury markers investigated here reflect injury in different parts of 
the renal tubule and are mediated by different processes. KIM-1, NAG, 
Cystatine C and ß-2-microglobuline were measured as markers for proximal 
tubular damage and H-FABP as marker for distal  tubular damage. KIM-1 is 
selectively expressed by injured proximal tubular cells.21 KIM-1 expression is 
related to tubulointerstitial  damage and correlates with the severity of kidney 
function impairment.22 NAG (135 kDa) is a lysosymal enzyme that is 
predominantly produced in the proximal tubule, and released into urine upon 
cellular damage. Cystatin C is an endogenous cysteine proteinase inhibitor, 
produced by most nucleated cells at a relatively constant rate and released 
into the plasma. In normal renal function, tubular reabsorption and 
catabolism of cystatin C is almost complete and cystatin C is thus only 
detectable in very small quantities in the urine.23 β-2-microglobulin (12 kDa) 
is a component of MHC class 1 molecules, which are present on all 
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nucleated cells. Β-2-microglobulin is freely filtered through the glomerulus 
and subsequently reabsorbed by proximal tubular cells. Urinary β-2-
microglobulin is a marker of proximal tubular reabsorption incapacity. H-
FABP was measured as marker of distal  tubular damage. H-FABP (15kDa) is 
an intracellular carrier protein that is present in cytoplasm of distal tubular 
cells. Urinary H-FABP results from release by structurally damaged tubular 
cells.24;25  
NGAL and MCP-1 were measured as markers of general  inflammation. 
NGAL (25 kDa) is expressed by neutrophils and other epithelial cells. It was 
found to reflect damage to glomeruli, and proximal and distal tubules.26-28 
MCP-1 (13-30 kDa) is expressed by inflammatory cells such as monocytes, 
and also by resident renal  cells, i.e. mesangial, endothelial, and tubular 
epithelial cells.29 Renal cells produce MCP-1 in response to a variety of pro-
inflammatory stimuli.30 
In chapter 2 these glomerular and tubular damage markers were measured 
in a cohort of 94 patients with diabetes mellitus with normo-, micro- and 
macro-albuminuria. As mentioned above, albuminuria is the end result of 
glomerular filtration and tubular reabsorption. It is increasingly appreciated 
that the renal interstitium plays a role in the pathogenesis of diabetic 
nephropathy, as the consequence of a prolonged exposure to hemodynamic 
and metabolic  injuring factors associated with diabetes mellitus.17;31 
Furthermore, persistent albuminuria secondary to glomerular lesions may be 
directly harmful to renal tubular cells, leading to tubular inflammation and 
fibrosis.32;33 In these patients we found that urinary excretion of all markers 
was higher when compared to non-diabetic healthy controls. Interestingly, 
this was already found in the normo-albuminuric diabetic, who had an eGFR 
and albuminuria comparable to the healthy controls. This suggests that even 
in diabetic patients without any sign of renal damage according to prevailing 
guidelines, already some kind of ‘tubular stress’ is evident. This indicates 
that the investigated markers may be very sensitive damage markers, being 
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already elevated in a very early stage of the disease. Furthermore, almost all 
tubular damage markers were found to be significantly associated with the 
degree of renal  damage, assessed as eGFR and albuminuria. This suggests 
that they might be fit to predict renal function in a longitudinal  study. Of all 5 
investigated urinary tubular markers, the distal tubular marker H-FABP was 
the only one that was significantly associated with eGFR, independent of 
albuminuria. This renders especially H-FABP a promising sensitive marker of 
early diabetic kidney disease. 
In this study, we measured all  damage markers in fresh urine samples. 
Previously it has been shown that frozen storage of urine samples during 1 
year is associated with a decrease in urinary albumin concentration, with a 
wide variation between urine samples in the amount to which albumin 
decreases.34;35  These storage effects are of importance. In epidemiological 
research albuminuria is often measured in urine samples that have been 
stored for prolonged periods of time. It has been shown that the value of 
urinary albumin excretion to predict mortality is considerably better when 
assessed in fresh urine samples in comparison to when assessed in the 
same samples after prolonged frozen storage.36  In a previous study it was 
demonstrated that urinary pH is a determinant of the decline in urinary 
albumin concentration during frozen storage at -20 ºC, with the largest 
decline at pH 5.0, whereas albumin in urine with pH 8.0 showed on average 
no decline.37  
Therefore we investigated in chapter 3  whether alkalinisation of urine 
samples before freezing preserves albumin concentration. 90 urine samples 
of patients with diabetes mellitus visiting a diabetes outpatient clinic  were 
collected and divided into 2 portions. The first portion was adjusted to pH > 8 
and the second was left unprocessed. Albumin concentration was assessed 
in these fresh samples and after 7 days, 1, 6 and 12 months of frozen 
storage at -20 ºC and -80 ºC. We found that pH adjustment to > 8 prevents 
decline and reduces increase in variability of albumin concentration in 
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samples that were stored frozen for 12 months at -20 ºC compared to pH 
unadjusted urine samples also stored at -20 ºC. However, no difference in 
average decline in urinary albumin concentration between unadjusted 
samples stored at -80 ºC and pH adjusted samples stored at -20 ºC was 
found. This renders pH adjustment to values >8 of urine samples and 
consequent storage at -20 ºC as a good alternative for frozen storage at -80 
ºC.
Since we planned to measure in our studies not only urinary albumin 
concentration, but also other urinary renal damage markers, and as yet little 
is known about the effect of frozen storage average decline and variability of 
urine concentration of these markers, we investigated in chapter 4  the effect 
of frozen storage on a panel of specific  damage markers of the glomerulus, 
proximal  tubule and distal tubule, and general  inflammation markers. First, 
we found that besides cystatin C all urinary markers decrease in 
concentration and show an increase in variability after one year of frozen 
storage. Second, we stored urine samples under several  different storage 
conditions to see whether this could prevent or reduce a decline in 
concentration. We alkalized urine samples before or after frozen storage or 
added protease inhibitors and stored samples for 1 year at -20 and -80 ºC. 
Unfortunately, none of the investigated protocols could prevent or reduce the 
decline or increase in variability that is observed with the various damage 
markers. Third, we investigated the correlation between fresh measured 
concentrations and concentrations measured after frozen storage. All marker 
concentrations assessed from frozen samples showed significant 
correlations to the freshly measured concentrations. Given these 
observations we conclude that, if possible, these markers are preferably 
measured in fresh urine samples. However, since these marker 
concentrations from frozen samples are still significantly correlated to 
concentrations from fresh samples, we feel  that results can be used to 
predict end points. However, results obtained from frozen samples should be 
interpreted with caution, since absence of a significant relation with the 
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endpoint under investigation can be due to absence of this relation, or due to 
storage effects. 
As discussed above it may be that urinary markers of tubular damage predict 
renal outcome in addition to albuminuria. Therefore it is investigated in 
chapter 5 in frozen urine samples obtained from patients more than 1 year 
after renal  transplantation whether specific  markers of tubular damage 
predict graft failure or decline in renal function. The most common used 
prognostic  urinary marker in chronic transplant dysfunction is total 
proteinuria. Proteinuria is not only the loss of albumin, but consists of a wide 
variety of proteins. Of note, chronic  transplant dysfunction is characterised 
by tubular histologic  changes, such as interstitial fibrosis and tubular atrophy.
38;39 It has even been demonstrated that tubular histologic  damage is better 
associated with renal  prognosis than glomerular damage.40 Therefore we 
measured specific  markers of tubular damage. Since it can take 
considerable time for a person with chronic transplant dysfunction to 
progress to graft failure, we did not only look at graft failure (only n=42 of 
606 patients), but also at loss of renal function as an endpoint.41;42 We 
showed after a median follow-up of 4.7 years that all tubular damage 
markers predicted graft failure, but not independent of proteinuria or 
albuminuria. Of the 4 investigated tubular markers KIM-1 and H-FABP also 
predicted change in eGFR. However, we found that albuminuria predicts 
both graft failure and change in eGFR better than all  investigated tubular 
damage marker and better than proteinuria. As Kasiske mentioned in an 
editorial  about this study, besides numerous strengths, also some limitations 
should be considered.43 For example, measurements were made only once 
and at variable times after kidney transplant. Results could have been 
different if measurements were made at the same (and preferably multiple) 
times post-transplant in all  patients. A limited number of studies recently also 
investigated the value of urinary tubular damage markers in patients after 
transplantation to predict renal  prognosis. In a cohort of 145 kidney 
transplant recipients it was shown that urinary KIM-1 is a powerful  predictor 
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of graft failure.44 In this larger cohort we corroborated that KIM-1 is a 
predictor of graft failure, and also of renal  function loss, adding information 
that the predictive value is not independent of albuminuria. One other study 
in patients with a stable graft showed that subclinical  tubulitis is associated 
with higher levels of urinary NGAL.45 The finding that albuminuria 
outperforms proteinuria is in line with the study of Halimi46, which also 
showed that albuminuria is a good predictor of graft loss, even in 
nonproteinuric patients. This study measured in 616 patients albuminuria 
and proteinuria. They looked at graft failure and all  cause mortality with a 
median follow-up of 3.3 years. In contrast, in our study we compared in a 
relatively large cohort with a median follow-up of 4.7 years the predictive 
value of 4 tubular markers in addition to proteinuria and albuminuria. 
Furthermore, since graft failure and death occur only in a limited amount of 
patients, we also investigated loss of renal function. 
We have investigated in patients with chronic kidney disease urinary levels 
of tubular damage markers in chapters 2 and 5. However, very little is known 
about the potential  value of these markers to predict renal outcome in the 
general population. This is an important issue since early identification of 
subjects at high risk for CKD progression offers possibilities to start early 
treatment and thereby to delay or prevent complications of CKD.15 Therefore 
we investigated in chapter 6 in subjects participating in the PREVEND study 
how urinary glomerular and tubular damage markers at baseline are related 
to progression of renal damage, measured as increase in albuminuria during 
follow-up. Progression of albuminuria during follow-up is particularly 
important, since a rise in albuminuria has been shown to be associated with 
a more rapid decline in renal function and increased mortality in patients with 
diabetes47 and in subjects from the general population with a higher risk for 
cardiovascular events.48 As in the introduction of this thesis already has 
been stated, albuminuria is the result of both glomerular leakage and tubular 
reabsorption. We hypothesized that tubular damage may be of help to 
predict an increase in albuminuria during follow-up. To investigate this 
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hypothesis we selected from the PREVEND cohort of 8592 participants 
those subjects without renal disease at baseline, and with the 20% most 
progression in albuminuria per year and albuminuria at the last follow-up visit 
>150 mg/24h. This yielded 183 subjects. These subjects were matched on 
sex, age and baseline albuminuria to controls (in a 1:2 ratio) that did not 
show such an increase in albuminuria. We showed that progressors in 
albuminuria in comparison to controls had higher urinary excretion of the 
glomerular marker IgG, but lower excretion of tubular damage markers 
KIM-1, NAG, cystatine C, beta-2-microglobulin and the general inflammation 
markers NGAL and MCP-1. Possibly because our matching criteria –we did 
not only match on age and sex, but also on baseline albuminuria- we did not 
find that higher proximal tubular damage markers were associated with 
progression in albuminuria during follow-up.
These data suggest that albuminuria increases in subjects with albuminuria 
associated with glomerular damage, whereas subjects with albuminuria 
associated with a tubular reabsorption defect do not show an increase in 
albuminuria. Second, we measured all plasma concentrations of the 
investigated markers, to investigate whether plasma concentrations 
influence the urinary excretion of these markers. Therefore fractional 
excretions of all  investigated damage markers were calculated. We found 
that the fractional excretion of IgG was higher in subjects with progressive 
albuminuria, whereas the fractional  excretion of the tubular damage markers 
was lower in these subjects. This analysis thus yielded similar results as 
studying only the urinary excretion of these markers, corroborating our 
conclusion that tubular albuminuria in these subjects is les harmfull 
compared to glomerular albuminuria. How do these data relate to current 
literature? It is known for a number of tubular damage markers that they 
predict progression of chronic  kidney disease assessed as decline in renal 
function49-52, but very little studies have looked into albuminuria, the early 
marker of kidney damage. Vaidya et al have reported that in patients with 
diabetes mellitus a spontaneous regression of albuminuria is associated with 
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lower urinary excretion of NAG and KIM-1.53 Urinary NAG predicts the 
subsequent occurrence of albuminuria in diabetic patients.54 We are to our 
knowledge the first to investigate these markers in a cohort of subjects 
obtained from the general population. 
In both chapter 6 and chapter 7 we investigated the value of a panel of 
biomarkers to predict renal prognosis. These markers however can not only 
be used to predict prognosis, but also to asses on a short-term basis the 
potential  renoprotective effect of medication, and in an individual  to titrate 
alleged renoprotective medication. Therefore we investigated in chapter 7 
the effect of dietary sodium restriction and addition of an angiotensin II 
receptor blocker (ARB) on urinary renal damage markers in 52 non-diabetic 
patients with chronic  kidney disease with significant residual proteinuria 
during ACE inhibition. Patients were enrolled in 4 treatment periods of 6 
weeks in random order. Treatment periods consisted of ACE inhibition on 
maximal dose plus placebo and ACE inhibition plus angiotensin receptor 
blockers (ARB) on supramaximal dose (Valsartan 320 mg/d). Both 
treatments were consecutively combined with a low sodium diet and a 
regular sodium diet. 24 hour urine was collected at the end of each 6 week 
treatment period and stored frozen at -80 ºC. Damage markers were 
measured in these samples. We found that the effect of sodium restriction on 
lowering tubular damage markers is more outspoken than addition of an 
ARB. Furthermore, we investigated whether more intensive treatment targets 
for proteinuria are followed by equal decline in tubular damage markers. We 
observed that the investigated markers do not decline proportionally to 
proteinuria, which would be expected, since proteinuria itself is supposed to 
be toxic to epithelial tubular cells. This suggests ongoing tubular damage, 
even when current treatment targets for proteinuria are met. 
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Future perspectives
In this thesis we show that determination of urinary excretion of renal 
damage markers holds great potential. Several  issues still  have to be 
clarified in future research. First, until now, most studies have investigated 
whether these markers are associated with kidney damage (assessed as 
eGFR or albuminuria) only in cross-sectional studies. Only a few prospective 
studies are now being published showing that some markers also predict 
renal prognosis in diabetic kidney disease.54-56  At this moment, however, is 
unknown whether these biomarkers will outperform or add to measurement 
of the biomarker that is presently used to define and predict chronic  kidney 
disease, being albuminuria. Furthermore, almost all studies investigating the 
predictive value of these markers are of retrospective design, rendering 
these studies vulnerable for several  sources of bias. One of them is that 
markers in general are measured in urine samples that have been stored 
frozen for prolonged periods in time. We showed that such storage is 
associated with a decline in marker concentration and an increase in 
variability. This will  influence the predictive value of these markers insofar 
that dilution of effect size may be anticipated. To overcome this problem, 
prospective longitudinal studies should be conducted, preferably using fresh 
urine samples. 
Second, most assays used have a considerable inter- and intra-assay 
variability. Improvement of assay performance is therefore necessary. 
Several  companies offer nowadays assays for the same marker probably 
aiming for different epitopes on the proteins to be measured. This can result 
in differences in damage marker concentrations in the same sample, which 
makes it difficult to compare the results of studies that use different assays. 
Standardization of assays for the various markers that are presently used 
still has to be done. 
Another point is that, obviously, pathological processes differ between 
different renal diseases. It could therefore well be that in other conditions 
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tubular damage markers do may be of help. Depending on the disease 
under investigation, it is most probable that a panel of urinary damage 
markers will  have the best predictive capacity to predict progression of 
kidney disease. Research at this moment is merely focussed on identifying 
single markers. Future research should therefore focus not only on one 
marker at a time, but at panels of markers, that wil  probably differ between 
patients groups and clinical characteristics. 
Clarifying these issues will necessitate large studies in well defined patient 
groups, using rigid methodology with respect to storage of urine samples 
and assay quality. Such studies will  be of help to clarify whether certain 
novel  urinary markers or combinations of markers can reliably predict renal 
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Nederlandse samenvatting
Het aantal mensen met een gestoorde nierfunctie is de afgelopen decennia 
sterk toegenomen. Een gestoorde nierfunctie betekent dat deze mensen een 
hoger risico hebben,om hart- en vaatziektes te krijgen,eindstadium nierfalen 
te ontwikkelen of om te overlijden. Mensen met een minder goede 
nierfunctie hebben hier aanvankelijk weinig klachten van, waardoor zij vaak 
pas laat medische hulp zoeken en daarmee pas in een laat stadium wordt 
ontdekt dat hun nierfunctie gestoord is. Screening op eiwitverlies in de urine 
(albuminurie) is momenteel de methode welke gebruikt wordt om patiënten 
met nierschade in een vroeg stadium op te sporen. Het belangrijkste doel 
van dit proefschrift was te onderzoeken of stoffen die in de urine 
uitgescheiden worden en schade aan de nier weergeven (toegevoegde) 
voorspellende waarde hebben boven de nu meest gebruikte schademarker, 
albumine uitscheiding in de urine. Deze nieuwe markers, zouden 
verscheidene toepassingen kunnen hebben. Naast dat ze zouden kunnen 
helpen om mensen met nierschade in een vroeg stadium op te sporen 
zouden ze ook gebruikt kunnen worden om te voorspellen bij welke 
patiënten de nierfunctie versneld achteruit zal gaan. Een derde toepassing 
zou kunnen zijn gelegen in het monitoren van de effecten van medicatie op 
de nier, waardoor bij  een te hoge uitscheiding van de markers in de urine 
tijdens behandeling de medicatiedosering kan worden aangepast. Hierdoor 
zou toekomstige schade kunnen worden verminderd of voorkomen.
Hoofdstuk 1 gaat over het screenen van mensen op gestoorde nierfunctie. 
De diagnose chronische nierschade wordt bepaald door twee factoren: een 
verminderde nierfunctie uitgedrukt als een glomerulaire filtratiesnelheid 
kleiner dan 60 milliliter per minuut of uitscheiding van meer dan 30 mg 
albumine in de urine per dag. De glomerulaire filtratiesnelheid (GFR) is de 
belangrijkste maat voor nierfunctie. Het geeft het aantal milliliters bloed weer 
dat door de nier wordt gezuiverd per tijdseenheid. Hoe hoger deze 
glomerulaire filtratiesnelheid, des te meer bloed door de nier wordt 
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gezuiverd, en des te beter de nierfunctie is. Albumine is het eiwit dat het 
meest in het bloed voorkomt. Uitscheiding hiervan in de urine betekent dat of 
het filter waardoor bloed in de nier gefilterd wordt defect is, of dat de 
terugopname van albumine in de nierbuisjes (niertubuli) niet goed werkt. In 
hoofdstuk 1 wordt besproken dat deze twee variabelen, glomerulaire 
filtratiesnelheid en albumine uitscheiding in de urine, welke beide de 
diagnose chronische nierschade bepalen, onafhankelijk van elkaar kunnen 
voorspellen wie een grotere kans heeft verdere nierfunctiestoornissen te 
ontwikkelen. In de gezonde nier komen er nauwelijks eiwitten door het 
nierfilter en de eiwitten die er wel doorkomen worden vervolgens in de 
niertubuli weer heropgenomen, zodat uiteindelijk de urine vrijwel geen 
eiwitten bevat. Het is onbekend in welke mate de heropname van albumine 
plaatsvindt door de niertubuli. Wat wel  vast staat is dat een beschadigde 
niertubulus albumine slecht opneemt. Het zou hierom goed kunnen zijn dat 
specifieke markers van schade van de niertubulus nog beter kunnen 
voorspellen wie nierschade heeft cq gaat ontwikkelen. Deze markers zouden 
bovendien voorspellende waarde kunnen toevoegen aan albumine 
uitscheiding in de urine in het voorspellen van klinische eindpunten, zoals 
het optreden van nierfunctie achteruitgang. 
Om te kijken of deze tubulaire markers voorkomen bij mensen met een 
verhoogde albumine uitscheiding in de urine, hebben we in hoofdstuk 2 bij 
94 patiënten met suikerziekte (die door hun ziekte een hoog risico lopen om 
nierschade te ontwikkelen) onderzocht of deze markers van nierschade in de 
urine aanwezig zijn. Ook hebben we ter vergelijking in urine van een 
controlegroep bestaande uit 45 gezonde mensen deze markers gemeten. 
Het bleek dat de schademarkers van de niertubuli al  verhoogd waren bij 
patiënten met suikerziekte in vergelijking met de waarden die werden 
gemeten bij de controlegroep. Dit gold zelfs voor de patiënten met 
suikerziekte die nog een normale nierfunctie en normale uitscheiding van 
albumine in de urine hadden (figuur 1). Deze resultaten suggereren dat de 
markers al  in een zeer vroeg stadium nierschade weerspiegelen, waardoor 
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ze van hulp zouden kunnen zijn om nierpatiënten al  in een heel vroeg 
stadium van de nierziekte op te sporen. Verder is onderzocht hoe de 
schademarkers zich verhouden tot de uitscheiding van albumine in de urine 
en hoe ze zich verhouden tot de nierfunctie (GFR). Het bleek dat de 
uitscheiding van bijna alle markers toeneemt naarmate er meer albumine 
uitscheiding in de urine is. Figuur 1 toont dit voor bijvoorbeeld albumine en 
NAG uitscheiding. Ook neemt de uitscheiding van deze markers toe 
naarmate de nierfunctie afneemt. Op grond hiervan kan geconcludeerd 
worden dat de onderzochte markers samenhangen met nierschade en dat 
het waarschijnlijk is dat zij  het ontstaan van nierschade al in een vroeg 
stadium kunnen voorspellen. 
Figuur 1: Concentratie van verschillende schademarkers van de nier in de urine. Gezonde 
controles zijn links afgebeeld; Normo betekent een normale uitscheiding van albumine in de 
urine; Micro betekent een licht verhoogde uitscheiding van albumine in de urine; Macro houdt 
een fors verhoogde uitscheiding van albumine in de urine in. Een p-waarde kleiner dan 0.05 
betekent dat de groepen statistisch significant van elkaar verschillen. 
Op dit moment is albumine in de urine een belangrijk middel om de mate van 
nierschade te definiëren.Het is dus belangrijk dit betrouwbaar te kunnen 
meten. In veel studies wordt gebruikt gemaakt van urinemonsters die 
ingevroren zijn geweest. Het is bekend dat door invriezen de concentratie 
van albumine in de urine omlaag gaat en er meer variatie ontstaat. In 
hoofdstuk 3 is onderzocht of het aanlogen van urine (toevoegen van een 
vloeistof die de zuurgraad van urine verminderd) voordat de urine ingevroren 
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wordt voorkomt dat de meetbare albumineconcentratie verandert door het 
zogenaamde vries-dooi effect. Hiervoor zijn urinemonsters van patiënten 
met suikerziekte verzameld en ingevroren. De albumine concentratie werd 
gemeten in het verse monster en op verschillende tijdspunten na invriezen. 
De monsters die 1 jaar werden bewaard zijn zowel bij -20º C en bij -80º C 
bewaard en vervolgens gemeten. Uit dit onderzoek is gebleken dat, als 
monsters 1 jaar bij  -20 ºC worden bewaard, aanlogen van de urinemonsters 
de afname van de albumineconcentratie en de toename in variabiliteit 
vermindert in vergelijking met de monsters die niet voorbehandeld worden. 
Verder werden geen verschillen aangetroffen tussen niet aangeloogde 
monsters die 1 jaar bij -80º C waren bewaard en de aangeloogde monsters 
die bij  -20º C waren bewaard. Dit maakt dat het aanlogen van urine en het 
vervolgens bewaren bij -20º C een geschikt alternatief is voor bevroren 
opslag bij -80º C. 
Aangezien we voor onze vervolgstudies niet alleen albumine, maar ook een 
aantal schademarkers van de nier wilden meten, en er erg weinig bekend is 
over de effecten van bevroren opslag op de concentratie en variabiliteit van 
deze schademarkers, hebben we in hoofdstuk 4 onderzocht wat de effecten 
zijn van bevroren opslag op de concentratie van een panel  van verschillende 
schademarkers van de nier. Een dergelijk onderzoek is van belang omdat 
eventuele vrieseffecten, zoals daling van de meetbare concentratie van deze 
schademarkers of toename in variabiliteit, ten onrechte het beeld zouden 
kunnen doen ontstaan dat schademarkers niet goed schade weerspiegelen 
of de nierprognose niet goed voorspellen. In de studie die hier wordt 
beschreven hebben we urinemonsters van 95 patiënten met suikerziekte 
wederom 1 jaar opgeslagen. Hierbij hebben we verschillende 
bewaarprotocollen toegepast. Zo hebben we urines voor het invriezen 
aangeloogd, hebben we proteaseremmers toegevoegd en hebben we na het 
ontdooien de monsters aangeloogd. Tevens zijn de monsters in twee 
verschillende vriezers zowel  bij -20º C als bij -80º C opgeslagen. Om te 
onderzoeken of een eventuele afname van de marker concentraties groter 
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wordt naarmate een monster langer wordt bewaard, hebben we monsters 
eerst vers gemeten (in dezelfde meetsessie twee keer, en nog een keer 
direct na de eerste meetsessie), na 1 week bevroren opslag, na 6 maanden 
en na 1 jaar. Hieruit bleek dat behalve cystatine C alle markers na langere 
opslag in concentratie afnamen en een toename in variabiliteit toonden na 1 
jaar bevroren opslag. Daarnaast werd duidelijk dat verschillende 
bewaarprotocollen (zoals voor of na invriezen aanlogen of proteaseremmers 
toevoegen) deze effecten niet konden voorkomen. Ten derde is onderzocht 
wat de relatie was tussen vers gemeten concentraties en de na bevroren 
opslag gemeten concentraties. Deze relaties bleken over het algemeen 
redelijk goed. Op grond van deze gegevens concluderen we dat deze 
markers het best gemeten kunnen worden in verse urine monsters. Indien dit 
niet mogelijk is dan kunnen urine monsters worden gebruikt die bevroren 
opgeslagen zijn geweest. Echter, er kan dan sprake zijn van een vrieseffect 
(afname in concentratie en toename in variabiliteit).  Als er dan geen relatie 
wordt gevonden tussen een marker die gemeten is in urine monsters die 
ingevroren zijn geweest en er geen relatie wordt gevonden tussen de marker 
concentratie en het onderzochte eindpunt, dan hoeft dit dus niet 
noodzakelijkerwijs te betekenen dat deze relatie er niet is. Het zou ook 
kunnen zijn dat deze relatie vertroebeld is door een vries-dooi effect.
Zoals eerder in hoofdstuk 2 is besproken, kunnen de in dit proefschrift in de 
urine gemeten schademarkers al  verhoogd zijn voor dat één van de 
conventionele maten voor nierschade (albumine en eGFR) afwijkend is. 
Daarom is in hoofdstuk 5 onderzocht of deze nieuwe markers van schade 
van de nier bij  patiënten die een niertransplantatie hebben gekregen 
voorspellen of die nier door chronische afstoting verloren gaat. Dit is 
onderzocht met behulp van urinemonsters die bevroren opgeslagen zijn 
geweest. Voor dit onderzoek is een groep van 606 patiënten onderzocht, die 
hiervoor 4.7 jaar gevolgd zijn. Van deze 606 patiënten verloren 42 de functie 
van hun transplantatienier. Tevens is onderzocht of de genoemde 
schademarkers gedeeltelijke achteruitgang in nierfunctie voorspellen. Uit de 
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uitkomsten is af te leiden dat alle onderzochte markers verlies van de 
transplantaatnier voorspellen, maar dat zij dit niet beter doen dan de nu in 
de klinische praktijk veel  gebruikte marker totaal  eiwit. Opvallend is echter 
dat de uitscheiding van albumine in de urine verlies van de transplantaatnier 
beter voorspelde dan de onderzochte schademarkers en ook beter dan het 
nu veel gebruikte totaal  eiwit in de urine. Als deelnemers in vier groepen met 
oplopende concentratie schademarkers worden ingedeeld, treedt het 
voorkomen van het verlies van functie van de transplantatienier meer op 
naarmate de concentratie van deze schademarkers hoger is (figuur 2). 
Omdat maar een klein deel van alle onderzochte mensen volledig verlies 
van functie van hun niertransplantaat hadden, is ook gekeken naar de mate 
van nierfunctie verlies. Twee van de vier tubulaire schademarkers 
voorspelden ook nierfunctie achteruitgang. Albumine in de urine voorspelde 
dit echter ook, en opnieuw beter dan het nu in de klinische praktijk veel 
gebruikte totaal eiwit in de urine. Hieruit kan geconcludeerd worden dat het 
in de klinische praktijk het beste is om bij deze patiëntengroep in de urine 
albumine te meten, omdat het beide eindpunten beter voorspelt dan totaal 
eiwit en beter dan de onderzochte nieuwe nierschade markers.
Figuur 2: de verticale as toont de incidentie van verlies van transplantatienier. Incidentie is het 
voorkomen van een gebeurtenis per bepaalde tijdsduur vervolgen. Op de x-as zijn alle 
onderzochte schademarkers opgedeeld in kwartielen van hogere concentratie.
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In hoofdstuk 2 en hoofdstuk 5 is concentratie van tubulaire schademarkers 
onderzocht bij patiënten met een chronische nierziekte. Er is echter ook 
weinig bekend over de waarde van deze markers bij mensen uit de 
algemene bevolking om te voorspellen of zij progressief nierschade gaan 
ontwikkelen . Het is van groot belang hier inzicht in te krijgen, omdat het 
vroeg opsporen van mensen die hoog risico lopen om nierschade te 
ontwikkelen, de mogelijkheid biedt in een vroeg stadium te starten met 
behandeling. Hierdoor kunnen eventuele gevolgen van nierschade worden 
voorkomen of verminderd. Daarom is in hoofdstuk 6 onderzocht of de 
verschillende schademarkers het ontstaan van nierschade (gemeten als 
toename van albumine uitscheiding in de urine) na het meerdere jaren 
vervolgen kunnen voorspellen. Voor dit onderzoek is gebruik gemaakt van 
deelnemers aan de PREVEND studie De PREVEND studie bestaat uit 8592 
mensen, die gemiddeld meer dan 9 jaar gevolgd zijn. Uit deze groep zijn 
diegenen geselecteerd met de 20% meeste toename in albumine 
uitscheiding in de urine. Dit leverde 183 mensen op. Deze mensen zijn 
gekoppeld aan 2x zoveel  controlepersonen, die wat betreft leeftijd, geslacht 
en hoeveelheid albumine in de urine aan de start van de studie 
overeenkomen. In de urine van al  deze mensen (549 in totaal) zijn 
schademarkers van de nier gemeten. Het bleek dat deelnemers die in de 
loop der jaren een forse toename in albumine uitscheiding hebben, in 
vergelijking met controlepersonen, een hogere urine uitscheiding van 
schademarkers van het nierfilter (glomerulus) hebben, maar juist lagere 
concentraties van schademarkers van de niertubulus.  Hieruit kan worden 
geconcludeerd dat verergering of het ontstaan van nierschade meer 
samenhangt met tekenen van een kapot nierfilter (glomerulus) en minder 
met een slecht functionerende niertubulus. Dit betekent dat albumine 
uitscheiding in de urine als gevolg van een tubulusopnameprobleem relatief 
onschuldig is, terwijl  albumine in de urine als gevolg van een lek nierfilter 
meer problematisch lijkt te zijn. 
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In zowel hoofdstuk 5 als 6 is onderzocht of schademarkers kunnen 
voorspellen wie nierschade zal  gaan ontwikkelen. Deze markers kunnen 
echter niet alleen gebruikt worden om het optreden van schade te 
voorspellen, maar bijvoorbeeld ook om te onderzoeken of een medicament 
een nierbeschermend effect heeft. Ook zou het meten van deze markers 
mogelijkheden kunnen bieden om de dosering van een medicament 
individueel aan te passen. Als bijvoorbeeld een patiënt een hoge 
uitscheiding van schademarkers in de urine heeft, dan kan de dosering van 
een nierbeschermend medicament aangepast worden totdat de uitscheiding 
van schademarkers normaal is. Hierdoor kan het medicament 
voorgeschreven worden in een dosering waarmee achteruitgang van 
nierfunctie het meest optimaal voorkomen kan worden. In hoofdstuk 7 is in 
dit kader onderzocht wat het effect is van een lage zoutinname en het geven 
van een angiotensine II receptor blokker (ARB). Dit laatste is een medicijn 
dat bij  patiënten met een nierziekte wordt voorgeschreven om achteruitgang 
van nierfunctie te voorkomen. Voor dit onderzoek zijn, in urine van 52 
patiënten met een chronische nierziekte, verschillende schademarkers van 
de nier gemeten. Patiënten werden behandeld in vier periodes van zes 
weken in willekeurige volgorde (normale zoutinname, normale zoutinname+ 
ARB, lage zoutinname en lage zoutinname+ARB).  Aan het einde van iedere 
zes weken durende periode is urine verzameld. Hierin zijn de 
schademarkers bepaald. Uit de verkregen gegevens kan geconcludeerd 
worden dat verlaging van de zoutinname een grotere afname van 
nierschademarkers met zich mee bracht dan het geven van een ARB. Verder 
is onderzocht of het nastreven van een strengere behandeldoelstelling voor 
de eiwituitscheiding in de urine (dat wil  zeggen het toevoegen van 
nierbeschermende maatregelen tot een totale eiwituitscheiding van minder 
dan 0.3 gram per dag wordt bereikt) gepaard gaat met lagere uitscheiding 
van de onderzochte schademarkers. Bij  de start van de studie hadden alle 
patiënten een eiwituitscheiding in de urine van meer dan 1 gram per 
dag..Het bleek dat een verlaging van de eiwituitscheiding tot kleiner dan 0.3 
gram per dag door lagere zoutinname of toevoeging van een ARB weliswaar 
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gepaard ging met lagere uitscheiding van schademarkers, maar dat deze 
afname niet proportioneel is aan de afname in eiwituitscheiding in de urine. 
Dit suggereert dat er nog steeds schade is, zelfs als de strengere 
behandeldoelstelling wordt gehaald. 
Conclusie
Dit proefschrift toont aan dat er voor het meten van de onderzochte 
schademarkers van de nier diverse nieuwe toepassingen kunnen zijn. Zo 
kunnen de markers van waarde zijn bij  het opsporen van patiënten met 
nierschade die door de conventionele methodes nog niet worden 
opgespoord (hoofdstuk 2). Ook kunnen de markers gebruikt worden om de 
prognose van nierschade te voorspellen, zoals in hoofdstuk 5 en 6. Verder 
zouden ze gebruikt kunnen worden om bij  individuele patiënten 
nierbeschermende medicijnen optimaal  te doseren. Dit zijn veelbelovende 
ontwikkelingen. De studies en uitkomsten in dit proefschrift zullen echter 
eerst moeten worden bevestigd in andere onderzoeken voordat ze in de 
klinische praktijk kunnen worden ingezet. Tot op heden is het nog niet 
volledig duidelijk of deze schademarkers beter zijn dan, of voorspellende 
waarde kunnen toevoegen aan de op dit moment meest gebruikte marker 
voor chronische nierziekte, namelijk albumine uitscheiding in de urine. Om 
dit verder te onderzoeken zijn grote studies nodig, in goed vastgestelde 
patiëntengroepen waarbij  het liefst verse urine monsters worden gebruikt, of 
zorgvuldige bewaarprotocollen worden gebruikt om de urinemonsters in te 
vriezen. Zulke studies kunnen dan duidelijk maken of bepaalde nieuwe 
schademarkers van de nier (of mogelijk combinaties daarvan) de 
voorspelling van het verloop van nierziekte kunnen verbeteren. Totdat zulke 
studies zijn verricht blijft de belangrijkste schademarker die gemeten kan 




Het feit dat ik nu mijn dankwoord aan het schrijven ben, betekent dat mijn 
boekje bijna af is. Het zou goed kunnen dat dit het enige deel van het boekje 
is dat echt iedereen leest. Dit wordt ongetwijfeld een lange lijst met namen 
van mensen die mij  allemaal geholpen/bijgestaan hebben. Mocht ik 
onverhoopt toch nog iemand vergeten zijn, bij deze op voorhand mijn 
oprechte excuses en natuurlijk ook mijn dank voor de hulp. 
Als eerste wil ik graag alle patiënten en PREVEND deelnemers bedanken 
die hebben deelgenomen aan de studies in dit proefschrift. Zonder jullie was 
dit proefschrift er niet geweest. Ook alle collega-onderzoekers, vrienden, 
kennissen en vrienden van kennissen van vrienden die allemaal belangeloos 
bloed hebben afgestaan of urine hebben verzameld: bedankt! 
Verder wil  ik graag mijn eerste co-promotor bedanken. Dr R.T. Gansevoort, 
beste Ron. Ik wil  je graag bedanken voor je kritische blik, enthousiasme en 
overzicht. Na drie jaar samenwerking verras je me nog steeds met je frisse 
kijk op mijn data en artikelen (en layout). Ik verbaasde me meer dan eens 
hoe je soms met minimale tekstuele wijzigingen (ook wel ’s wat meer 
trouwens) een manuscript flink verbeterde. Zonder jouw hulp en frequente 
begeleiding was dit proefschrift zeker niet geworden wat het nu is.
Verder wil ik uiteraard mijn promotor, professor P.E. de Jong hartelijk 
bedanken. Beste Paul, ik heb bewondering voor je enthousiasme en oog 
voor detail. Meerdere keren verbaasde je me met de snelheid waarmee je 
mijn manuscripten van opbouwende kritiek voorzag en scherpte waarmee je 
de inhoud doornam (een onlogisch getal in een grote tabel ontgaat jou niet!). 
Verder wil  ik ook mijn tweede en derde co-promotores bedanken. Dr S.J.L. 
Bakker, beste Stephan, dank voor je statistische en inhoudelijke input. Dr W. 
van Oeveren, beste Wim, wij hebben samen heel wat vrijdagmiddagen tot in 
de avond op het lab gezeten om onze veelvoud aan (te?) strak geplande 
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ELISA’s tot een goed einde te brengen. Ik heb veel  geleerd van je praktische 
insteek en laboratoriumkennis. Zonder dit alles was dit boekje niet mogelijk 
geweest. 
Graag wil ik de leden van de beoordelingscommissie prof R.O.B. Gans, prof 
J.F.M. Wetzels en prof H. van Goor bedanken voor het beoordelen van mijn 
proefschrift. 
Bij  een proefschrift is de praktische ondersteuning erg belangrijk. Beste 
Winnie, het was soms een hele klus om een afspraak met al  m’n begeleiders 
op hetzelfde moment op dezelfde kamer te plannen. Dank voor je hulp en 
natuurlijk de gesprekjes op de BRUG! Ook Jan Roggeveld, jij  stond altijd 
klaar om samples voor me te meten. Ook was je altijd weer bereid samen op 
speurtocht te gaan in het serumarchief om bepaalde monsters te zoeken. 
Hetzelfde geldt ook voor Bettine: ook jij  stond altijd klaar om ELISA tips te 
geven en monsters te meten. 
Een onmisbaar onderdeel  van een promotietraject zijn de collega AIO’s. Ik 
heb genoten van de goede sfeer, de vrimibo’s en de vanzelfsprekendheid 
waarmee iedereen elkaar hier helpt. 
Esther, heerlijk was het om je gevatte opmerkingen te horen (over zowel 
werk als privé). Beste Nynke, ik heb gedurende mijn begin veel van je 
statistische kennis mogen profiteren. Dank voor je vanzelfsprekende 
interesse! Verder ook bedankt voor je gezelligheid en natuurlijk ook voor je 
kooktips (misschien doe ik er ooit nog wat mee?). 
Beste Marije, roommie, ook jij  bedankt voor je statistical  coaching toen ik 
volstrekt onwetend op deze afdeling begon. Sorry voor alle keren dat ik je uit 
je concentratie trok voor een vraag en je vervolgens - geheel  Marije style - 
weer opnieuw moest ‘opstarten’. En natuurlijk ook bedankt voor de 
gezelligheid (dankzij jou bleef ik op de hoogte van de celebrity wereld) en de 
vele directe gevraagde en ongevraagde adviezen. 
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Beste Lieneke, ik heb genoten van je sprankelende vrolijkheid, je interesse 
en je theaterkwaliteiten. Gelukkig wist je, als ik weer onduidelijke frasen 
uitkraamde, precies wat ik bedoelde en op welke data wat precies was. Je 
hebt je ontzettend snel ontwikkeld tot een grote SPSS specialist. Met je 
boekje zal het daarom zeker goed komen! 
Beste Wendy, allereerst natuurlijk dank voor al je hulp bij het zien van alle 
diabetes patiënten in Zwolle, de metingen en het opzetten van de database. 
Verder was je een trouwe bezoekster van onze vrimibo’s, dank ook voor de 
gezelligheid daar! 
Beste Hanneke, jammer genoeg zijn we maar kort roommies geweest. Ik 
ken niemand die zo geconcentreerd kan werken. Dank ook voor je altijd 
gezellige aanwezigheid en je klinische blik op de zaak! Beste Lucia, ook jij 
van harte bedankt voor de vele gesprekjes, (mode- en haardracht-) adviezen 
en gezelligheid! Debbie, als roommie hoor jij hier ook. Dank voor je frisse kijk 
en heel  veel succes met onderzoek doen! Edwin, chef, we hebben maar kort 
een werkkamer gedeeld, maar je hebt mijn woordenschat aan studentikoze 
uitdrukkingen flink uitgebreid! 
Over naar de BRUG. Else, aan jouw stroom gevatte opmerkingen (op onze 
eerste ontmoeting: “Ferdau, is dat niet een anagram van fraude?”) komt 
nooit een eind. Ik heb genoten van je interesse en gezelschap op en buiten 
het werk! Ook super dat je mijn paranimf wilt zijn. Hilde, jij  kon wel eens 
degene zijn naar wie ik tijdens mijn onderzoeksperiode de meeste mailtjes 
heb gestuurd. Jij  ook bedankt voor je gezelligheid, interesse, trouwe 
aanwezigheid op de vrimibo en ontbijtsessies. Oosterpoort! 
Steef, jongen, ook jij  steekt je mening niet onder stoelen of banken. Bedankt 
voor de scherp geformuleerde adviezen en ik hoop nog vaak samen op 
wintersport te kunnen gaan. 
Arjan, ook jouw vrolijke aanwezigheid zal ik gaan missen! Tsjitske, op jouw 
nuchtere kijk en enthousiasme kon ik altijd rekenen. Ik had het idee dat we 
altijd als één van de laatsten op borrels overbleven. Dank voor je 
gezelligheid! 
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Dorien, één keer heb ik mogen ervaren wat jij meerdere malen per week 
doet. Respect! Maar ik houd het bij één springklasje… Bedankt voor je leuke 
gezelschap tijdens het werk en congressen! Jan, de man die op z’n rug kan 
zitten. Jij ook bedankt voor je mooie verhalen, gedetailleerde kennis van de 
lokale fauna waar dan ook en gezelligheid! Maartje, ook jou bedank ik voor 
je enthousiasme, prettige samenwerking en gezelligheid uiteraard! Ik ben blij 
dat we nu weer collega’s te zijn! Solmaz, bedankt voor je vrolijkheid, 
gezelligheid en lessen Farsi (hawo goebè!). Merel, waarschijnlijk ben jij  de 
volgende. Dank voor je plezierige aanwezigheid en veel succes in 
Amsterdam!
Michel, jij bent een vrolijke aanvulling op het stel. Jammer dat we maar kort 
tegelijk in het UMCG werkten. Goed dat er wat mannelijke input is in deze 
door dames gedomineerde onderzoeksclub! 
Verder wil ik ook alle andere AIO’s en inmiddels gepromoveerden die ik 
korter of langer heb gekend bedanken voor de gezelligheid op en buiten het 
werk. Mariam, bedankt voor je geduldige uitleg als ik iets expirimenteels 
weer volstrekt niet begreep. En natuurlijk voor de gezelligheid. Alaa, Anna, 
Astrid, Azideh, Carolien, Eelke, Folkert, Femke, Guiseppe, Gemma, Heleen, 
Jeffrey, Jelena, Kevin, Kiran, Laura, Leendert, Miriam, Pramod, Rutger, 
Saleh, Saritha, Shanti, Willem, Ineke en Janneke, bedankt!  
Ook de doktersassistentes van PREVEND mogen niet onbenoemd blijven! 
Martha, Annemarie, Annet, Annie en Martha, zonder jullie inzet bij de 
dataverzameling van PREVEND had mijn boekje er niet hetzelfde uit gezien. 
Dank ook voor de vele koffiemomenten toen we nog op dezelfde gang zaten 
en de huishoudelijke adviezen!  
De post-doc’s die mij  op verschillende manieren hebben geholpen wil ik ook 
graag hartelijk bedankten. Hiddo, bedankt voor de prettige samenwerking en 
de vele statistische adviezen! Martin, jij  ook bedankt voor het leuke COX-2 
stuk! Eefje, fijn dat ik mocht langslopen voor moeilijke statistische issues.
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Ook mijn nieuwe collega’s in het Martini ziekenhuis wil  ik bedanken voor de 
warme ontvangst! 
Vrienden mogen absoluut niet onbenoemd blijven in mijn dankwoord! Een 
promotietraject is alleen vol  te houden met goede vrienden die voor afleiding 
zorgen.
Aljar, bedankt dat je m’n paranimf wilde zijn. Ik zou zeggen, Romeo Delta. 
Verder is een vakantiedag ook niet compleet zonder jouw commentaar en 
‘probleempjes’ (weten we nu al wat de kooktemperatuur is van kwik in 
vacuum?). Hilbert, biertjes drinken, vakantievieren en weekendjes-weg zijn 
zonder jouw commentaar en nuchterheid niet hetzelfde. Hopelijk volgen nog 
vele air- sea- en land miles samen. Cees, glad you’re back, hoewel een vast 
logeeradres in Berlijn ook verleidelijk is. Gerda, jij  ook bedankt voor je frisse 
kijk op zaken en vriendschap. En natuurlijk voor het lay-outen van dit 
prachtige proefschrift! Liesbeth, ik geniet iedere keer weer van een nieuwe 
discussie of iets psychiatrisch is of normaal. Bert, super dat we straks weer 
in hetzelfde ziekenhuis werken. Dank voor je gezelligheid en je linkse 
kritische geluid! Rogier, fijn dat je weer terug bent. Wat mij  betreft gaan we 
nog heel wat baantjes trekken. Karin, leuk dat we elkaar weer veel zien in 
het Martini! 
Lieve familie, ook jullie zullen hier niet ontbreken. Sietske, Jarno en Julia, 
Marrit en Tim, bedankt voor de interesse en steun gedurende dit hele traject. 
Papa en mama, jullie hebben mij  altijd gestimuleerd en ondersteund in de 
dingen die ik graag wilde doen. Zonder jullie aanhoudende support had ik dit 
nu niet bereikt! 
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